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Abstract
In T and B cells, attenuation of an undefined negative regulatory element binding protein 
(NEŒ-BP) binding to a negative regulatory element (NRE) removes the suppression of 
transcriptional activity upon the promoter of a unique 55kDa IL-2 receptor subunit, 
CD25. This event leads to the expression of CD25 at the cell surface. In human B cells 
IL-4, a potent activator of CD25 transcription abolishes NRE binding activiy via a cychc 
adenosine monophosphate (cAMP)/ cAMP-dependent kinase (PKA)-sensitive pathway. 
Studies of the IL-4-regulated cAMP/PKA pathway showed that the catalytic subunit of 
PKA (PKAc) did not have a direct effect on NRE-BP in vitro, suggesting that PKAc has 
an indirect involvement in the loss of NRE binding activity. Studies with the intracellular 
signalling modulators Wortmannin and Rapamycin revealed that IL-4 does not attenuate 
NRE binding activity via PI-3 kinase signalling. Electrophoretic mobility shift assay 
(EMSA) analysis showed that IL-4 does not directly affect NF-kB activity.
The attenuating effect of IL-4 on NRE binding activity was also observed for protein 
binding to the entire NRRi region. Signalling tlirough the IL-13 receptor, which shares 
the IL-4Ra subunit with IL-4R, failed to attenuate NRRi binding activity suggesting that 
IL-4 causes a loss of protein binding to NRRi through the signalling generated by the yc 
subunit o f the IL-4R complex. EMSA studies using consensus and mutant NRRi 
oligonucleotides showed that NRE is the dominant site for protein binding within NRRi, 
although the consensus AP-1 site was required for maximum binding. Supershift 
experiments showed that the transcription factors YYl and Ets were unlikely to be 
NRE-BP and that CBP/p300 is unlikely to form a bridging complex over proteins 
binding to NRRi. Western blot and EMSA experiments characterised the putative AP-1 
binding site as a bona fide  AP-1 binding site; an antibody against the AP-1-family 
protein c-fos supershifted one protein species binding to radiolabelled CD25-NRRi
Transient-transfection of P3HR1 B cells with NRRj deletion mutants confirmed that 
NRE is the dominant suppressive region of NRRi. Lymphoid cells transfected with 
CD25 ST AT6  deletion mutant constructs showed an increase in reporter activity 
following treatment with phorbol myristate acetate (PMA). This finding is the first 
demonstration that PRRn is both functional and mitogen-sensitive in B cells. IL-4- 
sensitivity was assessed in lymphoid cells transfected with STAT6  CD25-CAT reporter 
constructs. These studies demonstrated that a putative STAT6  site overlapping NRRn 
was sensitive to EL-4. The remaining sites were insensitive to EL-4, suggesting they are 
not functional STAT6  sites. This finding suggests that a second EL-4 signalling 
mechanism, activation of the JAK7STAT pathway, may be involved in the upregulation 
of CD25 expression.
In summary, IL-4 up-regulates the expression of CD25 in human B cells through a 
cAMP/PKA-sensitive pathway, which attenuates protein binding to NRRi and may also 
activate the JAK/STAT pathway. NRE binding activity is unaflFected by direct action of 
PKAc, although this kinase is likely to exert an indirect effect. NRE is the dominant 
protein binding and functional region of NRRi, and supershift experiments characterised 
the retinoid sensitive region as an AP-1 binding site. The identity of NRE-BP candidates 
remains unknown and supershift experiments exclude YYl and Ets as NRE-BP and 
show that CBP/p300 does not form a bridging complex linking NRE-BP and AP-1. 
Studies with deletion mutants of putative CD25 STAT6  sites showed for the first time in 
human B cells, that PRRn is responsive to mitogenic stimulation and identified a STAT6 
site close to NRRn as IL-4 sensitive.
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CHAPTER ONE 
INTRODUCTION
24
1.1 B-LYMPHOCYTE DEVELOPMENT
B lymphocytes, in common with all haematopoietic cells, are derived from pluripotent 
stem cells which are produced in the bone marrow (Kee and Paige, 1995). Pluripotent 
stem cells give rise to all cells of the immune system and such cells are classed as 
leukocytes. Leukocytes can be categorised into B lymphocytes and T lymphocytes, as 
well as the broadly classed polymorphonuclear phagocytes and auxiliary cells (including 
platelets and mast cells). B lymphopoiesis is a fundamental event in the frmctioning of 
the immune system, and the ultimate products, namely high affinity antibody secreting 
plasma cells, form the main part o f an immediate immune response.
In both human and murine bone marrow, B lymphocyte differentiation has two main 
stages of development, the antigen-independent stage and the antigen-dependent stage. 
B cell development can be further divided into a succession o f immunoglobulin (Ig) gene 
rearrangements (Hardy et al., 1991;Melchers et al, 1995) or the ordered expression o f B 
cell-related markers (Osmond et a l, 1994), culminating in the formation and expression 
o f IgM. B lymphopoiesis takes a very similar course in both mouse and human bone 
marrow and efforts have been made to clarify development in both species, and to 
integrate the different models which describe B cell development (Ghia et al, 
1998;LeBien, 1998;Osmond et al, 1998).
1.1.1 Antigen-Independent B Cell Development
The antigen-independent stage is a developmental stage which occurs in foetal liver and 
in human and murine bone marow. Differentiation tlirough pro- and pre-B lymphocytes 
provides the B cell with a functional cell surface receptor for antigen and early B cell 
development is dependent on growth factors derived from stromal cells, such as IL-7 
(van Freeden-Jeffry, 1995). B cell development was initially characterised using A- 
MuLY transformed cell lines which demonstrated an ordered Ig heavy (H) chain
25
rearrangement of three elements, variable (V), diversity (D) and joining (J) gene regions 
(Alt et al, 1984). The heavy chain \x is expressed following successful rearrangement of 
Ig heavy chain D and J regions at the pro-B cell stage, followed by the pre-B cell step of 
allelic exclusion, which is acheived by successful Vh-(D)Jh rearrangement. Allelic 
exclusion was first identified by work in Balb/c mice embryos which demonstrated that 
both homologous chi'osomes expressing Vh~(D)Jh form complete gene regions, 
although only one of two Ig H chains is expressed, the other failing to complete 
successful gene rearrangements (Hozumi and Tonegawa, 1976). This is possibly a result 
o f the random nature o f H  chain rearrangement, making it highly unlikely that both 
alleles would simultaneously make a productive Vh"(D)Jh rearrangement. In addition, 
the successful rearrangement of one allele may inhibit further Vh-(D)Jh rearrangements 
at the other allele. Recent evidence has suggested that developing B cells which make a 
productive Vh-(D)Jh rearrangement in the first instance will quickly move into the next 
stage of development, preventing any further Vh-(D)Jh rearrangement at the other allele 
(Chang et al, 1999).
B cell differentiation was first described in adult mouse bone marrow tissue (Hardy et 
al, 1991). Different cell surface markers are expressed on developing B cells in mouse 
and human although there are also some similarities (Ghia et al, 1998). The 
phosphotyrosine phosphatase B220, an isoform of CD45, is found on the pro-B cell 
surface, as are CD43 and CD 19, at an early stage of development. Terminal 
deoxynucleotide transferase (TdT), is found in the nucleus at this stage. TdT is an 
intranuclear enzyme which is expressed during H chain V region gene rearrangement 
and works in tandem with recombinase activating gene (RAG) 1 and RAG 2  to regulate 
an ordered sequence of gene rearrangements at the Ig loci. Developing B cells gradually 
decrease TdT and CD43 expression while increasing B220. The differentiating pro-B 
cell becomes a pre-B-I cell, which initiates H-chain rearrangement by binding a D gene, 
the TdT-formed extra nucleotide (N) region and a J region. In forming a DNJh gene; the 
developing B cell enters the pre-B-II stage and increases in size. A V region gene is then
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joined to form a VrN-DNJh gene which is capable of producing a p-H chain. In the 
endoplasmic reticulum (ER) in some pre-BI and in most large pre-BII cells, Vpre-B(l/2) 
and ^ 5  (murine) or 7,5/14.1 (human) are expressed. These Ig like proteins are able to 
bind together via an extra p strand located in the Vpre-B chain to form a surrogate light 
chain (SLC) (Minegishi et al, 1999). In mice, the 75 chain is encoded by one gene, 
whereas the V pre-B chain is encoded by two genes. Mutational studies of Vpre-Bl 
homozygous knockout mice show that either isoform of the Vpre-B chain can interact 
with 75 to form the SLC in B cell development (Martensson et a l, 1999). Once formed, 
the SLC binds to the newly-formed p-H chain, displaces the ER chaperone binding 
protein BiP from the heavy chain and forms a complex in association with a signal 
transducing heterodimer consisting of two Iga  and IgP subunits, CD79a and CD79b. 
The complex leaves the ER with an a p  heterodimer flanking each side o f the SLC-heavy 
chain arrangement and translocates to the cell surface where it is expressed as a pre-B 
cell receptor (BCR). In some pro-B or pre-BI cells, surrogate light chains translocate to 
the cell surface without p-H chains and interact with different molecular weight 
glycoproteins to form complexes which may function as receptors. An example of tliis is 
their expression on the surface of pro-B cells in association with the integral membrane 
protein, calnexin (Nagata et a l, 1997). The functions o f this and other such receptor 
complexes have yet to be determined (Karasuyama et al, 1993;Sanz and de la Hera, 
1996).
The role o f the pre-BCR is not clearly defined, however expression at the cell surface 
enables the B cell to enter the cell cycle, expand and divide. Failure of pre-BCR 
expression can block finther development of B cells. This can be observed partially in 
75“/" mice and completely in common variable immunodeficiencey (CVTD) in humans 
(LeBien, 1998) The next step is driven by the transition o f large mitotic pre-BII cells to 
small resting pre-B-II cells (Figure 1.1). This involves the rearrangement of k  L-chain 
genes which in most cells will lead to the production of a ic chain. Those wliich have 
non-productive rearrangements, may go on to rearrange and produce 7 L-chains. When
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a cell has formed a complete in-phase k  or 7 gene it can express an L-chain which can 
associate with an H chain and the Iga/Ig(3 heterodimer complex and be processed to the 
cell surface as a complete BCR called surface immunoglobulin (slg)-M (Figure 1.1) 
(Melchers et al., 1995).
1.1.2 Receptor Editing Events
Emerging B cells are subject to challenge by auto antigens which can activate the BCR. 
The fate o f B cells at this stage is determined by positive or negative selection. Positive 
selection occurs when the BCR is altered by receptor editing, is no longer receptive to 
autoantigen challenge and the B cell is able to continue its development. Successful 
receptor editing is achieved by establishing tolerance to auto antigens through the 
upregulation o f RAGl and RAG2 expression, leading to the induction of secondary L- 
chain rearrangements and the replacement of the autoreactive BCR. By altering the 
antigen binding regions of IgM, this process enables immature B cells to avoid reacting 
with autoantigens. Due to the short life span of the immature B cell, if the IgM fails to 
lose specificity to autoantigen binding over a certain time, the B cell will undergo 
negative selection and die through apoptosis. A recent study on transgenic mice which 
expressed green fluorescent protein (GFP) under the regulation o f RAG measured the 
expression o f RAG tliroughout B cell development and reported GFP expression in all 
immature B cells in the bone marrow and spleen. It was proposed from this study that 
immature B cells which do not undergo autoantigen challenge decrease RAG levels and 
accelerate immediate B cell development to the stage of high IgM expression. B cells 
which are engaged by autoantigen arrest cell development at a stage where IgM levels 
are low and RAG levels are high, to increase editing efficiency. In addition, low levels of 
autoantigen challenge may stimulate editing without increasing RAG expression by 
slowing development from the RAG-expressing immature B cell in the bone marrow to 
the mature B cell in the spleen which does not express RAG (Yu et al., 1999). Immature 
murine B cells which exist in the bone marrow benefit from a bias in BCR signalling
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which inhibits autoreactive deletion and promotes the induction of RAGl and RAG2. 
Immature B cells which have left the bone marrow and entered into the periphery lose 
the BCR signalling bias and undergo apoptosis (Sandel and Monroe, 1999). This bias 
may be a result of phosphatidylinositol bis phosphate (PIP2) hydrolysis which generates 
the second messengers, diacylglycerol (DAG) and inositol 1 ,4,5 -trisphosphate (IP3) 
(Bijsterbosch et al., 1985). IP3 is known to play an important role in mobilising calcium 
from internal stores and DAG can activate several isotypes o f protein kinase C (PKC) 
such as the convential PKC-a,-p and -y as well as the novel PKC-5 and -e (Newton,
1995). PKC activation has been reported to rescue immature B cells fi'om apoptosis. 
Furthermore, PKC depleted or inhibited mature B cells are driven into apoptosis 
suggesting an important role for this kinase in the negative selection o f immature B cells 
(King et al, 1999). Owing to the diversity o f H and L chain rearrangement, at the point 
of sIgM expression, B cells are committed to an antigen binding specificity. Therefore, 
an individual B cell can only produce one type of antibody (Burnet, 1959) Furthermore,
antibody produced by immunoglobulin can only induce production o f antibodies of the 
same specificity, work on healthy mice showed that injections o f IgM antibodies 
induced direct plaque-forming cells o f the same specificity as the injected antibody 
(Forni et al, 1979). At this stage, B cells are termed slgM^ or virgin cells and are ready 
to enter the antigen dependent phase of development.
1.1.3 Antigen-Dependent B Cell Development
Immature cells which have not been subject to autoantigen challenge or have undergone 
successfiil receptor editing increase surface levels of IgM and enter the antigen 
dependent stage of B cell development (Figure 1.1). This is followed by the appearance 
o f IgD in low amounts. At this stage, B cells enter a transitional state and migrate from 
the bone marrow to the periphery. If there is no further autoantigen challenge then the B 
cells develop further, and the levels of IgD are increased and exceed the levels of IgM. 
The B cells progress to the mature stage of development and migrate to secondaiy
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lymphoid organs, such as the spleen or lymph nodes. B cells enter the secondary organs 
through a multi-step process which involves L-, P- and E-selectin-mediated attachment 
and rolling (Montoya et al., 1999), activation of chemokines, adhesion by activated 
integrins and finally, transendothelial migration (Butcher and Picker, 1996). The 
recruitment of B cells is achieved by the chemoattractant properties of small secretory or 
membrane-bound proteins (6-14kDa) called chemokines. The interaction of B cells with 
chemokines enables their entry into secondary lymphoid organs tlirough high endothelial 
venules in lymph nodes or the endothelial cell layer lining sinuses in the spleen. 
Chemokines found on lymph nodes and spleen include; liver and activation-regulated 
chemokines (LARC), macrophage derived chemokine (MDC), stromal cell-derived 
factor (SDF-1), secondary lymphoid tissue chemokine (SLC), Chemokine (CK) P-11, 
macrophage colony inhibitory factor (MCIF) and thymus-expressed chemokine TECK 
(Kim and Broxmeyer, 1999).
When presented with antigen, the mature B cell can respond in two ways. The first 
response involves a rapid clonal expansion and plasma-cell differentiation to give rise to 
a high antigen-affinity antibody producing cell. Mature B cells which do this are found in 
concentrated T lymphocyte areas such as the periarteriolar lymphoid sheath (PALS) of 
the spleen and are activated by interaction with CD4^ T-helper (h) cells (Tarlinton,
1998). The second response is a complex process which involves rapid clonal expansion 
o f the B cell within the microenvironment of the germinal centre reaction to form affinity 
matured, long-lived B cells called memoiy B cells (Hess et al., 1998).
1.1.4 The Germinal Centre Reaction
Germinal centres are areas found within B cell rich areas o f secondary lymphoid organs. 
Antigen activated B cells are recmited to germinal centre reactions by TH cells which 
have been primed and activated by interdigitating cells (IDC) found in the PALS. The 
activated cells then migrate to primary follicles where they undergo rapid clonal
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expansion, forming a secondary follicle called the germinal centre. The germinal centre 
polarizes into 'light' or 'dark' zone regions, the former is rich in follicular dendritic cells 
(FDC) and macrophages, while the latter is adacent to T-cell rich regions and contains 
rapidly dividing B cell blasts called centroblasts. In the dark zone, centroblasts clonally 
expand and diversify their BCRs by somatic hypermutation o f V regions and receptor 
editing. Re-expression o f RAGl and RAG2 in germinal centre B cells has been 
demonstrated, suggesting that receptor editing is achieved by the same mechanisms by 
which B cell tolerance is achieved during the emergence o f slgM"  ^ cells (Han et al.,
1996) After this phase o f development the cells enter a dormant phase and are defined as 
centrocytes. The centrocytes express their altered BCRs and enter the light zone where 
they encounter challenge by FDC-bound antigen. If BCR binding to the antigen is 
insufficent, the centroblast undergoes apoptosis and is quickly removed by macrophage 
clearance. Centrocytes which demonstrate high affinity binding to the antigen undergo 
positive selection. This event leads to one of two fates; the centrocyte may re-enter into 
the dark zone for further modification and selection, or secondly, the cell leaves the 
germinal centre reaction and remains in the secondary lymphoid tissue often for many 
years as a memory B cell (Lane, 1996).
Re-exposure to the antigen leads to another phase of development in T and B cell rich 
regions o f secondary lymphoid organs. In the T cell rich regions, memoiy B cells 
undergo rapid clonal expansion and develop into antibody-forming plasma cells (AFCs) 
to give an increased response to the antigen which is greater than in the primaiy 
response. Re-activated B cells which enter the B-cell rich regions again enter the 
germinal centre and are processed by the same mechanisms as the primary response. 
Memory B cells can be divided by Ig isotype expression ie. IgE, IgG, IgA, or by 
antibody secretion. Non-secretory memory B cells are thought to act as precursors for 
the rapid antibody secreting response and in antigen processing and presentation for the 
secondary response. However, any mechanism which maintains non-secretory memory B 
cells has yet to be identified (McHeyzer-Williams and Ahmed, 1999).
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1.1.5 Transcriptional Regulation of B Cell Development
The signalling pathways and patterns of gene expression which control the maturation of 
plasma cells and memory B cells are many and well documented (Henderson and 
Calame, 1998;Hess et a l, 1998;Tarlinton, 1998). In particular, the B cell specific 
activator ptotein, Octamer (Oct) binding factor (OBF)-l which is also known as OCA-B 
or Bob-1 has a prominent role in the formation o f memory B cells. OBF-1 interacts with 
the Oct binding family o f transcription factors Oct-1 and Oct-2 to bind to the highly 
conserved octamer site of Ig promoters where it is involved in upregulating the 
transcripton o f Ig genes. Studies with OBF-1 knockout mice showed that it was not 
required for early transcription o f Ig genes or for B cell development, but was essential 
for the B cell response following antigen challenge, and was necessary for the foimation 
of germinal centres (Schubart et al., 1996). This is supported by recent evidence which 
has shown that in the absence of OBF-1, germinal centre formation is blocked 
completely but primary B cell follicles, the marginal zone and plasma cells are all intact. 
The failure o f germinal centre development was shown to be thi ough the inhibition of 
the capacity of OBF-1 to integrate BCR, CD40 ligand (L) and IL-4 mediated signals to 
the germinal centre reaction (Qin et al., 1998).
Another important transcription factor in the formation o f the germinal centre is the Ets 
transcription factor family member Spi-B. Spi-B is closely related to PU. 1, an Ets 
transcription factor which is essential for the production of monocytes and lymphocytes. 
Spi-B knockout mice show defective secondary responses to T-cell dependent antigen 
challenge and demonstrate a defect in germinal centre formation and maintainance (Su et 
a l, 1997). Spi-B activity is understoood to be regulated by BCR signal transduction, as 
is PU. 1. Both Ets trancription factors have recently been shown in knockout mice to be 
essential for normal BCR signalling events. Deletion of both genes leads to the fomation 
o f defective germinal centres and the reduced capacity of B cells to proliferate in
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response to IgM cross linking in vitro (Garret-Sinha et al, 1999). A further transcription 
factor, Spi-C has been identified, and although not involved in the formation of germinal 
centre reactions, may be responsive to BCR activity in peripheral B cells (Bemark et al, 
1999).
The transcription factor B cell lymphoma/leukemia (BCL) - 6  has been shown to act as a 
supressor of signal transducer and activator of transcription (ST AT) genes such as the 
IL-4-regulated protein, STAT6 . The BCL-6  gene is expressed in the germinal centre of 
human tonsils, although not in plasma cells. The function o f BCL- 6  is not fully 
understood, however it appears to have an important role in B cell development (Dent et 
a l, 1997). Mice deficient in RAGl were reconstituted with bone marrow cells from 
BCL- 6  deficient mice and were found to have normal levels o f B cells in primary 
lymphoid tissue. In addition, these mice were able to produce IgG antibodies which were 
specific for T-cell dependent antigens, but did not have any germinal centres. Lack of 
BCL-6  did not affect levels o f plasma cells indicating that BCL- 6  expression is 
specifically required for germinal centre formation (Fukuda et a l, 1997). In direct 
contrast to BCL- 6  is the tumour necrosis factor (TNF) family member OX40-ligand 
(OX40L) which is expressed by activated B cells and CD40-activated human dendritic 
cells (Oshima et al, 1997). The receptor for OX40L is 0X40 (CD 134) and is expressed 
on activated T cells. Transgenic mice which constitutively expressed OX40L on 
dendritic cells showed increased levels o f CD4^ T cells within splenic B cell follicles in 
comparison with wild type mice (Brocker et al, 1999). A block of the OX40/OX40L 
interaction in mice lead to a diminution of CD4"^ T cells in B cell follicles and, as a 
result, impaired formation of AFCs. Both germinal centre and memory cell formation 
were unaffected (Stuber and Strober, 1996). Conversely, in transgenic studies, BCL-6  
knockout mice failed to develop germinal centres but formed normal AFCs. These 
findings demonstrate that the developmental pathways which lead to the formation of 
germinal centres and AFCs become independent o f each other after a stage of 
development, although the critical stage is as yet, undefined.
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Other important transcription factors in B cell development include; Early B cell Factor 
(EBF), Ikaros, E2A proteins and Pax5. EBF is expressed during primary B cell 
development and is essential for the progression of pro-B cell to pre-B cell development. 
EBF knockout mice show pro-B cells which lack DJh rearrangements, Iga  and p, 
surrogate light chain and RAG-1 and RAG-2 expression, therefore EBF is an essential 
early-stage B cell transcription factor (Hagman et al., 1993;Lin and Grosschedl, 1995). 
The Ikaros gene encodes a protein which can form homo- or heterodimers which bind 
DNA and activate transcription (Sun et al, 1996). Ikaros is an important protein 
throughout B cell development and its expression appears to increase as B cells mature. 
Ikaros knockout mice showed a complete block in early B cell development, prior to the 
pro-B cell stage. Ikaros is a ubiquitous transcription factor in B cells and potential sites 
for Ikaros regulation include the genes encoding RAGl, the IL-2 receptor, Iga, 75 and 
TdT (Georgopoulos et al, 1997;Sun et al, 1996) Ikaros has been shown to interact with
a similar lymphocytic transcription factor, Aiolos, in the regulation of lymphoid 
differentiaiton (Morgan et al., 1997).
E2A is a widely expressed transcription factor which is part of a larger family of 
transcription factors that share homology in their DNA binding domains and in their 
helix-loop-helix binding motif, and as such are called bHLH proteins (Kadesch, 1992). 
The expression of E2A appears to be specific and essential for B cell development, B 
lymphopoiesis is completely blocked in E2A knockout mice, whereas production of 
other haematopoietic lineages, including T cells, are unaffected (Zhuang, Soriano and 
Weintraub, 1994). The Pax5 gene encodes B cell specific activator protein (BSAP) 
which is important for the progression o f B cell development fi'om the pro-B to pre-B 
stage of development (Busslinger and Urbanek, 1995). Pax5 knockout mice show pro-B 
cells which have completed DJh rearangements, express c-kit, B220, CD43 and 
receptors for IL-7 although CD 19 is absent and VhDJh recombination is markedly 
reduced. As a result, B cell development in Pax5 knockout mice is arrested at the pro-B
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cell stage (Urbanek et al, 1994). A recent report showed that Pax5 was essential not 
only for the progression o f pro-B cell development to the pre-B cell stage but vital for B 
cell lineage commitment. Pro-B cells derived from Pax5"/" mice were shown to 
differentiate into functional lymphoid or myeloid lineages, following treatment with the 
appropriate cytokine. An example of this was the culture of Pax5"/" pro B cells with 
macrophage colony-stimulating factor (M-CSF)-producing ST2 cells which led to the 
production o f mature macrophages. The restoration of Pax5 activity using retroviral 
transduction prevented the pro-B cells from differentiating into other hematopoietic 
lineages, therefore showing that Pax5 is essential for B cell commitment (Nutt et al.,
1999).
1.2 BCR SIGNALLING
When challenged by antigen or anti-receptor antibody, the BCR aggregates and 
stimulates signal transduction through the Iga and IgP subunits (see Figure 1.2). Critical 
to the understanding o f BCR signalling has been the identification o f immunoreceptor 
tyrosine-based activation motifs (IT AMs) within these subunits (Reth, 1989). The IT AM 
motif, D/E-X7-D/E-X2-Y-X2-L-X7-Y-X2-L/I is found in the cytoplasmic domains of the 
multi-chain immune recognition receptor (MIRR) family, which as well as the BCR, 
includes the T cell receptor (TCR), and receptors for the Fc portions of IgG (FcyRI, 
FcyRIIA and C, FcyRIIIA) and IgE (FceRI) as members (Keegan and Paul, 1992). BCR 
aggregation leads to the recruitment of three distinctive groups o f non-receptor protein 
tyrosine kinases (PTKs) to the ITAM motifs. Src-family kinases consisting of Lyn, Fyn, 
Blk and Fgr, Syk/ZAP-70 kinases such as Syk, and Tec kinases, including Bruton's 
tyrosine kinase (Btk), Itk and Tec activate IT AMs by phosphorylating tyrosine residues. 
PTKs then interact with the activated IT AMs via Src Homology 2 (SH2) domains 
leading to PTK phosphorylation and resulting downstream tyrosine phosphorylation 
events. This mutual phosphoiylation serves two purposes; firstly, signal amplification 
thi'ough a positive feedback effect created by the cumulative recmitment o f PTKs and
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secondly, signal diversification through the recruitment o f multiple PTKs and the 
subsequent activation of their specific downstream signalling pathways. Signalling 
diversity in the BCR enables the B cell to undergo the developmental progressions of 
receptor editing, proliferation, maturation, survival and apoptosis (Benschop and 
Cambier, 1999;Tamir and Cambier, 1998)
Activation o f the BCR leads to aggregation of the receptor and increased 
phosphorylation of tyrosine residues within the IT AMs of Iga and IgP. This is achieved 
through the recruitment of Src-family PTKs which also become phosphorylated at the 
BCR receptor. Important to Src-family PTK phosphorylation is the role of the 
transmembrane tyrosine phosphatase CD45, which regulates BCR signalling by 
dephosphorylating Iga, Igp and the negative regulatory regions of Src-kinases such as 
Lyn (Satterthwaite and Witte, 1996). Another cell surface molecule which is involved in 
Src-mediated BCR signalling is CD 19, Interactions with downstream molecules such as 
phosphatidylinositol (PI) 3-kinase and the adaptor protein Vav define CD 19 as an 
important effector molecule in BCR signalling (Sato et al, 1997;Weng et al, 1994). A
recent study on CD 19 knockout mice showed a reduction in Lyn kinase activity, 
accompanied by a decrease in BCR phosphorylation when stimulated with anti-IgM 
antibody (Fujimoto et a l, 1999). This demonstrates that CD19 is able to further 
influence BCR signal transduction by regulating Src-family kinase activity.
1.2.1 Src -Family Activity
Src-family PTK activation results in the initiation of the p2F^® (Ras) pathway which 
leads to a series o f downstream tyrosine phosphorylation events thiough further PTK 
activation (Figure 1 .2 ). This is initiated by the recruitment o f the adaptor protein She. 
She binds the phosphorylated IT AM motif via its' SH2 domain and recruits another 
adaptor protein, again via SH2 domain interaction, called Gib2. Grb2  contains a Src
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Homology 3 (SH3) domain, which upon activation, recruits the GDP nucleotide 
exchange protein. Son of sevenless (Sos) (Li et al, 1993). Sos promotes GDP-GTP
exchange in the serine/threonine kinase Ras, via the activation of GTPase activating 
protein (GAP) and of the small GTP binding protein Rho (Boriak-Sjodin et al, 1998)
Ras is found at the inner surface o f the plasma membrane and upon activation forms an 
association with the cytoplasmic serine/threonine kinase Raf-1 and translocates the 
protein to the plasma membrane where it becomes phosphorylated. Activated Raf-1 then 
phosphorylates two mitogen activated protein kinase kinases (MAPKK) also referred to 
as MEKl and MEIC2. The activated MEKs phosphorylate serine and threonine residues 
in two MAP kinases (MAPK), termed extracellular signal-related kinase (ERK) 1 and 2 
or p42 and p44, respectively (Hashimoto et al, 1998). Activated MAP-kinases can then
phosphorylate and regulate cytosolic proteins such as cytoskeletal proteins or, after 
prolonged activation, dimerise and translocate to the nucleus where phosphorylation of 
transcriptional regulatoiy proteins such as cyclic-AMP response element binding protein 
(CREB), c-Fos, c-Jun and members of the Ets family can occur (Cohen, 1997). 
Additionally, MAP kinase can activate other kinases such as the p9 0 S6 ’^®k 
serine/tlireonine kinase which is involved in the regulation o f protein synthesis (Campbell 
et al, 1998).
1.2.2 The Role of Syk
Kinetic studies have shown that, upon BCR aggregation, activation o f the Src-family 
PTKs Lyn and Blk occurs before the increased activity of Btk and Syk, indicating that 
Src-family activation may be responsible for the activation o f additional substrates 
(Saouaf et a l, 1994). Therefore, Syk activation may be achieved by recmitment to 
IT AMs which have already been phosphoiylated through interactions with Src-family 
kinases. In T-cells, there is evidence to suggest an activating function o f Syk which is 
independent o f Src-PTK through studies involving a chimeric transmembrane protein 
model o f the TCR in human Jurkat T cells. This model consisted o f a CD 16 extracellular
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domain and either a Src-family or Syk kinase intracellular domain wliich were activated 
by anti-CD 16 antibody-mediated clustering o f the chimeras. Chimeric proteins which 
contained a Src-family intracellular domain failed to respond; however Syk containing 
chimeras initiated calcium mobilization indicating a positive response to antibody- 
induced stimulation (Kolanus et al, 1993). In addition, a recent study demonstrates that 
BCR aggregation induces the phosphorylation and activation o f the serine/threonine 
kinase p70^^^ in wild type and in Lyn-deficient DT40 B cells, but not Syk-deficient cells, 
where phosphorylation is blocked (Li et al, 1999). By way o f contrast, loss of Lyn in 
DT40 B cells demonstrates a profound decrease in BCR-induced Syk activation (El- 
Hillal et al., 1997). This information suggests that some Syk phosphorylation events on 
IT AM motifs in T cells can occur independently of Src-family and other, downstream 
PTKs in B cells, however Src-family PTKs clearly have a significant role in Syk 
activation at IT AM motifs in B cells. The activation o f Syk leads to the tyrosine 
phosphorylation of phosphatidylinositol-lipid-specific phospholipase Cy (PLCy), which 
occurs by recruitment to phosphorylated Syk and binding via SH2 domains, as well as 
interaction with activated Btk (Tamir and Cambier, 1998). The most common PLCy 
enzyme in B cells is PLCy2 and, following its recruitment to the membrane and 
subsequent activation, mediates the hydrolysis o f PIP2, and the resultant production of 
DAG and IP3 (Figure 1.2 and described earlier).
1.2.3 The Role of Btk
Btk activation is, like Syk, stimulated through Src-family kinase-mediated 
phosphorylation. Studies in human COS B cells over-expressing Btk and Src-family 
kinases show that BCR stimulation leads to Src-PTK-mediated phosphorylation and 
increased activity o f Btk, up to five times greater than when Btk is expressed alone 
(Rawlings et al., 1996). Studies in Lyn-deficient DT40 B cells found that initial BCR- 
induced Btk phosphorylation was significantly reduced before levels o f phosphorylation 
gradually returned to wild-type amounts. Conversely, BCR activation in Syk-deficient
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DT40 cells showed initial Btk phosphorylation in common with wild-type cells, but this 
decreased over a prolonged period of activation. The failure of Lyn"/Syk“ DT40 cells to 
phosphorylate Btk over any length o f time following BCR activation suggests that while 
either Lyn or Syk alone are capable of phosphorylating Btk, both are required to exert 
complete phosphorylation of Btk in BCR signalling (Kurosaki and Kurosaki, 1997). 
Therefore, the activation o f Btk in BCR signalling may be sustained by two stages of 
tyrosine phosphorylation, the first stage is the initial stage generated through the rapid 
phosphoiylation and activation of Src-family members (namely Lyn) and a second stage 
involving a long term activation mainly through interactions with Syk (Kurosaki, 1999). 
Further insight into the mechanisms involved in the activation of Btk can be drawn from 
a recent study of CD 19 knockout mice. This demonstrated that BCR-stimulated CD 19 
phosphoiylation initiates Btk activation through the recruitment and activation o f PI-3 
kinase. A product of PI3-kinase activation, PI 3,4,5-trisphosphate, may then recruit Btk 
to the phosphoiylated IT AM motif environment by binding its pleckstrin homolgy (PH) 
domain (Buhl and Cambier, 1999). The role of Btk in BCR-mediated signalling is also 
important in B cell development. The B cell immunodeficiencies X-linked 
agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice 
are a result of Btk abnormalities. XLA is characterised by the arrest o f B cell 
development at the pre-B cell stage, while Xid mice show, amongst other aberrations, 
decreased production of mature B cells (Satterthwaite et al, 1998).
1.2.4 The Activation of PLCy2
The activation of PLCy2 is initiated by Btk and Syk which phosphorylate tyrosine 
residues on PLCy2 SH2 domains (Figure 1.2). This was identified in DT40 B cells which 
were Btk deficient. Tyrosine phosphorylation o f PLCy2 upon BCR stimulation was 
reduced leading to the loss o f PI hydrolysis and calcium mobilisation (Takata and 
Kurosaki, 1996). As Syk and Btk are recmited to the IT AM motifs by different 
mechanisms, a shared protein or complex is required to co-localise both PTKs and
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activate PLCy2. In B cells a candidate molecule is B cell linker protein (BLNK), also 
termed Src homology (SH2) domain containing leukocyte protein o f 65kDa (SLP-65), 
which shows homology to a signalling element of the T cell receptor, SLP-76 (Wienands 
et al., 1998). Studies in DT40 B cells in wliich BLNK was over-expressed showed an 
increased tyrosine phosphorylation of PLCyl and 2, and transcriptional activation of 
nuclear factor of activated T cells (NF-AT). BLNK-deficient cells showed the opposite 
effects. Further co-expression experiments between BLNK and Syk revealed an
induction o f tyrosine phosphorylation and activation of PLCy suggesting that BLNK 
links BCR-activated PTKs with PLCy-driven signalling pathways (Fu et al., 1998). 
Figure 1.2 describes a possible mechanism of PLCy2 activation. Activated Syk 
phosphorylates BLNK and initiates its recruitment to the membrane, where it lies 
proximal to the IT AM motif region. Phosphorylated BLNK recruits PLCy2 to the 
membrane and to activated Syk, where it becomes tyrosine phosphorylated. Btk, present 
at the membrane as a result of the earlier interaction between PI 3,4,5-P] and its PH 
domain, phosphorylates other tyrosine residues, thereby fully activating PLCy2 (Ishiai et 
a l, 1999).
The products o f PLCy2 catalytic activity, the second messengers IP3 and DAG, generate 
an increase in intracellular calcium and activation of PKC. Increased calcium leads to the 
activation o f calmodulin-dependent protein kinase II and the serine/threonine 
phosphatase calcineurin. The activation of calcineurin leads to the activation of the 
transcription factor; NF-AT. Despite their name, NF-AT proteins are found not only in 
T cells, but in other immune system cells, such as B cells, mast cells, basophils and 
macrophages. NF-AT proteins consist o f a cytosplasmic component and a nuclear 
component. When calcineurin activates the cytoplasmic NF-AT it tranlocates to the 
nucleus where it combines with the nuclear NF-AT, which was identified as the activator 
protein (AP)-l complex of Fos and Jun family members (Jain et a l, 1992). The activated 
NF-AT complex regulates transcriptional events, such as the expression o f IL-2 (Rao et 
al, 1997). Activated PKC isoenzymes are serine/threonine kinases which are recmited to
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the inner membrane on activation and anchored by receptors for activated C-kinase 
(RACKs), perinuclear binding protein PICKl and cyclic adenosine monophosphate 
(cAMP) dependent A-kinase anchoring proteins (AKAPS). In BCR signalling, DAG and 
calcium-activated PKC isoforms are most likely to be bound to RACKs (Liu and 
Heckman, 1998). The regulatory mechanisms o f the effects o f PKC isoforms on cell 
growth, differentiation, and gene expression as a result of BCR signalling or any other 
system is largely unknown. PKCa, however, has been shown to directly phosphorylate 
and activate Raf-1 in a Ras-GTP-Raf-l complex, indicating that PKCa may serve as a 
secondary activation kinase to the Ras signalling pathway (Kolch et al, 1993;Marais et 
a l, 1998). Studies in DT40 B cells which were deficient in PLCy2 showed inliibition of 
MAP kinase following BCR aggregation, further supporting a role for PKC in the Ras 
pathway (Hashimoto et al, 1998) In addition, PKC0 has been shown to activate the
stress activated protein kinase (SAPK), c-Jun N-terminal kinase (INK), through 
interaction with calcineurin (Werlen et al, 1998).
1.3 CYTOKINES AND THEIR RECEPTORS
The role o f cytokines and cytokine receptor signalling is of paramount importance to the 
development and function o f B cells. Cytokines are small pleiotropic proteins between 8 - 
80kDa wliich stimulate auto- or paracrine effects on lymphoid cells. Cytokines include; 
Interleukins (XL), interferons (IFN), colony stimulating factors (CSF), tumour necrosis 
factors (TNF) and can act in synergy to tightly regulate the behaviour o f B cells and 
other cells of the immune system. Cytokines are involved in the differentiation, 
expansion and survival of B cells and act by binding specific cell-surface receptors which 
leads to receptor tyrosine phosphorylation and initiation of signal transduction pathways 
(Baird et al, 1999). The obseiwed effects of B cells at the site o f an immune response are 
generally a result of the combination of cytokines acting in a synergistic and/or inhibitory 
way. Examples of inhibitory combinations include IL-4 and IFNy (Rabin et al, 1986) 
and IL-4 and IL-2 (Jelinek and Lipsky, 1988).
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1.3.1 The JAK/STAT Pathway
Cytokine receptors are linked to a family of PTKs called the Janus kinases (JAKs) 
(Wilks et a l, 1991). Cytokine receptor ligand binding causes a dimérisation of the 
receptor subunits, leading to the activation o f JAKs and receptor phosphorylation. JAK 
family members include JAK 1-3 and Tyk2, all of which are broadly expressed, with the 
exception o f JAK3, which appears to be restricted to lymphoid and myeloid cells (Kane 
and Reddy, 1994). JAKs are the linking factor between receptor ligation and tyrosine 
phosphorylation of signalling proteins, in particular, a cytoplasmic family of 
transcriptional activators called the signal transducers and activators o f transcription 
(STATs). STAT family members number seven in total; ST AT 1-4, STATS A, STAT5B 
and STAT6 , all of which contain a carboxy-terminal SH2 domain, an SH3 domain and a 
conserved DNA binding region. Phosphotyrosines on cytokine receptors are bound by 
STAT proteins via their SH2 domains. STATs are tyrosine-phosphorylated and form 
homo or heterodimers with other STAT proteins tlirough SH2-tyrosine phosphorylation 
interactions. Dimerised STATs then translocate to the nucleus where they bind specific 
DNA sequences. These sequences are similar to the nucleotide consensus motif 
TTNCNNNAA found in the regulatory element of the promoter o f IFN-y inducible 
genes called the gamma interferon activated site (GAS) (Karras et al, 1996). STATs 
binding to GAS sequences regulate gene expression (Chen et al, 1998) . In addition, 
some STATs also require serine phosphorylation for optimal transcriptional activation 
following stimulation with IFN-y (Darnell Jr., 1997). JAKs are capable of activating 
more than one distinct signal transduction pathway. The IL-2 driven activation of JAKl 
and 3 leads to the initiation of the Ras/MAPK pathway and the activation of STAT5a 
and 5b, respectively (Evans et al, 1995;0'Shea, 1997).
42
1.3,2 Negative Regulation of Cytokine-Induced Signalling
Recently, two different classes of negative regulators of cytokine-induced signalling have 
been reported. The first type have various names including; JAK-binding protein (JAB), 
suppressor of cytokine signalling (SOCS), STAT-induced STAT inhibitor (SSI), and 
cytokine-inducible SH2 domain containing protein (CIS) (Aman and Leonard, 1997). 
These inhibitor proteins act by binding to and blocking the kinase activity of JAKs and 
are activated by cytokines themselves, indicating they may constitute a negative 
feedback mechanism on cytokine signalling. A study of IL-2 signalling in human T cells 
and peripheral blood lymphocytes demonstrates a role for the SOCS-3 inhibitor protein 
in suppressing STATS phosphorylation and lymphocyte proliferation, mainly through its 
involvement with tyrosine phosphorylated JAKl and the IL-2 receptor (3 subunit 
(Cohney et al, 1999). Work done on primary human monocytes demonstrated that the 
inhibitory function of IFN on IL-4-stimulated STAT6  induction and gene expression was 
shown to be at least partly regulated by IFN-induced expression o f SOCS-1 
(Dickensheets et a l, 1999). A recent investigation of JAB activity in M l myelogenous 
leukemia cells identified a JAB binding site as a specific tyrosine residue (Y1007) in the 
activation loop o f JAK2. The study demonstrated that JAB bound this region via SH-2 
domain interaction, blocking JAK2 phosphorylation and its resultant activity (Yasukawa 
et al, 1999). The second class of inhibitory protiens are called protein inhibitor of 
activated STAT (PIAS) which bind to a specific STAT protein and block DNA binding 
and transcriptional activation by the formation of homo or heterodimers (Chen et al, 
1998). A study of IL- 6  induced STATl and STAT3 activation in murine myleoblast M l 
cells showed that PIAS3 bound to STAT3 and not STATl (Chung et al, 1997). 
Additionally, work on human Daudi B cells identified a STATl specific inhibitor PIASl 
which blocked IFN stimulation through STATl but not STAT2 or STAT3 (Liu et al, 
1998). Both these findings suggest that each STAT protein has a specific PIAS inhibitor.
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1.4 BL-4 AND THE BL-4 RECEPTOR
Interleukin-4 is a type 1 cytokine which is synthesised by TH2 cells, CD4^ T cells, 
basophils and mast cells (Nelms et al., 1999). IL-4 was first reported as a B cell growth 
factor (BCGF), distinct from IL-2 , in the supernatant o f phorbol myristate acetate 
(PMA)-treated murine EL4 thymoma cells, where it caused an enhanced proliferation of 
normal mouse B cells in response to anti-Ig antibodies (Howard et ai, 1982). In B cells, 
IL-4 stimulates a pleiotropic response which includes; the induction of cellular 
proliferation and differentiation (Keegan et al., 1994a), expression of class II major 
histocompatability complex (MHC) (Noelle et al, 1984), stimulation o f Ig class 
switching to IgE and IgG4 in human B cells or IgE and IgGl in mouse B cells (Gascan 
et al, 1991;Vitetta et a l, 1985), and the upregulation of the expression of the low 
affinity Fc receptor for IgE, CD23 (Bonnefoy et al, 1997a). Studies on concanavalin A 
(Con A)-stimulated spleen cells from IL-4 knockout mice showed diminished semm 
levels o f IgGl and IgE, when compared with wild type cells, although T and B cell 
development was normal (Kuhn et al, 1991). This obseivation was repeated in IL-4 
receptor (R)~a knockout mice which showed a similar decrease in IgGl and IgE 
production (Noben-Trauth et al, 1997). Mutations in human IL-4Ra have been linked 
to allergy and tliis has been investigated in studies measuring the signalling effects of BL- 
4 on mutated human EL-4 receptors which have been transfected into murine cells. 
Identification o f all allergy-linked IL-4Ra mutations may be required before these 
studies are able to generate further information (Wang et al, 1999).
The IL-4 receptor is broadly expressed on many haematopoietic and non-haematopoietic 
cell surfaces. It consists o f a main 140kDa BL-4Ra subunit which interacts with a 
64kDa Y chain (yc) that, in addition to EL-4, is common to the receptors of EL-2, EL-7, 
EL-9 and EL-15 (Raskin et a l, 1998) In humans and mice, mutations in yc lead to a
defective EL-2 receptor which profoundly diminishes levels of peripheral blood T cells 
and although B cells are produced normally, they are non-functional. This is a condition
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which occurs in males, and wliich without a bone marrow transplant, is fatal. The disease 
is termed X-linked severe combined immunodeficiency (XSCID) (Leonard, 1996). When 
IL-4 binds to its receptor it forms a complex with the IL-4Ra chain with which the yc 
chain then interacts and initiates intracellular signalling pathways (Figure 1.3) (Letzelter 
et al, 1998). The IL-4Ra subunit is not unique to IL-4, as EL-13 additionally binds IL- 
4Ra although it does not interact with yc, indicating an unique mechanism of action 
(Figure 1.3) (Lin et al., 1995). The IL-13Ra chain was identified following work on 
monocytic U937 cells which showed that EL-4 could induce ST AT6  tyrosine 
phosphorylation and DNA binding activity in the absence of yc, and in doing so, defined 
a 70kDa receptor component which could facilitate IL-4 signalling via STAT6  activation 
(Dawson et al, 1997). The cytoplasmic domain of IL-13Ra has recently been 
characterised, revealing that receptor signalling is mainly driven via Tyk2 activation 
(Orchansky et a l, 1999). Two types o f human IL-13 receptor chains have been cloned. 
The first receptor was cloned from the Caki-1 human renal carcinoma cell line and is 
called EL-13Ra. In addition, IL-13Ra was characterised and shown to have a 50% 
homology with the human IL-5Ra chain (Caput et al, 1996). The second IL-13 
receptor is identified as EL-13Ra' and was cloned from the human T-cell leukemia virus 
(HTLV)-l-infected MT-2 cell line, using murine IL-13R cDNA. The human IL-13Ra' 
receptor in common with the cloned mouse BL-13R, has no homology with any other 
cytokine receptors. This is in contrast to the IL-13Ra chain (Aman et al, 1996). Work 
done on Chinese hamster ovary (CHO) cells demonstrated that in cell types where yc is 
not expressed, the IL-4 receptor complex is made up of the IL-4Ra and the IL-13Ra' 
chain (Murata et al, 1998). In B cells, the main action of IL-4 on its receptor is to induce 
heterodimerisation o f the IL-4Ra chain with the yc chain, leading to the activation of IL- 
4R signal transduction pathways (Rammer et al, 1996).
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1.4.1 IL-4R Signalling Pathways
Activation o f the IL-4 receptor results in the activation of tyrosine kinases which 
phosphorylate protein substrates on tyrosine residues and initiate intracellular signalling 
cascades such as the PI-3 kinase or the previously described PLCy pathways (Figure 
1.3) (Miyajima et al., 1992). The IL-4 receptor does not have any endogenous kinase 
activity therefore requires the involvement of receptor-associated tyrosine kinases to 
initiate signalling, namely JAK kinases (Taniguchi, 1995). Thiee members o f the JAK 
kinase family; JAKl, JAK2 and JAK3 are activated in response to IL-4R ligation. JAKl 
in most cell lines and JAK2 in certain cell lines associate with the IL-4Ra subunit 
(Miyazaki et al, 1994;Murata, Noguchi and Puri, 1996). A study of a female human 
with autosomal recessive SCID which showed an absence of JAK3, and the findings that 
JAK3 knockout mice display immunodeficiencies similar to XSCID, demonstrate that 
JAK3 is associated with the yc chain (Nosaka et al, 1995;Park et al, 1995;Russell et al, 
1995). JAKl and 3 activition leads to the recruitment and activation of STAT6  which is 
essential for the induction of several IL-4 responsive genes, such as CD23 and MHCII 
(Kaplan et al, 1996;Shimoda et a l, 1996). STAT6  homodimers translocate to the 
nucleus where they bind GAS sequences, in particular the nucleotide sequence 
TTCCANGGAA, and activate transcription (Ihle, 1996). How STAT6  or STATs in 
general are able to activate transcription is unclear although it is thought that activated 
STATs may form complexes with other transcriptional factors in the nucleus such as 
with nuclear factor-xB (NF-kB) (Shen and Stavnezer, 1998) In nematode pre-infected
STAT6  knockout mice, IL-4-induced up-regulation of MHC Class II expression, CD23, 
IgE and IgGl were all profoundly reduced. In addition, IL-4-supported T and B cell 
proliferation were diminished (Takeda et a l, 1996) A recent study o f IL-4R stimulation
in the murine pro-B cell line Ba/F3 and peripheral human T cells showed that in addition 
to STAT6  activation, IL-4R heterodimers containing yc phosphorylate tyrosine residues 
of both STAT5a and 5b. This demonstrates that IL-4R signalling can follow several 
different transduction pathways, depending on the components of the receptor complex
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(Lishke et al, 1998). Further to this study, mutated human IL-4R subunits stably 
expressed in Ba/F3 cells were used to establish that disruption of a proline rich 'boxl' 
motif in either the IL-4Ra or yc subunit abolished JL-4-induced tyrosine 
phosphorylation of JAKl and JAK3. These mutations also blocked IL-4-induced STAT5 
activation and cell proliferation indicating that either subunit may activate STAT5 
activity via JAKl and JAK3 following IL-4 stimulation though a specific cytoplasmic 
domain (Friedrich et al, 1999). IL-4R-induced STAT5 activity has also been reported in 
primary human B cells (Rolling et al, 1996).
1.4.2 IL-4R Interactions with 1RS
Another signalling component affected by IL-4R activation was identified when a 170- 
kDa phosphoprotein was found to be specifically phosphorylated by IL-4 induced 
signalling. This protein was called the IL-4 phosphorylation substrate (4PS) and shown 
to be related to insulin receptor substrate (IRS)-l, a substrate phosphorylated following 
treatment o f non-haematopoietic cells with insulin or insulin-like growth factor (IGF)-l. 
The homology between 4PS and IRS-1 was so high that 4PS was renamed as 1RS-2. 
Stable transfectants of the factor-dependent myeloid progenitor cell line 32D, which 
expressed IRS-1 or IRS-2, phosphorylated their particular substrate in response to IL-4 
treatment. In addition, IL-4 stimulation appeared to initiate cell growth suggesting that 
IRS-1 and 2 link IL-4R signalling pathways to cellular poliferation (Sun et al, 
1995;Wang et a l, 1993). Figure 1.3 shows that IRS-1 and 2 become associated with the 
IL-4Ra and yc chain following EL-4R activation. The IRS-1 and 2 activating region of 
the IL-4Ra is contained within a 1 2 0  base-pair cytoplasmic region between amino acids 
437 and 557. This region shows a considerable homology to sequences in insulin and 
IGF-1 receptors which activate IRS-1 and 2. Mutation of the tyrosine residue (Y497) in 
this region results in decreased proliferation in response to IL-4 and inhibition of 1RS-1 
and 2 phosphorylation. This activating region is termed the insulin IL-4 receptor, or the 
I4R motif (Keegan et al, 1994b). Although it appears that BL-4Ra is the predominant
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chain, studies have also shown that yc is required for tyrosine phosphorylation of 1RS 1 
and 2  suggesting that other cytokines which share this subunit may also use 1RS 
activation to promote cellular proliferation (Johnston et al, 1995;Russell et a l, 1993). 
The link between activation o f the IL-4 receptor and tyrosine phosphotylation of 1RS 1 
and 2 is thought to involve the JAK kinases. JAKs 1, 2 and 3 have been shown to 
directly phosphorylate IRS-1 and experiments on JAK-deficient human fibrosarcoma 
cells indicate that JAKl is essential for IL-4-driven stimulation o f 1RS-1 (Wang et al, 
1997;Yin et a l, 1995). IRSl and 2 contain several tyrosine phosphorylation sites which 
are bound by SH2 domains enabling interactions with other SH2 containing signalling 
molecules (Sun et al, 1991). Grb-2 interacts with phosphorylated IRS-1 and 2 leading 
to the activation o f the previously described Ras/MAP kinase signalling pathway, and 
interacts with the regulatoiy subunit o f PI-3 kinase activating an unique signalling 
cascade. However IL-4 is incapable of activating Ras in B cells and other hematopoietic 
tissues and therefore the single most important signalling pathway linked to IRSl and 2  
phosphorylation in B cells is the PI-3 kinase pathway (Welham et al, 1994).
1.4.3 The PI-3 Kinase Signalling Pathway
PI-3 kinase is a dual specificity lipid kinase which has several isoforms. PI-3 kinase 
catalyzes the addition o f a phosphate to the 3-position o f the inositol ring of 
phosphoinositides and can also phosphorylate serine and threonine residues. There are 
four different lipid products generated by the lipid-phosphoiylating activity of all PI-3 
kinase isoforms; phosphatidylinositol 3-phosphate (PIP), PI-3,4-P%, PI-3 ,5 -P2 and PI- 
3,4,5-P] (PIP3) (Rameh and Cantley, 1999). Nine isofoims have been identified in 
mammalian cells and they are grouped into thi'ee classes with respect to their activity and 
structural characterisitcs (Domin and Waterfield, 1997). Of the PI-3 kinase isoforms, 
only one is activated in response to IL-4, and is described in Figure 1.3. This particular 
complex consists o f an 85kDa regulatory subunit (p85) and a llOkDa catalytic subunit 
(pi 10). The p85 subunit contains two SH2 domains in the C-terminus and an N-terminal
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SH3 domain and is an adaptor molecule which links the p i 10 catalytic subunit to 
tyrosine phosphorylated proteins. IL-4 receptor activation therefore recruits p85 to 
tyrosine phosphorylated IRS-1 and 2 via SH2 domain interaction. This interaction 
results in a conformational change in the PI-3 kinase complex and leads to the activation 
of p i 10. The activated p i 10 subunit has the capacity to phosphorylate membrane lipids 
as well as serine and threonine residues (Dhand et al, 1994). A recent study investigated 
the role o f PI-3 kinase in tL-4 receptor signalling using the pro B cell line Ba/F3. Over 
expression o f the proto-oncogene c-Cbl enhanced the mitogenic signalling and survival 
effects of IL-4, which were blocked when cells were treated with the PI-3 kinase 
inhibitor Wortmannin (Ueno et al, 1998). In addition, c-Cbl has been reported to 
function as a ligand for the SH3 domains o f signalling molecules as well as interacting 
with Grb2 and PI-3 kinase in Jurkat T cells (Meisner et al, 1995). These studies suggest 
that c-Cbl may link phosphoiylated IRSl and 2 with PI-3 kinase signalling pathways. 
When PI-3 kinase is activated it immediately generates PIP2 and PIP3 . These products 
activate the intracellular kinases PKC(!^  and Akt kinase, otherwise known as protein 
kinase B (PKB), both of which have important roles in cell survival (Franke et al, 1997)
The activation of PKB is dependent on 3-phosphinositide-dependent protein kinase 1 
(PDKl) and leads to the serine phosphorylation and resultant inactivation o f glycogen 
synthase kinase -3 (GSK-3) (Alessi et a l, 1997). A study in hematopoietic cells 
demonstrated that Wortmannin blocked the capacity o f IL-4 to prevent apoptosis, 
further underlining the importance of PI-3 kinase in EL-4 mediated signalling (Zamorano 
et al, 1996).
1.4.4 Regulation of IL-4R Signalling by SHP and SHIP
Tyrosine phosphorylation events driven by IL-4 are modulated, like other cytokine 
signalling, by the dephosphorylating actions of phosphotyrosine phosphatases (PTP). 
Important to EL-4 signalling are the SH2-containing phosphatases SHP-1, SHP-2 and 
the SH2 -containing inositol-5-phosphatase (SHIP) (Scharenberg and Kinet, 1996). SHP-
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1 and 2 have a high degree of homology to each other and share two SH2 domains 
found in the N-terminal region whereas SHIP has one SH2 domain but two SH3 binding 
motifs. These domains are important in linking SHP-1/2 and SHIP to phosphorylated 
molecules in order that they may dephosphoiylate them. In B cells this involves a low 
affinity receptor for IgG called FcyRIIbl, which can be activated along with sig and 
inhibits B cell proliferation, and a integral membrane protein called paired 
immunoglobulin-type receptor B (PIR-B) which is activated when co-ligated to the BCR 
(Ashman et al, 1996;Blery et a l, 1998). The SH2 domains o f SHP-1/2 and SHIP are 
particularly sensitive to a domain found in the cytoplasmic regions o f FcyRIIbl and PIR- 
B called the immunoregulatory tyrosine inhibitory motif (ITIM). Upon phosphorylation, 
ITEM motifs attract SHP-1/2 and SHIP by acting as a docking site for their SH2 
domains. Studies of pervanadate-induced phosphatase inhibition in Daudi B cells show 
that JAKl and STAT6  become activated. Given the involvement o f JAKs and STATs in 
IL-4 signalling, these findings indicate a regulatory role of SHP-1/2 and SHIP in BL-4R 
signalling (Haque et al, 1997). SHP-1 has been shown to interact with the IL-4Ra chain 
after IL-4 treatment and to dephosphorylate p85 (Imani et al, 1997). A PIR-B-
stimulated inhibitory role o f SHP-1 over Syk and Btk has also been demonstrated in 
DT40 B cells (Maeda et al, 1999). SHP-2 has recently been shown to interact with the 
p85 subunit of PI-3 kinase, along with SHIP, in ligand-stimulated BaF/Flt3 
haematopoetic cells (Zhang et al, 1999) and with FcyRIIb, following BCR activation in 
the human Burkitt lymphoma cell line BL41 (Sarmay et al, 1999). A potential role for 
SHIP is to dephosphorylate PIP3 and initiate the PIP2 driven activation of PKB (Franke 
et al, 1997). The roles o f SHP-1/2 and SHIP are therefore important, not only in IL-4R 
signalling, but in B cell regulation as a whole.
1.4.5 Activation of cAMP Signalling
In tonsillar B cells, IL-4 has been reported to stimulate an increase in IP3 and calcium 
levels, followed by a delayed accumulation of cAMP. Both events were shown to be
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essential for the induction of CD23 expression (Finney et al, 1990). An increase in IP3 
and intracellular calcium leads to the activation of DAG and PKC (previously described 
in text and shown in Figure 1.2). The activation of the cAMP pathway is another 
important feature of IL-4-induced B cell signalling (Daniel et al, 1998). The cAMP-
dependent signaling pathway is usually activated when a ligand binds to a membrane 
receptor which becomes activated and, in turn, activates a linked guanosine triphosphate 
(GTP)-binding (G) protein. The G protein complex consists o f an a  subunit o f which 
there are three types; Gs which is stimulatory and Gi and Go which are inhibitory and a 
p/y subunit heterodimer. When a G-protein is activated, the G a subunit dissociates from 
the heterotrimeric complex and binds to GTP where it modulates effector proteins until 
a GTPase enzyme ends the association and G a returns to the complex (Hamm and 
Gilchrist, 1996). Activation o f Gas protein and to a lesser extent the dissociated p/y,
stimulates the activation of the enzyme adenylate cyclase (AC) which has nine different 
isoforms distributed over many tissue types (Simmonds, 1999). Activation of AC 
catalyzes the conversion o f ATP to cAMP. The effect of cAMP activity is dependent on 
the intracellular concentration of a diverse group of proteins called phosphodiesterases 
(PDEs) which degrade intracellular cAMP and appear to counteract the role of AC, 
particulaiy where AC is expressed in high levels. There are over forty isoforms of PDB 
which have been grouped into seven families named PDEl-7, with respect to their 
specficity for cyclic nucleotides. PDEs which show the greatest affinity for cAMP are 
PDE4 and 7, although 1,2 and 3 show a weak involvement (Houslay and Milligan,
1997).
1.5 THE cAMP SIGNALLING PATHWAY
Cyclic AMP activates cAMP dependent protein kinase, or protein kinase A (PKA). PKA 
is tetrameric complex which consists of two catalytic (C) subunits bound to a 
homodimer o f two regulatoiy (R) subunits. There are three isofoims o f C subunits; 
Ca, P and y, which have similar properties, and two R subunits; RI and RII, which have
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specific cAMP binding properties and are localised differentially within a cell. There are 
two isotypes of PKA; type I PKA consists of a RICa and RICP complex which is found 
mainly in the cytoplasm, and type II PKA which consists of a RIICoc and RIICp complex 
which is mainly associated with cellular structures and organelles (Taylor et al, 1990). 
The subcellular localisation of type II PKA is due to its association with AKAPs. 
AKAPs are a large family of proteins which can promote activation of PKA by locating 
it near a site o f stimulation, or it can limit PKA activation by localising it with enzymes 
which are inhibitory to cAMP (Colledge and Scott, 1999). Binding o f cAMP exerts a
conformational change on the PKA complex and the catalytic subunits become activated 
and released. PKA specifically phosphorylates serine and thi eonine residues found within 
RRXS/T motifs leading to phosphorylation o f ion channels, cytoskeletal proteins and 
intracellular enzymes (Kennedy and Krebs, 1991). Another function of PKA is the 
phosphorylation and activation of PDEs, which results in an increase in cAMP 
degradation. A study in bovine vascular smooth muscle cells showed that PKA could 
activate the cAMP specific PDE4 indicating that PKA regulates a negative feedback 
effect on cAMP by the phosphorylation of PDEs (Eckholm et al., 1997). The cAMP 
pathway terminates in the regulation o f several transcription factors which include; 
CREE, cAMP response element modulator (CREM), activating transcription factor 
(ATF)-l andNF-KB.
1.5.1 cAMP-Regulated Transcriptional Regulation
The cAMP responsive element (CRE) is a DNA sequence which has the consensus 
nucleotide sequence TGACGTCA, found within gene promoter regions and relays 
cAMP signalling activity to the gene (Montminy et al., 1986). CREB belongs to a group 
of transcription factors which contain basic region leucine zippers (bZIP) (Landshulz et 
al, 1988) The cAMP-responsive bZIP transcription factors form a distinct group which
also includes AP-1, CREM and ATF-1 (Meyer and Habener, 1993). CREB, CREM and 
ATF-1 share an amino-terminal proximal kinase-inducible domain (KID) which is
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flanked by a glutamine-rich transactivation domain. Transcriptional activity of CREB is 
regulated within KID, in particular, by the phosphorylation o f serine residue 133 
(Gonzalez and Montminy, 1989). Although this residue is the target for PKA activity, 
other kinases can also phosphorylate serine 133. The ribosomal S6  kinase RSK2 has 
been reported to function as a CREB kinase as has PKC indicating a potential 
amplification of cAMP signalling by other transduction pathways (Xing et al, 
1996;Yamamoto et al., 1988) The maximal effect of phosphorylation of serine 133
within the KID domain of CREB is achieved thiough the association o f a 256kDa 
nuclear factor which acts as a transcriptional coactivator called CREB binding protein 
(CBP) (Kwok et al., 1994). CBP recognises phosphorylation o f serine 133 through a 
domain called KIX which enables CBP binding to CREB on an arginine residue found 
close to serine 133 (Parker et al, 1996). A nuclear factor called p300 is homologous to 
CBP and can additionally interact with CREB. CBP and p300 can both be bound by the 
adenovirus E l A protein which has an inhibitoiy effect on CREB activity. CBP and p300 
function to regulate other transcriptional events, enabling signals, most of wliich regulate 
differentiation, to integrate with gene expression (Shikama et al, 1997). Other 
transcription factors which act on CBP/p300 include; the transcriptional coactivator 
p/CIP, AP-1, and STAT complexes (Torchia et al, 1997).
1.5.2 cAMP Activation of NF-kB
The transcription factor NF-kB is widely expressed and plays an important part in 
immune and stress responses by regulating gene expression. It is comprised of protein 
homodimers or heterodimers that share a 300 amino acid homology domain region and 
belong to the Rel family o f proteins. Members of the Rel family found in mammalian 
cells include c-Rel, pl05, plOO, RelA (p65) and RelB (Baldwin, 1996) In Drosophila
melanogaster cells there are Rel proteins which have similar characteristics to 
mammalian homologues, examples are; Dorsal, important in dorso-ventral patterning, 
and Dif, an inducible transcription factor which is important in immune responses (May
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and Ghosh, 1998). NF-kB is found in the cytoplasm of most cells, bound to inhibitory 
proteins called inhibitor (I)kB of which there are three isoforms; iKB-a, |3 and s. When 
NF-KB is induced by such factors as TNFa and IL-1, serine residues at positions 32 and 
36 of IkB become phosphorylated. This phosphorylaton is induced by IkB kinases (IKK) 
which are activated by signalling elements which have been induced by TNFa and IL-1, 
called TNF receptor associated factor (TRAF)-2 and TRAF6  respectively. TRAFs 
interact with a MEK kinase called NF-KB-inducing kinase (MK) which leads to the 
activation o f IKK and the resultant phosphorylation of IkB serine residues. This leads to 
polyubiquitination and degradation of IkB by the 26 S proteasome enabling NF-kB to 
translocate to the nucleus where it is able to regulate gene expression (DiDonato et al, 
1997;Maniatas, 1997). cAMP and PKA exert cell-specific effects on NF-KB-induced
reporter gene expression. A study showed that elevation o f intracellular cAMP resulted 
in the inhibition o f NF-kB induced activation of E-selectin, vascular cell adhesion 
molecule-1 (VCAM-1), intacellular adhesion molecule-1 (ICAM-1) and TNFa in human 
monocytic and endothelial cells (Ollivier et a l, 1996) The effect o f PKA on NF-kB may
be independent o f cAMP, since the catalytic subunit of PKA has been shown to directly 
phosphorylate and activate the p65 Rel protein o f NF-kB following the degradation of 
IkB. The same study revealed that cAMP-induced PKA did not significantly affect NF- 
kB activity (Zhong et a l, 1997). The p65 NF-kB subunit has also been reported to 
interact with CBP and p300 (Gerritsen et a l, 1997).
1.6 IL-2 AND THE BL-2 RECEPTOR COMPLEX
IL-2 was originally identified as a growth factor for T cells (Morgan, Ruscetti and 
Gallo, 1976). It is a multifunctional cytokine that modulates the growth, differentiation 
and apoptosis of lymphocytes including; T, B and natural killer (NK) cells, as well as 
monocytes and some haematopoetic cells (Smith, 1988). IL-2 is produced mainly by 
CD4+ Th cells and to a lesser extent by CD8 + cells and large granular lymphocytes. In 
common with the IL-4R complex, the IL-2 receptor has no intracellular kinase activity
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and relies upon the activity o f non-receptor tyrosine kinases to activate IL-2-induced 
signalling pathways. The EL-2 receptor consists of three subunits; the constitutively 
expressed 751cDa (3 and 64kDa yc chains and an unique, inducible 55kDa a  chain (see 
Figure 1.4). These subunits are also termed CD 122, CD132 and CD25, respectively. 
The IL-2R(3 subunit is additionally found in the IL-15 receptor complex along with yc; 
however, both IL-15R and IL-2R have different a  subunits (Waldmann, Tagaya and 
Bamford, 1998). The constitutive expression o f EL-2R(3 and yc creates a heterodimeric 
IL-2 receptor complex which has a dissociation constant (Kd) of 10~^M for IL-2 and is
referred to as the intermediate affinity complex. The induction of BL-2Ra (CD25) 
expression leads to the formation o f a heterotrimeric complex with IL-2R(3 and yc and 
an increased Kd o f lO'^^M for IL-2. This complex is recognised as the high affinity
complex. CD25 expressed alone generates a low affinity binding complex for EL-2, with 
a Kd value o f 10"^M (Minami et al., 1993). Although CD25 is unable to activate
intracellular signalling pathways, experiments with chimeric EL-2R molecules on 
leukemic large granular lymphocytic (LGL) cells and T cells indicated that CD25 is able 
to present EL-2 to an EL-2R(3/yc complex on adjacent cells, thereby promoting IL-2 
signalling (Richer and Waldmann, 1998), The role of CD25 in the receptor complex can 
therefore be defined as one which enhances ligand affinity and effect, while the role of 
EL-2RP and yc is to initiate intracellular signalling events. EL-2 is an important biological 
activator of the expression o f CD25 in T cells (Malek and Ashwell, 1985). A recent
study on a mouse T cell line grown in IL-2-containing medium showed that, in vitro, IL- 
2  has a wide and essential role on the expression of genes which encode cytoskeletal 
proteins, oncogene regulators and transcription factors (Herblot et al, 1999). EL-2 
binding to the intermediate or high affinity receptor complex in lymphoid cells leads to 
the activation o f several previously described signalling pathways (Figure 1.4). These 
are; the Ras/MAP kinase pathway which regulates mitogenesis, the PI-3 kinase pathway 
which is involved in cytoskeletal organisation and the JAK/STAT pathway, in particular 
JAKl and JAK3 which activate STAT3 and STATS, which exert multiple effects via 
transcriptional regulation (Nelson and Willerford, 1998).
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1.6.1 The Expression of CD25
CD25 is expressed at an early stage o f development and marks the initiation of T cell 
receptor (TCR) reaiTangement and commitment to the T cell lineage. Following 
successful TCRp rearrangement, constitutive CD25 expression is lost and is not 
observed at any other stage o f T cell development (Godfrey and Zlotnick, 1993). CD25 
expression is induced in mature resting T cells upon TCR stimulation or by non-TCR 
activation in response to IL-1 or TNFa (Plaetinck et a l, 1990;Rothenberg, 1992). In 
murine B cells, there is a similar obseiwation of expression as CD25 is found on pre-B 
cells (Rolink et a l, 1994). In murine and human mature B cells, CD25 is upregulated in 
response to BCR activation (Benschop and Cambier, 1999). In addition to BCR induced 
expression, IL-4 has also been reported to upregulate CD25 expression in resting human 
tonsillar B cells by inducing a loss o f activity on proteins binding to a negative regulatory 
region which suppresses CD25 transcription (Hewitt et al, 1997). Other compounds 
which have been reported to upregulate CD25 expression in B cells are; CD40 specific 
antibody (Ab) and anti-Ig Ab (Burlinson et al, 1995). The reported effect of IL-4 on B 
cells is in direct contrast to the effect on T cells, where IL-4 is reported to have an 
inhibitory effect on CD25 expression (Jankovich et al, 1989).
1.6.2 Human CD25 Promoter Regulation
Expression of human CD25 is regulated by three positive regulatory regions (PRR^m) 
and two negative regulatory regions (NRRi_n) in the proximal promoter region o f the 
CD25 gene (Figure 1.5a). PRRi is located between nucleotides -276 and -244, relative 
to the major transcription start site. It contains binding sites for NF-kB and serum 
response factor (SRF) which have been shown tlirough transient transfection studies to 
control PRRi activity (Pierce et al, 1995). PRRI is responsive to mitogenic and 
antigenic signals resulting from TCR activation or stimulation by phorbol ester, IL-1 and
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TNFa. PRRn is a T-cell specific promoter and is found between nucleotides -137 and - 
64. PRRn contains binding sites for the Ets family protein, Elf-1 (Graves and Petersen, 
1998) and the non-histone chromatin-associated protein HMG-l(Y) (Landsman and 
Bustin, 1993). This region is principally involved in basal promoter activity and in T-cell 
specific CD25 expresssion (John et al, 1995). Antigen is the primary stimulus which 
induces CD25 transcription, although IL-2 is required to elicit a maximum and 
prolonged expression (Sperisen et al, 1995). PRRm is an IL-2 responsive element (rE) 
located between nucleotides -3780 to -3703 (or according to another group, 
approximately 80 nucleotides around position -4150) and is similar to PRRn as it also 
contains binding sites for Elf-1 and HMG-l(Y). In addition, PRRm contains a GATA 
site and a binding site for STAT5 which is activated in response to IL-2 ligation of the 
IL-2R, leading to an upregulation of CD25 expression. While the binding site for 
STATS has an enhancing effect on PRRm induction, Elf-1 appears to negatively regulate 
the constitutive expression of CD25 in unstimulated T cells (John et al, 1996;Lecine et 
al, 1996).
1.6.3 The Human CD25 Negative Regulatoiy Regions
Transient transfection studies using deletion mutants of the CD25 promoter identified 
two negative regulatory regions; NRRim between nucleotides -400 and -368, and -300 
to -313 respectively. Figure 1.5b shows that within the NRRi 31 base pair (bp) region is 
an llb p  core element (TTCATCCCAGG) which regulates both basal and mitogen 
induced transcription in Jurkat T cells and is referred to as the negative regulatory 
element (NRE). UV cross-linking studies indicated that NRE is bound by a 50kDa NRE- 
binding protein (NRE-BP) which leads to the repression of NRE activity. NRE-BP was 
also found to repress an element related to NRE in the promoter region o f the 5' long 
terminal repeat (LTR) of type 1 human immunodeficiency virus (HIV-1) (Smith and 
Greene, 1989). In human tonsillar B cells, transient transfection studies using deletion 
mutants lacking both the NRE and the entire NRRj region demonstrated that NRE is a
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functional repressor of CD25 transcription in B cells. DNA-binding protein activity 
which binds specifically to the NRE region was lost and CD25 expression induced when 
the cells were treated with human recombinant IL-4 (Hewitt et al., 1997). The identity 
of NRE-BP is undefined, however an IFN-regulated gene called stimulated trans-acting 
factor of 50kDa (Staf-50) was shown to down-regulate transcription regulated by the 
promoter region o f HIV-1 LTR, suggesting a possible candidate for this protein (Tissot 
and Mechti, 1995;Tissot et al., 1996). Immediately 3' to NRE is a retinoid sensitive 
region (GCTGAC). Retinoic acid has been reported to induce transcriptional regulation 
of CD25 in human B cells (Bhatti and Sidell, 1994). In addition, treatment with IL-4 
stimulates a loss o f binding activity for retinoic acid response element (RARE)~specific 
oligonucleotides. Wliile it is clear the retinoid-sensitive sequence has an active role in the 
CD25 promoter gene, protein binding activity to this region has yet to be characterised 
(Hewitt et al., 1997).
Overlapping the putative RARE sequence, is a further element (TGACTCC) which is 
highly homologous to the consensus AP-1 binding site (Figure 1.5b). In lymphocytes, 
the role of AP-1 is important in the regulation o f gene expression which induces 
lymphocyte differentiation and activation (Foletta et al, 1998). AP-1 is a homo- or 
heterodimeric complex which binds the consensus nucleotide sequence TGACTCA 
(Vogt and Bos, 1990). The complex is made up of two protein families called fos and 
jun that dimerise via a leucine zipper interaction. The fos family members include c-fos, 
fos-related antigen-1 (ffa-1), fra-2, fosB and its truncated form, fosB2. There are three 
jun family members; c-jun, junB and junD. Jun proteins can homodimerise or 
heterodimerise with fos, whereas fos is unable to homodimerise and cannot bind DNA 
alone (Halazonetis et al., 1988). AP-1 complexes belong to the same family o f bZIP 
proteins as the previously described CREB, CREM and ATF-1, but can also interact and 
form protein complexes with NF-icB enhancing DNA binding and function. A study of 
p65 and NF-kB interaction demonstrated in vitro a synergistic activation of the 5' LTR 
o f the the HIV-1 virus in human cell lines (Stein et al., 1993). An important mediator of
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the transcriptional regulation of AP-1 is the MAP kinase signal transduction pathway 
(Angel and Karin, 1991;Karin et al., 1997). The MAP kinase pathway regulates the level 
of gene transcription which transcribes fos and jun proteins, shortly after cell stimulation. 
AP-1 protein function is activated mainly by phosphorylation (Whitmarsh and Davis, 
1996). In B cells, another previously described pathway which is important in AP-1 
induction is the PKC signalling pathway. A study co-cross-linking sIg with the CD40 
receptor in B cells demonstrated that activation of the PKC pathway was essential for 
cellular proliferation, as PKC depletion blocked cell cycle progression (Kawakami and 
Parker, 1993).
1.6.4 AP-1 Expression in B Cells
In primary B cells and B cell lines, surface Ig cross-linking was shown to induce c-fos 
expression (Chan et al., 1993). A study of murine B cells examined the effect o f B cell 
activation through the individual stimulation o f the sig and CD40 receptors on AP-1 
regulation, using anti-Ig Ab and CD40 ligand. Both fonns of stimulation lead to the 
expression o f junB and junD but not c-jun. JunB induction by anti-Ig Ab was dependent 
on PKC whereas CD40 mediated induction was independent o f PKC. In addition, both 
forms of receptor stimulation lead to the expression of c-fos, fosB and fra-1 but not fta- 
2, however fosB was only induced by anti-Ig Ab activation. Both c-fos and fosB were 
induced independently of PKC signalling whereas fra-1 expression was PKC-dependent 
(Huo and Rothstein, 1995;Huo and Rothstein, 1996). AP-1 is involved not only in 
positive regulatory transcriptional activity, but also negative regualtory activity. A 
truncated form o f fosB has been reported to inhibit fos and jun transcriptional activity 
and junB has been found to be less active in AP-1 complexes than c-jun (Chiu et al., 
1989;Nakabeppu and Nathans, 1991). In B cells, AP-1 has been reported to be 
associated with the activation of the K-light chain promoter and the IgH chain gene, 
indicating a role for AP-1 in Ig synthesis (Grant et al., 1995;Schanke et al, 1994). Given 
the reported role o f AP-1 in B cell promoter regions, it is highly likely that the
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TGACTCC region of NRRj, if bound by AP-1, has an important role in the regulation of 
expression o f CD25.
1.6.5 The Murine CD25 Promoter
In common with the human CD25 promoter region, IL-2-driven stimulation of the 
mouse CD25 promoter is controlled by an IL-2rE. The murine IL-2rE is found 1.3kb 
upstream o f the major transcription start site, spanning positions -1377 to -1312. The 
IL-2rE contains three elements which are involved in enhancer activity; site I 
(CTTCTGAGAAG) site II, (TTCTGATAA) and site III (AACTTCCTGA) (Sperisen et 
al., 1995). Sites I and II contain regions which are bound by STAT proteins. A study 
using a hybrid between a mouse cytolytic T cell line and a rat thymic lymphoma (PC60 
cell line) demonstrated STATS bound sites I and II and mediated BL-2 stimulation of 
CD25 transcription (Meyer et al., 1997). In addition, studies in STATS A knockout mice 
showed a severe reduction in IL-2-induced CD25 expression (Nakajima et al., 1997). 
Site III contains two consenenseus sequences for Ets proteins and studies on PC60 cell 
nuclear extract demonstrated that Elf-1 binds to this site and regulates IL-2 
responsiveness (Serdobova et a i, 1997). The binding regions of sites I,II and III in the 
murine CD25 IL-2rE are fully consei*ved in the BL-2rE of the human CD25 promoter 
gene (Bucher et al., 1997).
A recent report demonstrated that BL-2, in addition to activating STATS, may prime the 
CD25 gene for transcription by making CD25 chromatin available to transcription 
factors on the IL-2rE (Rusterholz et al, 1999). Transcriptional control o f the murine 
CD25 gene is regulated by an additional promoter proximal region (PPR) and is induced 
by the activating effects of IL-1. It is located between nucleotides -584 to -54 and has 
been shown to be necessary for the rapid appearance o f CD25 mRNA following BL-1 
stimulation, in PC60 cells (Freimuth et al., 1989). In common with the human 
counterparts PRRi and PRRn, mouse PPR was shown to be sensitive to the
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transcriptional activities o f KF-kB (Nabholz et al., 1995). A further region has recently 
been identified on the CD25 promoter. The NF-AT family members NF-ATp and NF~ 
ATc have been reported to bind two sites located between positions -585 and -650, 
upstream o f the proximal CD25 promoter in murine T cells (Schuh et al., 1998).
1.7 AIMS OF PROJECT
The aims of this project are three-fold. The first aim is to study and characterise the 
signalling mechanisms generated by IL-4 that lead to the loss o f NRE binding activity 
and the up-regulation of CD25 expression. It has been shown, in this laboratory, that IL-
4-driven CD25 expression is mediated via a cAMP/PICA-sensitive pathway. The effects 
of addition of the catalytic subunit of PKA, PKAc, to cell extracts on NRE-BP activity 
will be investigated. Use of cell signalling inhibitors and transient-transfection of model 
cell lines with CD25-CAT reporter constructs will address other potential signalling 
pathways through which IL-4 may up-regulate CD25 expression.
Secondly, the nature of protein binding to the NRRj region will be studied. It has already 
been shown that IL-4 attenuates NRE-BP binding to NRE, but the effect of this cytokine 
on the entire NRR% region is unknown. NRE-BP has yet to be defined and several 
proteins will be assessed as candidates for this important molecule. NRRi contains a 
retinoid sensitive region which is characterised by a consensus AP-1 binding site. Protein 
binding to NRE and the consensus AP-1 binding region within NRRi will be assessed by 
EMSA analysis. In addition, protein binding to the consensus AP-1 binding site will be 
investigated in an attempt to characterise the region.
The transcriptional activity of NRE and the consensus AP-1 binding region will be 
assessed by transiently-transfecting lymphoid cells with NRRi deletion mutant 
constructs. Finally, four putative STAT6  binding sites within the proximal promoter 
region o f CD25 will be investigated by transfecting lymphoid cells with CD25 deletion 
mutant reporter constructs and then examining the effects o f IL-4 stimulation. This 
project will investigate the signalling events that up-regulate CD25, the identity and 
interactions of proteins binding to NRRi and the transcriptional activiy of the region, as 
well as other specific areas within the CD25 promoter.
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Figure 1.1. Human B Cell Development
Cellular stages of B cell development in human bone marrow (antigen-independent) and 
periphery (antigen-dependent). Antigen-independent model based on figure presented by 
(Ghia et al., 1998).
The differentiating pro-B cell develops into a pre-B-I cell, which initiates H-chain 
rearrangement by binding a D gene, the TdT-formed extra nucleotide (N) region and a J 
region. In forming a DNJh gene; the developing B cell enters the pre-B-II stage and 
increases in size, A V region gene is then joined to form a VhN-DNJh  gene which is
capable o f producing a p-H chain. In the endoplasmic reticulum (ER) in some pre-BI 
and in most large pre-BII cells, Vpre-B(l/2) and X5 (murine) or A,5/14.1 (human) are
expressed. These Ig like proteins are able to bind together via an extra j3 strand located 
in the Vpre-B chain to form a surrogate light chain (SLC). Once formed, the SLC binds 
to the newly-formed p-H chain and forms a complex in association with a signal 
transducing heterodimer consisting of two Iga and Igp subunits, CD79a and CD79b. 
The complex leaves the ER with an a(3 heterodimer flanking each side of the SLC-heavy 
chain arrangement and translocates to the cell surface where it is expressed as a pre-B 
cell receptor (BCR). Immature cells which have not been subject to autoantigen 
challenge or have undergone successful receptor editing increase surface levels of IgM 
and enter the antigen dependent stage of B cell development
When presented with antigen, the mature B cell can undergo rapid clonal expansion and 
plasma-cell differentiation to give rise to a high antigen-afifinity antibody producing cell. 
Alternatively, the cell enters the germinal centre reaction and remains in the secondary 
lymphoid tissue often for many years as a memory B cell.
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Figure 1.2. B Cell Receptor and Associated Signal Transduction Cascades.
When bound by antigen or anti-receptor antibody, the BCR aggregates and initiates 
signal transduction pathways through the Iga and IgP subunit-ITAM motifs. The main 
signalling pathways shown are driven by a cascade of phosphorylation events involving 
cytoplasmic and membrane proteins.
PLCy2 activation is achieved following BCR stimulation. Src-family member Lyn 
becomes activated leading to the tyrosine phosphorylation of ITAM motfs in Iga  and 
IgP subunits. Syk is recruited to the phosphorylated IT AMs via SH2 interaction. Lyn- 
activated PI-3 kinase produces PI-3,4,5-P3 which recruits Btk to the membrane by 
binding its PH domain. Lyn then phophorylates tyrosine residues in Syk and Btk leading 
to their activation. Syk phosphorylates BLNK and recruits it to the membrane where a 
Syk-BLNK-Btk complex is formed. Phosphorylated BLNK then recruits PLCy2 to the 
complex where it becomes tyrosine phosphorylated and activated, initiating a signal 
transduction pathway. Adapted from (Kurosaki, 1999).
65
%'i
■.;5
S
PH DOMAIN
SH3 DOMAIN 
Q  SH2 DOMAIN
PROLINE-RICH 
DOMAIN
BLNK
PLC-Y2
E U
I Calcineurin
G A P ^O  1^ 0
n n p lK asI g tp
Plasma 
Membrane
MEK2 NF-ATII
NUCLEUS
Figure 1.3. IL-4 Receptor Complexes with yc and IL-13R Subunits and Signalling
Pathways.
In B cells, the most common IL-4 receptor complex is formed by IL-4Ra and yc. 
Signalling pathways initiated by IL-4 binding are the PI-3 kinase pathway and several 
JAK/STAT interactions.
The PI-3 kinase pathway activates downstream proteins such as PKB and PKCC 
stimulating cell growth and survival. JAKl and JAK2 are activated via phosphorylation 
at the IL-4Ra receptor. Both forms initiate the dimérisation o f STATSa and STATSb 
which migrate into the nucleus and regulate transcriptional events culminating in cellular 
proliferation. JAK3, phosphorylated by the yc receptor subunit, activates STAT6 
dimérisation events resulting in the expression of CD23 and MHC Class II expression at 
the cell surface.
This model is partially based on a figure from (Nelms et al, 1999).
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Figure 1.4. High Affinity JLe-2 Receptor Complex and Associated Signalling
Pathways.
Expression of the unique CD25 subunit at the cell surface creates a complex with the (3 
and yc subunits which binds IL-2 with high affinity. IL-2R activation leads to the 
initiation o f signalling events via the p and y subunits, including JAK/STAT, Ras/MAP 
kinase and PI-3 kinase pathways. The pathways terminate at the nucleus where they 
regulate transcriptional activity.
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Figure 1.5 a). The Humait CD25 Promoter Region.
Schematic diagram of the human CD25 promoter region including the distal PRRm and 
the proximal regions; PRRim and NRRim. In addition, four putative STAT6  sites 
consensus and non-consensus to the TTCNMNNGAA GAS sequence, are outlined as 
open boxes.
Figure 1.5 b). The Human CD25 Proximal Promoter Region
Diagram of the proximal region of the CD25 promoter gene. Shown are the NRE and 
RARE/AP-1 binding regions of NRRi which form the main negative regulatory domain 
of the CD25 promoter. This region forms the main area of investigation. Adjacent to 
NRRi are the smaller negative regulatory region NRRn and the promoter regions; PRRi 
and PRRn-
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CHAPTER 2 
MATERIALS AND METHODS
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2.1 MATERIALS
2.1.1 Chemicals
All chennicals used were purchased from Sigma-Aldrich Ltd., Dorset, UK., unless 
otherwise stated.
2.1.2 Oligonucleotides
Consensus NEE and AP-I sequences shown in bold, and mutated sites are shown in 
italics.
CD25-NRRI 5'-GCTCCTTCATCCCAGGTGGTCCCGGCTGACTCCTGAGGA-3’ 
CD25-lSjRRi-Ml 5'-GCTCCT7MGArC7MGGTGGTCCCGGCTGACTCCTGAGGA-3' 
CD25-mRi-M 2 5'-GCTCCTTCATCCCAGGTGGTCCCGGCCGACrCCTGAGGA-3' 
CD25-NRRI-M3 S^-GCTCCTTAGATCTAGGTGGJCCCQQCCGACTCClOAGGK-y 
CD25 -AP1 5 GCTGACTCCTG 3 '
CD25-APlm 5'-GCCGAC7'CCTG-3'
CD25-NTŒ 5 CCTTCATCCCAGGTG 3
CD25-NREm S'-CQTTAGATCTAGGTG-y
The above oligonucleotides were synthesised and supplied by CRC Beatson 
Laboratories, Glasgow, UK.
CD25~NRE 5 CTTCATCCCAGGT 3
CD25-NREm y-hCTTGGGATGAAG-y
The above oligonucleotides were synthesised and supplied by Cruachem Ltd., Glasgow, 
UK.
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CD25-NRE 5 TTCATCCCAGG 3
CD25-NREm 5'-AAGTAGGGTCC-^-^3'
The above oligonucleotides were synthesised and supplied by Genosys Biotechnologies, 
Cambridgeshire, UK.
YYl
YYlm
5'-CGCTCCGCGGCCATCTTGGCGGCTGGT-3*
5'-CGCTCCGCG^mrC7TGGCGGCTGGT-3'
The above oligonuclotides were synthesised and supplied by Santa Cruz Biotechnology, 
Inc., Middlesex, UK.
]S]F-kB 5'-AGTTGAGGGGACTTTCCCAGGC-3'
The above oligonucleotide was synthesised and supplied by Promega, Southampton, UK
2.1.3 PCR Primers
Full length CD25 5' primer 
NRE deletion 5' primer 
NRRi deletion 5' primer 
PRRi-1S1F-kB 5' primer 
PRRi STAT6 A deletion 
5' primer
PRRn STAT6 B deletion 
5' primer
PRRn STAT6 C deletion 
5' primer
5-GACAAGCTTGAATTCTCAGGATCCTTCAGTTC-3'
5-GCAAAGCTTTGGTCCCGGCTGACTCCTGAG-3'
5'-GCAAAGCTTTGAGGACGTTACAGCCCTGA-3’
5'-CTTCAAGCTTGGGAATCTCCCTCT-3'
5'-TTCAAAGCTTCTCATCAACCCCAGC-3'
5-TTGAAAGCTTACCGCAAACTA-3'
5'-CAAACAAGCTTGTCATCAAAA-3'
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3' universal primer 5'-GCAGCAGrC04CCTGCAGAAGGCCCAGTTGC-3'
The above PCR primers were synthesised and supplied by CRC Beatson Laboratories, 
Glasgow, UK, Restriction enzyme sites are contained within the primers for cloning 
purposes. Shown in bold is the H i n d ^  site and in italics, the Sal I site.
2.1.4 Antibodies 
Antibody
Rabbit polyclonal IgG anti-CBP 
Rabbit polyclonal IgG anti-Ets-l/Ets-2 
Rabbit polyclonal IgG anti-IL-4 Stat
Supplier
Santa Cmz Biotechnology, Inc. 
Santa Cruz Biotechnology, Inc. 
Santa Cruz Biotechnology, Inc.
Mouse monoclonal IgG2a anti-phospho-Tyr Santa Cmz Biotechnology, Inc.
Rabbit polyclonal IgG anti-YYl Santa Cmz Biotechnology, Inc.
Anti-mouse Ig, horseradish peroxidase Amersham Life Science Ltd., Amersham, UK. 
(HRP)-linked whole sheep antibody
Anti-rabbit Ig, HRP-linked whole donkey Amersham Life Science Ltd., Amersham, UK. 
antibody
Monoclonal rabbit anti-human IgM (p-chain Sigma-Aldrich, Ltd. 
specific)
2.1.5 Intracellular Signalling Modulators
Compound Name and Mode of Action
Cytokine Recombinant Human IL-4.
Stimulates IL-4 Receptor. 
Enzyme Inhibitor Wortmannin (KY 12420).
Blocks activation of PI-3 kinase.
Supplier
Genzyme Diagnostics,
Cambridge, UK. 
Calbiochem-Novabiochem 
Ltd., Nottingham, UK.
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Immuno- Rapamycin. Calbiochem-Novabiochem
modulator Inhibits activation o f p70^^ kinase. Ltd.
Protein PD98059 (2 -Amino-3 -methoxyflavone). Calbiochem-Novabiochem Ltd.
Kinase Inhibitor Inhibits MAP kinase activation by
blocking ERK phosphorylation.
PKI. Inhibitor ofPKA activation. Sigma-Aldrich, Ltd.
H-89. Inhibitor of PKA. Sigma-Aldrich, Ltd.
2.1.6 Tissue Culture Materials
Material
RPMI-1640 medium 
Glutamine/Penicillin/ Streptomycin 
Foetal Calf Serum
Supplier
Gibco-BRL Life Sciences, Paisley, UK. 
Gibco-BRL Life Sciences, Paisley, UK 
Gibco-BRL Life Sciences, Paisley, UK.
Complete R PM I1640 medium
lOOU/ml penicillin 
lOOng/ml streptomycin 
5mM glutamine
10% (v/v) Foetal Calf Semm (FCS)
Incomplete RPMI-1640 medium
lOOU/ml penicillin 
lOOng/ml streptomycin 
5mM glutamine
2.1.7 Isolation of High Density Tonsillar B cells
Human tissue was obtained from juvenile tonsillectomy with the kind consent of parents 
and courtesy of Mi'. Sadiq at the Royal Hospital for Sick Children, Glasgow, UK.
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Percoll, Histopaque and 2-Aminoethylisothiouronium bromide (AET) were purchased 
from Sigma Aldrich Ltd.
Sheep Red Blood Cells in Alsever's Solution were supplied by SAPU, Carluke, LTK.
2.1.8 Electrophoresis and Western Blotting
Aciylamide/bis-acrylamide was obtained from Biorad Laboratories, U.K. N,N,N',-N'- 
tetramethylenediamine,Tween 20 and the Kodak X-ray exposure cassettes were from 
Sigma, Poole, Dorset, U.K The 220kDa-14.3kDa molecular weight markers, nitro­
cellulose and Enhanced Chemiluminescence (ECL) kits were from Amersham Life 
Science Ltd., Amersham, UK. Fuji Medical X-ray film was from Genetic Research 
Instrumentation, Essex, U.K. The Atto dual chamber mini gel electrophoresis kit was 
supplied by GRI, Sussex, U.K.
2.1.9 Electrophoretic Mobility Shift Assay (EMSA)
[y-3^P]ATP was obtained from Amersham Life Sciences Ltd., Buckinghamshire, UK. 
Oligonucleotides and antibodies were acquired as described in the above Tables. Gels 
were mounted and electrophoresed on a Vertical Gel Electrophoresis System, Bethesda 
Research Laboratories, Gaithersburg, USA using a Shandon Vokam 500-150 power 
pack.
2.1.10 Transient-Transfection of Lymphoid Cells
All cells were electroporated in 4mm electroporation cuvettes obtained from Flowgen, 
Kent, UK, using a Biorad Gene Puiser and Capacitance Extender. pCAT-E' basic vector 
was obtained from Promega Life Sciences, Southampton, UK. Great EscAPe pSEAP 
control vector and Chemiluminescent SEAP Assay were purchased from Clontech,
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Hampshire, UK. CD25 proximal promoter region plasmids were generated in this 
laboratory, as described (Hewitt et al., 1997). T>~threo-\dichloroacetyl-\-C^^'\ 
Chloramphenicol was purchased hom Amersham Life Sciences Ltd., Buckinghamshire, 
UK and Acetyl Coenzyme A was from Sigma-Aldrich, Dorset, UK. Thin layer 
chromatography was performed using PE SIL G silica gel plates, purchased from 
Whatman Ltd., Kent, UK. BAS-III phosphorimage plates and X-ray film were from Fuji 
Photo Film, Japan. Phosphorimage analysis was performed using a Fujix BAS-1000 
Phosphorimager. Chemiluminescent SEAP assay analysis was carried out on an SLT 
Spectra Luminometer. Solvent evaporation was achieved using a speedivac unit 
consisting o f a Jouan RC 10.22. centrifuge connected to a Jouan RCT 90 refrigeration 
unit and JAVAC DD75 High Vacuum Pump.
2.1.11 Plasmid Purification
Plasmid purification and QIAquick gel extraction kits were purchased from Qiagen, 
West Sussex, UK. Restriction enzymes and buffers were purchased from Promega, 
Southampton, UK and Boehiinger Mannheim, East Sussex, UK. Centrifugation steps 
were carried out on a Beckman J2-HS centrifuge using type JA-14 and type JA-20 
rotors.
2.1.12 Flow Cytometiy
All flow cytometry was performed using a FACScan flow cytometer (Becton Dickinson, 
UK) and all information processed using either a Becton Dickinson Consort 30 system 
containing; a Hewlett Packard 3000 series computer, 91533B hard disk drive, 9144 
cassette drive and a 46020A keyboard, or the Becton Dickinson application for 
Macintosh, CELLQuest. RPE- and FITC-conjugated monoclonal mouse antibodies were 
obtained from Dako, Glostrop, Demnark. Streptavadin qauntum red (SA-QR) and 
propidium iodide were purchased from Sigma-Aldrich, Dorset, UK.
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2.2 METHODS
All solutions are described in the Appendix; section 8  pp. 189-193.
2.2.1 Preparation of 2-Aminoethylisothiouronium Bromide (AET)-Erythroctes
Five millilitres of sheep red blood cell (SRBC) suspension was pelleted then washed 
twice in 25ml incomplete RPMI-1640 medium by centrifugation at 350 x g. The washed 
erythrocytes were resuspended in 4ml of filter-sterilised AET solution and incubated at 
37^C for 20 min. The erythrocytes were then washed a further five times in 10ml 
incomplete RPMI-1640. Washed AET-SRBC were retained in 10ml incomplete RPMI- 
1640 at 4^C for a maximum o f one week.
2.2.2 Isolation of High-Density Resting Tonsillar B Cells
Freshly excised tonsils were spilled into incomplete RPMI-1640 medium. Following 
passage thi'ough a fine wire mesh, the cell suspension was washed thiee times in 
incomplete RPMI 1640 then aliquoted onto 10ml of Ficoll-Hypaque and centrifuged for 
15 min at 350 x g. The mononuclear cells were harvested fiom the interface, pooled and 
subjected to three further washes before being pelleted with 1ml AET-SRBC for five 
minutes at 90 x g. T cell populations were removed by rosette formation following 30 
min incubation on ice with 1ml foetal calf serum (FCS) and centrifugation thi ough 10ml 
of Ficoll for 2 0  min at 350 x g. The non-rosetted cell population was harvested fiom the 
interface, washed and then centrifuged for 30 min through a five-step, discontinuous 
percoll gradient made from dilutions in a incomplete RPMI-1640 medium/1 Ox sterile 
PBS buffer to give densities o f 1.055g/ml, 1.065g/ml, 1.075g/ml, 1.08g/ml and 1.09g/ml 
at 1 0 0 0  X g. Quiescent tonsilar B cells were isolated in this gradient forming a high 
density solution within the 1.09g/ml-1.08g/ml interface. Cells were removed and washed
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twice in incomplete RPMI-1640 medium then once in complete RPMI 1640 medium.
Cells were rested for Ih in a 37^C incubator before treatment and then returned for the 
required incubation period.
2.2.3 Preparation of Whole Cell Extracts
High density tonsillar B cells were incubated for 16h in complete RPMI-1640 medium 
prior to extraction. Whole cell extracts were prepared from human B and T lineage cells 
which had been subjected to 24h incubation in fresh complete RPMI-1640 medium 
before stimulation. Following stimulation, the cells were washed in ice-cold PBS, |
resuspended in 1ml RIPA buffer and incubated on ice for 20 min. The lysates were then 
centrifuged at 11,592 x g in a bench-top microfuge to remove cellular debris. The 
supernatant was retained and stored at -20°C. Ten micrograms of lysate were boiled 
with 5 pi o f 2 x sodium dodecyl sulphate (SDS) loading buffer before addition to the 
SDS-PAGE gel.
2.2.4 Preparation of Cytosolic and Nuclear Cell Extracts
Primary tonsillar B cells or B cell lines were cultured overnight in complete RPMI-1640 
medium prior to extraction. A total of 5 x 1 0  ^ cells were harvested for each extraction 
and washed in 1 0 ml ice-cold PBS. Pellets were then resuspended in 300p.l cytosolic 
extraction buffer and incubated on ice for 30 min. A volume of 250pl of 1% (w/v) NP- 
40 was added to lyse the cellular membrane and the nuclei were immediately separated 
by centrifugation at 322 x g in a benchtop centrifuge. The supernatant was retained as 
cytosolic extract, with the addition of 60pl 50% (w/v) glycerol. Extracts were stored at - 
70®C. The nuclear pellet was resuspended in 1 0 0 pi o f nuclear extraction buffer and 
placed on a revolving vertical platform for 30 min at 4®C. Nuclear fragments were 
pelleted at 11,598 x g on a Hareus biofuge for 15 min and supernatant retained as 
extract and stored at -70^C.
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2.2.5 SDS-PAGE Electrophoresis and Western Blotting
A 10% (w/v) acrylamide separating gel was prepared using a 'Biorad' mini rig. The gel 
was poured and a layer o f (CH3)2CHOH added at the top which was drained when the 
gel had polymerised. A 5% (w/v) acrylamide stacking gel was poured on top and a 
teflon comb inserted. Once set, the gels were transferred to an Atto dual chamber mini 
gel electrophoresis kit and fully submerged in Tris-glycine electrophoresis buffer. The 
comb was removed and up to 15 pi of each of the samples was loaded in a pre­
determined order. An equal volume o f SDS loading buffer was loaded into any unused 
wells. The electrophoresis kit was attached to a Shandon power pack and an initial 
current of 15 milli-Amperes (mA) was applied until the sample had moved in to the 10% 
separating gel whereupon the current was increased to 25mA until the samples had 
migrated to the bottom o f the separating gel.
Whatman 3MM paper and nitrocellulose membrane, cut to the same size of the gel were 
soaked in protein transfer buffer and carefully assembled with the gel and two porous 
pads in a Biorad protein transfer apparatus. The nitrocelluose membrane was layered 
over the gel facing the anode side and the 3MM paper and porous pads were layered 
over both the anode- and cathode-facing sides. The apparatus was filled with transfer 
buffer and packed in ice, then subjected to 80V over 1.5h. After this time the apparatus 
was disconnected and the nitrocellulose membrane retained. The membrane was treated 
with a 10% (w/v) non-fat dried milk or a 5% (v/v) Tween-20 (Polyoxyethylene-sorbitan 
monolaurate) solution, both made up in PBS, overnight at 4®C and then washed three 
times in PBS. The membrane was then treated with a rabbit polyclonal IgG primary 
antibody in 1% (w/v) non-fat dried milk or 0.1% (v/v) Tween-20, both made up in PBS, 
for 4 hours at 4^C on a Luckham RIOOO rotator. Excess antibody was removed by three 
10 min washes o f the membrane with 0.1% (w/v) Tween-20 in PBS before a secondary 
horse-radish-peroxidase (HRP) antibody in 1% (w/v) non-fat dried milk or 0.1% (w/v)
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Tween-20 in PBS, as above, was added for 1.5h at 4^C on the rotator. Excess antibody 
was removed by washing, in 0.1% (v/v) Tween-20 in PBS, as described.
The membrane was transferred to a Kodak X-ray exposure holder and treated with 1 0 ml 
of combined ECL detection reagents for 1 min. The membrane was then exposed to X- 
ray medical film, for a time ranging from 30s to 5 min. The X-ray film was developed 
using a Kodak X-omat processor.
2.2.6 Restriction Enzyme Double Digestion
Ten microlitres of plasmid was mixed with 10 units of restriction enzyme and 2 pi of 
restriction enzyme buffer, both specific for the particular cleavage site, to a final volume 
of 20pi and incubated at 37^C for Ih. For double digests, the least isotonic restriction 
enzyme buffer was used in the first instance. After the first incubation, the DNA was 
precipitated by addition of ipl 3M CHaCOONa and 50pl 100% (v/v) CH3CHOH then
incubated for Ih at -TO^C. Centrifugation at 11,592 x g for 5 min in a Biofuge pelleted 
the DNA, the supernatant was removed and the pellet washed in 70% ice-cold 
CH3CHOH. A repeat centrifugation repelleted the DNA and the CH3CHOH was 
discarded. Plasmid DNA was resuspended in lOpl of TE buffer and further digested by 
mixing with appropriate restriction enzyme and buffer as previously described.
When final restriction digests were complete, 2pi of 2x loading buffer was added to the 
mixture. Twelve microlitre aliquots were loaded into wells in a 1% agarose gel 
containing 4ng/ml ethidium bromide. Samples were run alongside 1 kilo base and 1 0 0  
base-pair DNA ladders at 150V or lOOV (if low melting point agarose was used in the 
gel). The gel was then transferred to a transilluminator, exposed to UV light and the 
digested DNA analysed and photographed using a high intensity video camera and 
processor.
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2.2.7 Radiolabelling of Oligonucleotides
Oligonucleotides (3.5pmol) were radiolabelled with Ipl (lOmCi/ml of 3000Ci/mmol) [y- 
32p]ATP, and mixed with Ipl lOx T4 polynucleotide kinase buffer and Ipl T4 
polynucleotide kinase with 7pi dHaO Following a 10 min incubation at 37®C, the 
reaction was stopped by the addition o f Ipl 0.5mM EDTA pH 8.3 and 89pl TE buffer. /
2.2.8 Electrophoretic Mobility Shift Assay (EMSA)
Samples containing 2 0 % (w/v) 5x binding buffer and 5pg protein extract, were 
incubated with and without the presence of excess unlabelled oligonucleotide for 1 0  min 
at room temperature. For supershift EMSA, 0.1 pg o f antibody was added to the sample, 
then incubated for 30 min at room temperature. All samples were then incubated at 
room temperature for 20 min with 3.5pmol radiolabelled oligonucleotide in a final 
volume o f 1 0 pi.
Samples were loaded on to either a 5% (w/v) or 7% (w/v) non-SDS denaturing gel and 
electrophoresed on a vertical gel electrophoresis system at 150V for 1.5 h. Migration of 
samples was marked by 10pi of 2 x loading buffer in an adjacent well. Gels were then 
placed on Whatman 3MM filter paper and dried on a gel drier at SO^C under vacuum for 
Ih. The gels were transferred to a high-speed developing cassette then exposed to X-ray 
film for a variable time and stored at -70^C. X-ray film was devloped using a Kodak x- 
omat procesor.
2.2.9 Transient-Transfection of Lymphoid Cells
Tonsillar B lymphocytes, B lineage cells and T lineage cells were cultured overnight in 
fresh complete RPMI-1640 medium. Cells were washed in incomplete RPMI-1640, 
resuspended at 5xl0^cells/ml then transferred to 4mm electroporation cuvettes
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containing 40pg of appropriate plasmid and 40pg of p-SEAP control plasmid and 
incubated on ice for 10 min. Cells were electroporated at 0.35kV/960pF for 10s then 
returned to ice for a fiirther 1 0  min incubation. Cells were added to lOmls complete 
RPMI-1640 and incubated at 37^C for a minimum of 2h. For phorbol ester and IL-4 
treatments, all cell lineages were treated with and without lOnM Phorbol-13 Myristate 
Acetate (PMA) and recombinant human IL-4 at doses indicated in individual figure 
legends in the Results section. Cells were incubated for 24-48h prior to haiwest and 
assay.
2.2.10 Chloramphenicol Acetyl Transferase (CAT) Assay
Transfected cells were harvested from culture and washed in lOmls PBS. Cells were 
resuspended in 1ml PBS, transferred to an Eppendorf tube, and pelleted at 322 x g for 
10 min on a Heraeus 'Biofuge'. The supernatant was discarded and the pellet 
resuspended in lOOpl of 250mM Tris-HCl, pH 7.8. Extracts were made by three 
continuous cycles o f freeze-thaw in a dry ice/ethanol mixture followed by a 37^C hot 
plate. After centrifugation at 11,578 x g for 10 min, a lOpl aliquot was taken from each 
sample and retained for protein analysis using a protein assay, as described in section
2 .2 .1 2  or 2.2.13. Cellular acetylases were deactivated by heating the extract to 65^C for 
10 min. Extracts were then incubated on a 37^C hot plate and lOpl of 50mM acetyl 
coenzyme A and Ipl o f 2.5pCi T>-threo-{dichloroacetyl-\-C^'^^ chloramphenicol was 
added to each sample. Tonsillar B cell extracts were incubated for 12-16hrs and B and T 
cell lineage extracts were incubated for 90 min, all at 37^C. Addition of 600pl ethyl 
acetate and brief vortexing terminated the reaction. Organic extraction of samples was 
performed by centrifugation at 11,578 x g for 2 min and the upper layer was retained. 
Samples were dried down in a speedivac for 2h and the lyophilisate resuspended in 2 0 pl 
of ethyl acetate. Samples were spotted on to a thin layer chromatography plate which 
was developed in a tank containing 200mls 5% CH3 0 H/9 5 % CHCI3 . Plates were
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developed for Ih then air dried before exposure to a phosphorimage plate for 2 h, then 
X-ray film for 48h.
2.2,11 Chemiluminescent Secreted Alkaline Phosphatase (SEAP) Assay
Aliquots of 1ml supernatant were retained from every transiently-transfected sample, 
following cell harvest after 48h incubation. Fifteen microlitres of each sample was added 
to a 9 6 -well mirotiter plate in triplicate and assayed using the Great EscAPe 
Chemiluminescent secreted alkaline phosphatase (SEAP) Assay. Samples were mixed 
with 45 pi o f a dilution buffer (as supplied by the manufacturers) and heated to 65^C for 
30 min to eliminate endogenous alkaline phosphatase activity. Samples were ice cooled 
to room temperature then incubated with 60 pi of an assay buffer which contains L- 
homoarginine for 5 min at room temperature. Chemiluminescence was achieved by 
addition o f 60pi o f a chemiluminescent substrate (CSPD) diluted 20-fold by a 
chemiluminescent enhancer and a further 10 min incubation at room temperature. The 
level o f SEAP reporter gene activity, expressed as units of alkaline phosphatase (AP) 
activity, for each sample was determined by reading plates in a SLT Spectra 
luminometer and taking a mean of each triplicate assay. The following calculation was 
used to normalise CAT reporter activity values derived from quantitative analysis of 
TLC resolved samples, to individual AP values. Baseline values were defined by CAT 
and AP activity measured from untreated cells, transiently-transfected with the full 
length CD25 plasmid, pCD25 CATE'.
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X = Baseline AP Value
Y = Co-Transfection AP Value
Z = CAT Value
A = Corrected CAT Value
B = Baseline CAT Value
C -  AP Normalised CAT Reporter Activity
Y/X
Therefore
A
A
’ B
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Figure 2.1 The Restriction Enzyme Map of pSEAP.
The pSEAP2-control plasmid restriction enzyme map. The region coding for SEAP is 
located between positons 245 and 1794, relative to the origin (ori), next to the SV40 
enhancer region. The plasmid contains an ampicillin resistance gene and is punctuated by 
two multiple cloning sites (MCS) at positions 1-41 and 245-264.
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2.2.12 Bicinchonic Acid (BCA) Protein Assay
BCA assay solution was made by mixing a solution containing 1% (w/v) 4,4 dicarboxy-
2 ,2  biquinoline, disodium salt, 2 % (w/v) Na carbonate, 0.16% (w/v) sodium potassium 
tartrate, 0.4% NaOH, 0.95% (w/v) NaH2C0 3  pH 11.25, with 4% (w/v) CuS04 in a 
1:49 ratio. Standards consisted o f bovine serum albumin (BSA) diluted in either RIP A, 
nuclear or cytosolic buffer and made up in 0 .2 mg/ml increments from 0  to 2 mg/ml in a 
final volume of 10|il. The samples were aliquoted into lOpl volumes and all were added 
to a 96 well plate and then mixed with 0.2mls of BCA assay solution. The plate was 
incubated at room temperature for 30 min then analysed at an absorbance of 492nm on 
an SLT Spectra plate reader. Unknown sample protein concentrations were calculated 
by plotting a best-fit straight line o f the absorbance at 492nm versus each standard 
protein concentration then using the absorbance data reading for unknown values from 
that line.
2.2.13 Protein Assay
"BioRad" protein assay buffer was diluted 1 in 5 in distilled H2O and filtered through 
Whatman 3MM paper. BSA protein standards were made up in Eppendorf tubes as 
previously described, in either RIPA buffer or nuclear extract buffer to a volume of 20pi. 
A 1:10 dilution o f sample was prepared by extracting 2 pi and mixing with the 
appropriate buffer in a final volume o f 20pl. The assay buffer was added to each tube in 
a final volume of 1ml. After brief vortexing, the standards and samples were transferred 
to disposable 1ml spectrophotometer cuvettes and analysed on a spectrophotometer at 
an absorbance o f 595nm. Sample protein concentrations were derived from a standard 
curve, as previously described, then multiplied by the appropriate dilution factor to give 
a final protein concentration.
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2.2.14 Preparation of Competent Cells
A sample of approximately 2pi of JM109 or DH5-a Escherichia (E.) coli cells was 
collected from aliquots stored at and transferred to 10ml Luria Bertani (LB)
media. The innoculated media was incubated at 37^C overnight in a shaker at 300rpm. A 
2ml aliquot was transferred to 200ml and incubated in a 37^0 shaker at SOOrpm. Regular 
1ml samples were withdrawn from the culture and optical density (OD) was determined 
by spectrophotometry at an absorbance of 550mn. The culture was allowed to grow 
until an OD value of 0.45 was reached for both cell types. The culture was then 
transferred to 200ml centrifuge tubes, incubated on ice for 15 min then pelleted by 
centrifugation at 3000 x g at 4^C for 5 min in a JA14 rotor. The supernatant was 
discarded and pellet resuspended by addition of 80ml Tfbl buffer, then incubated on ice 
for 15 min. Cells were pelleted as previously described, the supernatant discarded and 
the cells resuspended in 8 ml o f Tfbll bufer. Cells were aliquoted and either used 
immediately or frozen by exposure to an ethanoLdry ice mixture and stored at -70^0.
2.2.15 Transformation of Competent Cells
Competent JM109 or DH5a E. coli cells were added in lOOpl amounts to pre-chilled 
sterile Eppendorfs at 4^C. Two microlitres of each plasmid was added to the cells and 
gently mixed before incubating on ice for 30 min. The mixture was heat-shocked by 
direct transfer to a hot plate at 42^C for 40s, then returned to ice. Each sample was 
treated with 1ml SOC medium then incubated at 37^0 on an orbital shaker at 300rpm 
for Ih. LB agar plates containing 50pg/ml ampicillin were innoculated with the 
transformed cells by spreading, and allowed to dry before inversion and 37^C incubation 
overnight.
■Î
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2.2.16 Plasmid Purification
A single colony of transformed E. coli JM109 or D H la  cells was picked from a freshly 
streaked LB agar plate with a sterile tip then cultured in 10ml LB media containing 
50jag/ml ampicillin. The innoculated media was incubated at 37^C overnight in a shaker 
at 300rpm. A 1ml aliquot o f culture was retained and assessed by mini-prep purification 
and restriction enzyme digest for the presence of the ligated DNA.
2.2.17 Mini-Prep
A 1ml aliquot was retained from the 10ml overnight culture and pelleted by 
centrifugation at 3944 x g for 5 min. The pellet was resuspended in lOOpl of a 90% (v/v) 
sucrose-tris-EDTA- Triton-X (STET)/10% (v/v) lOmg/ml lysozyme solution and 
denatured by boiling in water for 2 min. Centrifugation at 11,598 x g for 10 min pelleted 
cell debris and the supernatant was retained in a fresh Eppendorf. DNA was precipitated 
by the sequential addition of 400pl 0.3M CHsCOONa and 500pl (CH3)2CHOH then 
incubated at -20^C for Ih. DNA was pelleted by centrifugation at 11,598 x g for 1 0  min. 
The DNA pellet was washed with 100pi 70% (v/v) CH3CHOH then retained following 
centrifugation at 11,598 x g for 5 min. The supernatant was discarded and excess 
ethanol evaporated by air drying for 5 min. Purified DNA was resuspended in 30pl of 
TE buffer and analysed by double restriction enzyme digest as previously described but 
with the inclusion of 1 pi 25mg/ml RNAse A.
2.2.18 Maxi-Prep
Innoculated media were further diluted to 200mls in LB medium containing 50pg/ml 
ampicillin. The culture was grown at 37^C for 12-16h on a shaker at 300rpm. Bacterial 
cells were then haiwested by centrifugation at 6000 x g for 15 min at 4^C in a Beckman 
JA-20 rotor. All plasmid DNA was isolated and purified using a Qiagen plasmid
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purification kit. Cells were resuspended in 1 0 ml buffer PI then treated with 1 0 ml lysis 
buffer P2. Samples were gently mixed then incubated at room temperature for 5 min. 
Ten millilitres of ice-cold neutralization buffer P3 was added then samples gently mixed 
before incubation on ice for 20 min. The lysis mixture was pelleted by centrifugation at 
20,000 X g for 30 min at 4°C using a JA-20 rotor. The supernatant was transferred in a 
fresh tube then centrifuged at 20,000 x g for 15 min at 4^C. Plasmid DNA was collected 
hy column gravity filtration of the supernatant, then washed in buffer QC. DNA was 
eluted by washing the column with 15ml buffer QF and was collected in a fresh tube. To 
precipitate DNA, 10.5ml room temperature (CH3)2CHOH was added to the samples 
which were then pelleted by centrifugation at 15,000 x g for 30 min at 4®C using a JA- 
2 0  rotor. The pellet was washed in 70% (v/v) room temperature CH3CHOH, repelleted 
by centrifugation (as above) for 10 min then air dried for 5 min. The plasmid DNA pellet 
was resuspended in 700 pi TE buffer and DNA concentration determined by 
spectrophotometric analysis o f a 1 :1 0 0  dilution in a quartz cuvette at an absorbance of 
260nm.
2.2.19 Polymerase Chain Reaction (PCR)
Human CD25 STAT6  deletion mutant constructs were synthesised by PCR in a volume 
of 100 pi, consisting of a lOOng pCD25 CAT-E' basic template, 20% (v/v) 10 x Taq 
buffer, 0.5% (v/v) Taq polymerase, 1.5mM MgCl2, 250pM deoxynucleotide 
triphosphate (pNTP) mix, 0.5pmol/pl universal primer and 50pmol/pl STAT6  deletion 
mutant primer. The mixture was placed in a thermal cycler and subjected to a 3 min 
94^C denaturing phase, 35 x 30s cycles of amplification at 94^C, two sequential 1 min 
phases at 55^C and 72^0, and a final 1 0  min phase at 72^0. PCR products were purified 
by electrophoresis on a 1% low melting point agarose gel containing 4ng/ml ethidium 
bromide at lOOV, UV exposure and the amplified nucleic acid bands cut out.
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Purification was achieved using a QIAquick gel extraction kit which involved weighing 
the gel slice, then adding three volumes of extraction buffer to one volume of gel. The 
mixture was heated at 50^C, for 10 min, with occasional vortexing. Addition of 
approximately lOpl o f 3M CHsCOONa, (pH 5.0) lowered the pH of the mixture to 7.5 
which prevented DNA degradation. One gel volume equivalent of (CH3)2CHOH was 
added to increase the yield o f DNA fragments which were then bound to a column by 
drawing the mixture through a vacuum manifold. The DNA was washed with 70% 
ethanol which was removed by applying a vacuum. Excess buffer was removed by 
transferring the column to an eppendorf and centrifugation at 8,050 x g for 1 min on a 
biofijge. DNA was eluted in 50pl TE buffer and then collected in a sterile Eppendorf 
tube by centrifugation at 8,050 x g.
Restriction fragments with cohesive ends were generated by restriction enzyme double 
digest with Hind III and Sal I. The digestion products were separated by 
electrophoresis on a 1% (w/v) low melting point agarose gel and identified by running 
alongside 1 kilobase and 1 0 0  base-pair ladders and cut out using a sterile scalpel. The 
desired fragment was purified as described above. The same restriction enzyme double 
digest was employed with a pCAT-E' basic vector which contained Hind  III and Sal I 
cutting regions in a multiple cloning site. The digested vector was separated by 
electrophoresis on a 1% (w/v) low melting point gel, the cut band was discarded and the 
vector was retained and purified as before. Vector concentration was determined at an 
absorbance o f 260nm in a quartz cuvette and adjusted to lOOng/pl in TE buffer.
Ten nanograms o f purified cut pCAT-E' basic vector was mixed with approx 700ng of 
restriction fragments with cohesive ends, Ipl DNA ligase and Ipl DNA ligase buffer 
then incubated for 12h at 17^C. The pCAT CD25 STAT6  deletion mutant constmct was 
then inserted into competent E. coli. cells by transformation. Transformed E. coli cells 
were then cultured in LB broth and transferred to a larger volume until sufficient growth
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was achieved. The plasmid DNA was isolated from the culture and purified as described 
in section 2.2.18, then stored at -2 0 ^0 .
2.2.20 Cydic-AMP Dependent Kinase (PKA) Assay
Tonsillar B cell or B cell lineage extracts at a concentration of 3mg/ml were added in a 
volume o f lOpl to a PKA reaction mixture consisiting o f 4pl 5x PKA bufifer, 2 pl 
1.25mM ATP and 2pl lOOpM okadaic acid. Extracts were pre-incubated at 30%  for 10 
min then treated with or without 50pg/ml PKA catalytic subunit in the presence of 2pl 
dH2 0 , 2 pi o f the PKA inhibitor PKI, at a concentration of 1 mg/ml or 2pi o f the PKA 
inhibitor, H-89 at a concentration o f 0.5pM. Aliquots o f 2pi were taken from eveiy 
reaction mixture after 0, 5, 10, 20, 30, 60 and 120 min incubation at 30^0 and were 
added to Eppendorfs containing 20% (v/v) 5x binding buffer then incubated with and 
without the presence o f excess unlabelled oligonucleotide for ten minutes at room 
temperature. Each sample was then mixed with radiolabelled probe and subjected to 
EMSA as described above.
2.2.21 FACScan Analysis of B Lymphoid Cells
After incubation of either treated or untreated tonsillar B cells or B cell lines, 5 x 10  ^
cells/ml were harvested and washed twice in PBS by centrifugation at 250 x g. The 
pellet was then resuspended in 100pi PBS and transferred to a 12  x 75mm plastic tube. 
Cells were treated with 3 pi o f RPE-conjugated anti-human B cell CD 19, 3 pi of FITC- 
conjugated anti-human B cell CD25 or 3 pi of FITC-conjugated anti-human T cell CD3, 
then after brief vortexing, incubated in dark conditions on ice for 30 min. Cells were 
pelleted by centrifugation at 250 x g then resuspended in 500pi PBS. Samples were 
treated wth 5 pi 1 mg/ml propidium iodide to enable gating of dead cells, then analysed by 
flow cytometry. CD25 expression was calculated by dividing the number of 
CD19+/CD25+ B cells with the combined total of CD19+/CD25- and CD19+/CD25+ B
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cells. The value obtained was multiplied by 100 to give the percentage of B cells 
expressing CD25. The value of percentage CD3 or CD 19 expression was calculated 
using the same method.
2.2.22 Statistical Analysis
All statistics were calculated as a Standard Error Mean (SEM) using Student's Paired t 
Test.
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CHAPTERS
CELLULAR SIGNALLING MECHANISMS IN IL-4 STIMULATED B CELLS.
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3.1 Introduction
IL-4 stimulates several cell signalling pathways in B cells through the IL-4R complex, 
leading to a number o f cellular events which regulate B cell function. The events that 
follow the binding of IL-4 to its receptor involve receptor-associated kinases which 
phosphorylate specific signalling molecules. This leads to the induction of B cell 
proliferation, differentiation and gene activation, leading to the expression of 
immunologically important molecules, such as MHC class II, CD23 and CD25. Signal 
transduction pathways important in IL-4R signalling in B cells include cAMP (McKay 
and Cushley, 1996), PLCy, PI-3 kinase and the induction of the JAK/STAT activation 
mechanism (Finney et a l, I990;Nelms et al, 1999).
Adjacent to the NRRi_n regions of the human CD25 promoter region lies PRRi. The 
PRRi region is sensitive to antigen and mitogen-induced signalling and contains binding 
sites for SRF and the ubiquitous transcription factor NF-kB. Both cAMP and PKA have 
been shown to regulate NF-kB either directly or indirectly (Baeurle and Henkel, 
1994;011ivier et al, 1996) The fact that NF-kB has a multifactorial role in 
transcriptional regulation, is sensitive to cAMP and PKA, and binds to PRRi suggests 
that it may be involved in IL-4-induced CD25 expression.
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3,2 Isolation of Quiescent Tonsillar B Cells and their Activation by IL-4.
Quiescent tonsillar B cells were isolated as described in section 2.2.2. Samples were 
retained before and after treatment with SRBC-AET, which induced T cell resetting. 
Aliquots were stained with FITC-labelled anti-CD3 and RPE-labelled anti-CD 19 to 
quantitate the populations o f T and B cells, respectively. Samples were analysed by 
FACScan using two-colour flow cytometry and all CD3VCD19+ and CD3+/CD19" cells 
were assessed. Figure 3.1a shows that samples analysed before SRBC-AET treatment 
had a large population of CD3 /CD19^ (upper left quadrant) cells and a similar 
population o f CD3+/CD19" (lower right quadrant) cells. Figure 3.1b shows samples 
analysed after SRBC-AET treatment, which had enriched the population of CD3 
/CD 19+ (upper left quadrant) cells and had significantly reduced the population of 
CD3+/CD19' cells (lower right quadrant). The decrease in CD3+/CD19' cells after 
SRBC-AET treatment suggests that a proportion of T cells have been rosetted and 
subsequently removed, leaving a population which is enriched for B cells. The isolated 
tonsillar B cells were treated with recombinant human (rh) IL-4 and incubated over a 
period of 24-48h. Cells were harvested and stained with RPE-anti-CD19 and FITC-anti- 
CD25 then analysed by flow cytometry for CD19+/CD25+ B cells. Figure 3.2 panel a) 
shows a population of untreated tonsillar B cells after 24h incubation. A high percentage 
of cells were CD 19+ and are identified in the upper left quadrant. In the upper right 
quadrant, there is a population o f CD19+/CD25+ B cells. Figure 3.2b shows a population 
of tonsillar B cells which had been treated with rh-IL-4. In the upper left quadrant, there 
remained a subset o f CD 19 single positive B cells. In the upper right quadrant there was 
a modest increase in the population of B cells which were CD19+/CD25+, suggesting 
that IL-4 treatment leads to the up-regulation of CD25 expression in quiescent tonsillar 
B cells.
97
3.3 EMSA Studies of NRE Binding Activity in IL-4-Treated Tonsillar B Cells.
The IL-4-driven up-regulation of CD25 expression is mediated, at least in part, by a 
cAMP/PKA signalling pathway. This signalling pathway was investigated by treating 
quiescent tonsillar B cells with pharmacological compounds which modified cAMP/PKA 
activity. Quiescent tonsillar B cells were treated with and without IL-4 and, over a four 
hour incubation, samples were taken and cell extracts prepared. The extracts were 
incubated with a radiolabelled CD25-NEŒ oligonucleotide, then assessed for protein 
binding activity by EMSA analysis. Experiments were performed to assess the effect of 
IL-4 treatment and to examine the effect of an adenylate cyclase stimulating compound, 
Forskolin, on NRE binding activity in tonsillar B cells. Figure 3.3 panel a shows the 
single specifically shifted species indicative of a protein binding to the radiolabelled 
CD25-NRE oligonucleotide which was competed by the addition of an unlabelled five­
fold excess o f CD25-NRE. Treatment of B cells with either IL-4 or Forskolin caused a 
loss of binding activity over a four hour period (Figures 3.3b and 3.3c, respectively). A 
similar result was observed following treatment with the Gsa~protein activator, Cholera
Toxin (data not shown).
3.4 EMSA Studies of the Effects of PKA Catalytic Subunit on Quiescent Tonsillar 
B cells.
The role o f the cAMP/PKA signalling pathway in IL-4-induced CD25 expression was 
further investigated using an assay which assessed a possible direct effect of PKA on 
NRE-BP. EL-4 stimulated loss o f NRE-BP binding activity in the CD25 promoter in 
tonsillar B cells is mimicked by the cAMP-inducing agent Forskolin. Previous work in 
this laboratoiy showed that the PKA-specific inhibitor, H-89, could block the effects of 
EL-4, whereas the PKC-specific inhibitor, bis-indolylmaleimide, had no effect (McKay et 
al., 1999) From this information, an experiment was designed to assess whether the
direct action of the catalytic subunit o f PKA (PKAc) could abrogate the DNA binding
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activity o f NRE-BP over a short period o f time, EMSA experiments on samples taken 
during the incubation reaction would demonstrate, if PKAc acted directly on NRE-BP, 
that protein binding to radiolabelled CD25 oligonucleotide would be lost. If  the action of 
PKAc was indirect then protein binding would be unaffected in samples taken 
throughout the reaction (Figure 3.4). An incubation reaction containing EDR B cell 
whole cell extract was treated with and without PKAc and with or without the presence 
of one of two specific PKA inhibitors, H-89 and protein kinase A inhibitor (PKI); each 
reaction mixture also contained the phosphatase inhibitor, Okadaic acid. Samples were 
taken over a two hour period then extracts prepared and incubated with a radiolabelled 
oligonucleotide sequence which either contained the short CD25-NRE sequence, or the 
NRE-intact/AP-1-mutant oligonucleotide, CD25-NRRi-M2, then analysed by EMSA.
Figure 3.5i (left panel) shows oligonucleotide binding activity in EDR B cell whole cell 
extract to radiolabelled CD25-NRE oligonucleotide which is competed by the addition 
of an unlabelled two-fold excess of CD25-NRE. In control reactions lacking PKAc, 
protein binding was unaffected over 20 minutes of incubation (figure 3.5ii) and up to 
two hours o f incubation (data not shown). Figure 3.5iii shows protein binding activity in 
samples taken from incubation reactions with PKAc. A single protein species bound to 
radiolabelled CD25-NRB oligonucleotide which was unaffected over the first 2 0  minutes 
of incubation and up to two hours o f incubation (data not shown). The PKA inhibitors 
PKI and H-89 had no effect on protein species binding to radiolabelled CD25-NRE 
oligonucleotide or CD25-NRRi (data not shown). These findings were also shown in 
repeated EMSA studies on PKA assay samples using radiolabelled CD25-NRRi-M2 
oligonucleotide(Figures 3.5i-iii, right panel).
3.5 Effect of Signalling Inhibitors on BL-4-Driven CD25 Expression.
The signalling mechanisms by which IL-4 initiates the up-regulation o f CD25 expression 
were investigated. Freshly-isolated quiescent tonsillar B cells were pre-treated with cell
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signalling inhibitors, before stimulation with IL-4. In particular, a potential role of PI-3 
kinase on IL-4-driven CD25 upregulation was tested by treating cells with the PI-3 
kinase inhibitor, Wortmannin. A ftirther inhibitor, Rapamycin, was used to study the 
efiect of blocking the activation o f a downstream PI-3 kinase-sensitive serine/tlireonine 
kinase, p70^^ kinase. As IL-4R signalling does not utilise the Ras/MAP kinase signalling 
pathway in B cells (Welham et al, 1994), the MEK kinase inhibitor PD98059 was used 
as an internal control. After inhibitor pre-treatment, tonsillar B cells were treated with 
and without IL-4 and incubated for 24-48 hours. Samples were removed at 24 and 48 
hours and the B cells were analysed for CD25 expression by flow cytometiy.
Figure 3.6 shows a graph outlining the effect o f inhibitors on the capacity of IL-4 to up- 
regulate CD25 expression. IL-4 treatment of tonsillar B cells over 24 and 48 hours of 
incubation lead to a three- and four-fold increase in the expression of CD25, 
respectively. Pre-treatment of tonsillar B cells with 2pM or 20pM PD98059 over 24 and 
48 hours had no effect on the capacity of IL-4 to upregulate CD25 expression, as 
anticipated. Pre-treatment of tonsillar B cells with 5nM and 50nM Wortmannin over 24 
and 48 hoursdid not effect IL-4-driven CD25 expression. Finally, pre-treatment with 
500pM and 50pM Rapamycin failed to affect IL-4-mediated upregulation of CD25 
expression in tonsillar B cells over 24 and 48 hours of incubation. Inhibition of PI-3 
kinase and p70®  ^ kinase activation appears to have no effect on the capacity of EL-4 to 
increase CD25 expression in tonsillar B cells.
3.6 EMSA Studies of NF-kB Expression in IL-4 Treated EDR B cells.
The effect o f IL-4R signalling on NF-KB was investigated using EMSA analysis of EDR 
B cell whole cell extract, cytosolic extract and nuclear extract. Firstly, EDR B cells were 
assessed for the expression o f NF-kB both in untreated and EL-4-treated whole cell 
extracts which were prepared over a four hour incubation period. Secondly, the 
activation o f NF~kB was assessed. In most cells, inactive NF-kB is located in the cell
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cytoplasm, bound by IkB. Activation o f NF-kB is achieved by the IKK-induced 
phosphorylation of IkB, which leads to degradation of the complex and the subsequent 
uncoupling of IkB from NF-kB, The transcription factor then migrates to the nucleus 
where it can regulate gene expression (May and Ghosh, 1998). Therefore, in order to
investigate NF-kB activation, both cytosolic and nuclear extracts were prepared from 
EDR B cells which were treated with and without IL-4. Extracts were prepared over a 
four hour incubation period then incubated with radiolabelled NF-kB oligonucleotide 
and analysed by EMSA.
In whole cell, cytosolic and nuclear extracts, two slow mobility species specifically 
bound to radiolabelled NF-kB oligonucleotide. Figure 3.7 panel a shows a study of EDR 
B cell whole cell extracts. Protein binding to radiolabelled NF-kB was competed by an 
unlabelled five-fold excess of NF-kB oligonucleotide. Figure 3.7b shows that protein 
binding to radiolabelled NF-kB was unaffected in untreated samples taken over four 
hours. Extracts which were generated from cells treated with IL-4 showed that protein 
binding to radiolabelled NF-kB was also unaffected over four hours. Figure 3.7c shows 
a study o f EDR B cell cytosolic extracts. Protein binding to radiolabelled NF-kB was 
unaffected in both treated and untreated samples generated over four hours of 
incubation. Figure 3.7d shows a study of EDR B cell nuclear extract. Protein binding to 
radiolabelled NF-kB was unaffected in samples generated over four hours without IL-4 
treatment. Extracts prepared from IL-4-treated cells showed that protein binding to 
radiolabelled NF-kB in samples generated over three hours of incubation was 
unaffected; however protein binding was slightly diminished in samples generated after 
the fourth hour of incubation.
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3.7 Discussion.
EL-4 has been shown to up-regulate CD25 expression in human B ceils (Burlinson et al, 
1995;Butcher et al., 1990;Zola et al., 1991). This important immunological frmction was 
investigated by studying the signalling pathways that are activated by IL-4R stimulation. 
These include cAMP/PKA, PKC, PI-3 kinase and JAK/STAT pathways. JAK/STAT 
signalling is discussed in Chapter 5 and therefore will not be considered in this section. 
IL-4 up-regulates CD25 expression in human quiescent tonsillar B cells. EMSA studies 
of IL-4-treated B cells shown in Figure 3.3b demonstrate that IL-4 abrogates NRE 
binding activity over four hours of incubation. This effect was mimicked by the 
pharmacological activator, Forskolin (Figure 3.3c), which increases the intracellular 
concentration o f cAMP via the stimulation of AC. These findings support previous 
studies, and indicate that IL-4 causes the expression of CD25 in human B cells by 
abolishing NRE-BP binding to NRE via a cAMP/PKA sensitive mechanism.
A potential role of EL-4-activated PKAc is direct phosphorylation o f NRE-BP, thus 
attenuating NRE binding activity and enabling CD25 expression. Failure of PKAc to 
abolish protein binding to three different NRE sequence-containing oligonucleotides, 
demonstrates that PKAc does not have a direct phosphorylating effect on NRE-BP in 
human B cells (Figure 3.5b). This was unexpected as the finding that H-89 blocked the 
effects o f IL-4 on NRE binding activity suggested that PKAc may directly uncouple or 
degrade NRE binding proteins. A possible explanation is that PKA acts to stimulate 
further downstream effector molecules, and has no direct contact with NRE-BP. A 
candidate for PKA-induced activation which may induce NRE-BP degradation is the 
cAMP/PKA-regulated transcription protein CREB. The shared cAMP response element 
and ATF-1 binding region (TGACGTCA) is homologous to the putative AP-1 site 
(TGACTCC) within NRRi indicating a potential site of interaction for CREB (Lee and 
Masson, 1993). Therefore, activated CREB, which interacts with CBP, may bind to the
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putative AP-1 site and enable CD25 transcription by activating the region, thus inducing 
the loss o f NEŒ binding activity.
The role o f the multi-functional PI-3 kinase on IL-4-driven CD25 expression was 
investigated using two inhibitors; Wortmannin, the PI-3 kinase-specific inhibitor and 
Rapamycin, a specific inhibitor of the PI-3 kinase-inducible p70®  ^ kinase. Both 
Wortmannin and Rapamycin did not affect the capacity of IL-4 to up-regulate CD25 
expression on tonsillar B cells over 24 and 48 hours (Figure 3.6). IL-4R stimulation 
leads to the activation o f PI-3 kinase signal transduction; however, the failure of either 
Wortmannin or Rapamycin to block CD25 up-regulation strongly suggests that PI-3 
kinase is not involved in IL-4-driven CD25 expression in human B cells. The finding that 
PI-3 kinase inhibition failed to affect IL-4-driven CD25 regulation additionally suggests 
the involvement of downstream proteins such as PKB and PKCÇ, as well as p70®  ^kinase 
is unlikely. The Ras/MAP kinase signalling pathway is unstimulated by IL-4 in B 
lymphocytes. Previous work in this laboratory indicates that PKC activation has no 
effect in IL-4-driven CD25 expression, therefore any involvement o f PLC-y2, IP3 or NF- 
AT is unlikely (McKay et al, 1999).
Finally, the role of the ubiquitous transcription factor NF-kB in IL-4-regulated CD25 
expression was investigated. Figure 3.7b shows that whole cell extract protein binding to 
the NF-xB probe was unafffected by IL-4 treatment. This study serves as a control for 
the expression of NF-kB in B cells. The fact that NF-kB is constitutively expressed and 
that its activation state is dependent on IkB-binding suggests that analysis of whole cell 
extract can only determine the expression o f NF-kB, rather than its activation 
(DiDonatoet al, 1997). Cytosolic extracts were probed with radiolabelled NF-kB 
oligonucleotide (Figure 3.7c) and in common with whole cell extract, EMSA analysis 
showed that protein binding was unaffected in cells treated with IL-4. This suggests that 
IL-4 does not directly activate NF-kB. IL-4-induced phosphoiylation of IkB would lead 
to the uncoupling of the IkB-NF-icB complex and the migration of NF-kB to the
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nucleus. This may be indicated by an attenuation of protein binding to the NF-kB probe 
in cytosolic extract. Figure 3.7d showed that nuclear extracts bound protein to the NF- 
kB probe which in untreated cells was unaffected over four hours. In IL-4-treated cells, 
binding was unaffected after three hours although after four hours, binding was 
somewhat diminished. Given the capacity of IL-4 to abolish NRE binding activity after 
approximately one hour o f incubation (Figure 3.3b), it is unlikely that the diminution of 
NF-KB-binding is directly linked to IL-4 signalling. In addition, the failure o f IL-4 to 
abrogate protein binding to radiolabelled NF-kB in cytosolic extracts over four hours 
(Figure 3.7c) suggests that any effect o f IL-4 on NF-kB witliin the nucleus is likely to be 
a result o f secondary effects. This finding was unexpected as PRRi, which lies adjacent 
to NRE, contains a binding domain for NF-kB which has been reported to be sensitive 
to mitogen stimulation in T cells (Pierce et al., 1995).
A possible mechanism o f secondaiy action may be through cAMP/PKAc activation of 
CREB. Studies have shown that CBP, the transcriptional protein which binds CREB, 
can interact with the p65 subunit o f NF-kB and potentiate transcriptional activity. The 
interaction o f CBP with NF-kB is dependent on CBP involvement with CREB 
(Gerritsen et al., 1997). Another possible role o f IL-4R signalling in NF-kB activation is 
the activation of cAMP-independent PKAc. Studies have shown that PKAc is contained 
within the NF-kB-IkB complex in an inactive state. When NF-kB is activated by the 
degradation of IkB, the PKAc subunit also becomes activated and phosphoiylates the 
NF-kB p65 subunit. This leads to a marked increase in the transcriptional activity of NF- 
kB (Zhong et al, 1997). If  PKAc is able to stimulate the NF-kB p65 subunit from within 
the complex then it is possible that PKAc generated outwith the complex may either 
directly activate NF-kB or potentiate the activation o f NF-kB by combining with 
complex PKAc upon the phosphoiylation of I-kB. Therefore, a cAMP-independent or 
dependent activation o f PKAc can enhance NF-kB transcriptional activity. An increase 
in NF-kB transcriptional activity leads to an increase in the expression of IicB, therefore 
it is possible that inactivation and relocation of NF-kB in the cytosol by complexing with
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IkB may explain the loss o f binding after four hours. The possible IL-4-driven loss of 
NF-kB binding activity in nuclear extracts is not consistent with the unaffected protein 
binding o f the cytosolic extract.
In summary, IL-4 treatment o f human B cells up-regulates the expression of the unique 
IL-2 receptor component, CD25. EMSA studies on EDR B cells demonstrated that IL-4 
achieves CD25 up-regulation by removing NRE binding activity, via a cAMP/PKLA- 
sensitive pathway. The exact mechanisms coupling the IL-4R to cAMP accumulation are 
unclear. Experiments on EDR B cell extracts showed that PKAc does not have a direct 
effect on NRE-BP, suggesting that PKAc activates further unidentified downstream 
molecules which abolish NRE-BP binding to NRE. Experiments investigating signalling 
pathways failed to identify a further mechanism involved in the IL-4-driven up­
regulation of CD25 expression. Inhibitor experiments which blocked the activity of PI-3 
kinase and p70®  ^ kinase failed to prevent IL-4-induced up-regulation of CD25. EMSA 
studies demonstrated that NF-kB activity was diminished after four hours of IL-4 
treatment, however this is unlikely to be a direct effect of the IL-4-stimulated 
cAMP/PKA pathway.
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Figure 3.1 Isolation of Tonsillar B Cells from a Mononuclear Cell Population.
Aliquots o f tonsillar mononuclear cells (Panel a) and isolated tonsillar B cells (Panel b) 
(1 X 10  ^cells) were stained with RPE-conjugated monoclonal anti-CD 19 antibody and 
FITC-conjugated monoclonal anti-CD3 antibody and analysed by flow cytometry. 
Populations of CD37CD19+ cells are located in the upper left quadrant o f both panels 
and CD3+/CD19" cells in the lower right quadrants.
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Figure 3.2 BL-4 Induces CD25 Expression in Tonsillar B Cells.
Aliquots o f unstimulated tonsillar B cells (1 x 1 0  ^ cells) from healthy donors were 
harvested after 24h treatment in the absence (Panel a) or presence (Panel b) o f 500U/ml 
IL-4, and stained with RPE-conjugated monoclonal CD 19-specific antibody and FITC- 
conjugated monoclonal CD25-specific antibody, then analysed by flow cytometry. In 
both panels, CD19+/CD25' cells are located in the upper left quadrant and 
CDI9+/CD25+ cells are in the upper right quadrant. Data was generated from the 
analysis o f 1 0 ,0 0 0  events (1  event == 1 cell).
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Figure 3.3 EMSA Analysis on the Effect of cAMP/PKA Activation on NRE-BP.
Figure 3.3a shows analysis of 5gg of untreated EDR whole cell extract by EMSA for 
binding to ^^P-labelled CD25-NRE oligonucleotide in the absence or presence of 2-fold 
excess unlabelled CD25-NRE oligonucleotide as competitor. Whole cell extracts were 
prepared at hourly intervals from quiescent tonsillar B cells after incubation with 
500U/ml EL-4 (Fig. 3.3b) or lOOpM Forskolin (Fig 3.3c), and 5pg of protein extract 
was analysed by EMSA for binding to ^^P-labelled CD25-NRE oligonucleotide. Specific 
binding activity for NRE-BP is indicated by horizontal arrows
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Figure 3.4 Hypothesis on the Effect of PKAc on NRE Binding Activity.
EL-4R signalling stimulates a cAMP/PKA sensitive pathway which leads to the loss of 
NRE binding activity. The loss o f NRE-BP to NRE is sensitive to PKAc and this may be 
through a direct or indirect mechanism of action (upper panel). A proposed model to 
explain the activity of PKAc on NRE binding activity is shown in the middle panel. 
Treatment o f B cell extracts with activated PKAc may lead to either a direct (arrow A) 
or indirect effect (arrow B) on NRE binding activity, indicating whether PKAc acts to 
directly attenuate NRE-BP binding or stimulates ftirther downstream elements which 
affect NRE binding activity. Predicted EMSA results are indicated in the bottom panel.
109
cAMP accumulation 
and PKA activation
Loss of NRE-BP activity
Cell
extract
PKAc
NRE-BP
NRE-BP
Predicted EMSA 
A B
NRE-BP 
< ►
Figure 3.5 EMSA Analysis on the Effect of PKAc on NRE Binding Activity.
Whole cell extracts were prepared from EDR B cells (5 x 10  ^ cells). Aliquots of 30pg 
were mixed with 4pl 5x PKA buffer, 2pl 1.25mM ATP and 2pi lOOpM okadaic acid and 
incubated at 30*^ C with or without 2pl of 50pg/ml PKA catalytic subunit, 2 pi of Img/ml 
PKI and 2pl o f 0.5pM H-89. Aliquots were taken after 0, 5,10,20,30,60 and 1 2 0  min. 
The left hand panel shows analysis of 5pg of untreated EDR whole cell extract by 
EMSA Fig 3.5i) for binding to ^^P-labelled CD25-NRE oligonucleotide in the absence 
or presence o f 2-fold excess unlabelled CD25-NRE oligonucleotide as competitor. 
Figure 3.5ii shows the binding activity of a control, untreated extract taken over 20 min. 
Figure 3.5aiii shows binding activity of an identical extract exposed to 5pg PKAc over 
the same period. The right hand panel shows analysis of 5pg of untreated whole cell 
extract by EMSA (Fig 3.5bi) for binding to ^^P-labelled CD25-NRRi-M2 
oligonucleotide in the absence or presence of 2-fold excess unlabelled CD25-NRRi-M2 
oligonucleotide as competitor. Figure 3.5bii shows the binding activity o f a control, 
untreated extract taken over 2 0  min. Figure 3.5biii shows binding activity o f an identical 
extract exposed to 5pg PKAc over the same period. Specific binding activities for 
untreated extracts are indicated by horizontal arrows.
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Figure 3.6 Effect of Signalling Pathway Inhibitors on IL-4-Driven CD25 
Expression in Tonsillar B Cells.
Aliquots o f 1 X 10  ^ tonsillar B cells were harvested after 24h and 48h treatment in the 
absence or presence of 50pM and 500pM Rapamycin, 5nM and 50nM Wortmannin, 
2pM and 20pM PD98059 and 500U/ml IL-4, then stained with RPE-conjugated 
monoclonal anti-CD 19 antibody and FITC-conjugated monoclonal anti-CD25 antibody 
and analysed by flow cytometry. Both graphs are representative o f CD19+/CD25^ cells 
as a percentage of the total population of CD19^/CD25- and CD19+/CD25+ cells. 
Values represent means of relative reporter activity (±SEM) from ten independent assays
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Figure 3.7 Effect of IL-4 on NF-kB Expression in EDRB Cells.
The binding activity o f 5pg aliquots of protein extract prepared from unstimulated EDR 
B cells for ^^P-labelled NF-kB oligonucleotide was assessed by EMSA (Fig. 3.7a) in the 
absence or presence of unlabelled 5-fold excess NF-kB oligonucleotide. Whole cell (Fig 
3.7b), cytosolic (Fig 3.7c) and nuclear extracts (Fig3.7d) were prepared at hourly 
intervals from EDR B cells after incubation in the absence or presence o f 500U/mI IL-4, 
and 5pg o f protein extract assessed by EMSA for binding to ^^P-labelled NF-kB 
oligonucleotide. Specific binding activities are indicated by horizontal arrows.
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CHAPTER 4
REGION I (NRRi) OF THE HUMAN CD25 PROMOTER.
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STUDIES OF PROTEIN INTERACTIONS WITH NEGATIVE REGULATORY
4.1 Introduction.
The NRRi region of the human CD25 promoter is characterised by an 11-bp NEJE region 
and a retinoid-sensitive region characterised by the presence o f a consensus AP-1 
binding site. In T cells, the NEŒ region (TTCATCCCAGG) is suppressed by a 50kDa 
silencer protein which was identified in UV cross-linking studies (Smith and Greene, 
1989). Binding o f this protein to NRE leads to the prevention o f CD25 gene expression 
in T cells. A possible candidate for NRE-BP is the ubiquitous transcription factor YYl. 
Although greater than 50kDa in mass, NRE has the minimal 5'- CAT -3' binding region 
for this 65kDa transcription factor and YYl has been reported to have a negative 
regulatory effect on gene transcription (Shi et al., 1991). Other molecules of interest 
include the Ets family o f transcription factors because NRE contains a 3 -GGA-5' core 
Ets binding site on the antisense strand, and the nuclear factor CBP/p300, which 
interacts with the cAMP/PKA stimulated CREB. The putative AP-1 binding site, 
adjacent to NRE, is homologous to the cAMP response element which is bound by 
CREB (Montminy et al., 1986). Given the size of CBP/p300, some 300kDa in mass, it is 
unlikely to fulfil the role o f NRE-BP. However, CBP/p300 may form a complex with the 
proteins binding to NRRi, possibly acting to bridge them together.
Retinoic acid (RA) also has an inhibitory effect on B cell function; studies in human B 
cells show that RA-treatment inhibits IL-4-induced IgE production and also prevents 
apoptosis (Lomo et al, 1998;Worm et al, 1998). In addition, RARE-specific 
oligonucleotide binding is blocked by IL-4, and RA has been shown to influence CD25 
expression in human B cells (Bhatti and Sidell, 1994). This indicates that proteins 
binding to NRE and the retinoid sensitive region may have a synergistic effect on 
silencing CD25 expression. The role o f AP-1 proteins binding to the putative 
TGACTCC binding site may have a positive or negative regulatoiy effect on gene 
transcription. In lymphocytes, AP-1 proteins have been shown to induce differentiation
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and activation (Foletta et al, 1998). Conversely, a truncated form o f fosB can inhibit fos 
and jun transcriptional activity (Nakabeppu and Nathans, 1991).
Work in Chapter 3 has described NRE binding activity in control and IL-4-stimulated 
cells. What is unknown is the nature o f protein binding to NRRj as a whole and whether 
the interaction between NRE and NRE-BP is affected by other proteins. In addition, the 
identity o f NRE-BP is still unknown, although there are several candidate proteins which 
require investigation. The putative AP-1 binding site has yet to be characterised, and if 
this site does bind AP-1 family members, the role of this region in NRE binding activity 
requires clarification.
4.2 Origins and Effect of IL-4R Signalling on Protein-Binding to N R R i.
The two binding regions, putative or otherwise, found within NRRi indicate that this 
sequence may be bound by several protein species. The fact that IL-4 can abolish NRE 
binding activity has been established; however, the effect of IL-4R signalling on protein 
binding to NRRi has not. In addition, IL-4R signalling can be driven by a complex o f the 
IL-4Ra subunit with either the yc chain or the IL-13R subunit (Dawson et al, 1997). 
Although the IL-4R complex in lymphocytes is comprised o f the IL-4Ra subunit and yc, 
the subunit-origin of IL-4R signalling which leads to the attenuation of NRE binding 
activity has not been determined.
EDR B cell whole cell extracts and quiescent tonsillar B cell nuclear extracts were 
prepared from cells treated with and without IL-4 over four hours. Extracts were probed 
with radiolabelled CD25-NRRi oligonucleotide and analysed by EMSA, Figure 4.1 
shows a study of EDR whole cell extracts. Figure 4.1a shows that three protein species 
bound to radiolabelled CD25-NRRi, the uppermost of which was competed by an 
unlabelled two-fold excess of CD25-NRRi oligonucleotide. In extracts prepared from 
untreated cells (Figure 4.1b), protein binding was unaffected over four hours. In
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contrast, ceil extracts prepared from IL-4-treated cells failed to bind protein to 
radiolabelled CD25-NRRi after two hours (Figure 4.1c). Figure 4.2 shows a study on 
tonsillar B cell nuclear extracts. Figure 4.2 shows that three protein species bound 
radiolabelled CD25-NRRi, all of which were competed by an unlabelled two hundred­
fold excess o f CD25-NRRr oligonucleotide. Protein binding in untreated cells was 
unaffected (data not shown); however, in common with EDR B cells, protein binding to 
the NRRi region was abrogated after two hours o f IL-4 treatment (Figure 4.2).
In order to assess the subunit origins o f IL-4R signalling, the effect of IL-13 on protein 
binding to NRRi was investigated. Quiescent tonsillar B cells were treated with a range 
of concentrations of IL-13 for four hours. Samples were taken hourly and nuclear 
extracts generated then probed with radiolabelled CD25-NRRi oligonucleotide then 
analysed by EMSA. Three protein species bound to radiolabelled CD25-NRRi, all of 
which were competed by the addition o f an unlabelled excess o f CD25-NRRi 
oligonucleotide. Figure 4.3 a shows that two protein species bound radio labelled CD25- 
NRRi, both o f which were competed by an unlabelled two hundred-fold excess of 
CD25-NRRi oligonucleotide. Figure 4.3b shows that protein binding was unaffected 
throughout the four hour incubation in untreated extracts and Figure 4.3c shows binding 
was unaffetced in extracts generated ftom cells treated with 3ng/ml o f IL-13. Figures 
4.3d and 4.3e show protein binding was unaffected in extracts generated from cells 
treated with 6 ng/ml and 12ng/ml of IL-13, respectively. This experiment was repeated, 
except extracts were probed with the NRE-intact/AP-1-mutant CD25-NRRi-M2 
oligonucleotide. Protein binding to radiolabelled CD25-NRRi-M2 was unaffected with 
and without treatment with a range of IL-13 concentrations (data not shown). These 
data are consistent with the interpretation that IL-13 does not affect protein binding to 
NRE or NRRi.
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4.3 EMSA Studies of Oligonucleotide Binding in Human Lymphoid Cells.
The NRE region and the putative AP-1 binding region in the NRRi sequence were 
analysed by EMSA experiments on cell extracts using four consensus and mutant 
oligonucleotides (described in section 2.1.2). Binding to NRE and the putative AP-1 
binding site was investigated in an attempt to characterise protein binding to the NRRi 
region. Cell extracts of untreated tonsillar B cells and a panel o f B and T-lineage cells 
were probed with radiolabelled NRRi oligonucleotides and then analysed by EMSA. 
Extracts were probed with radiolabelled CD25-NRRi, then protein binding was 
challenged by the individual addition o f an unlabelled two hundred-fold excess of CD25- 
NRRi, CD25-NRRi-Ml, CD25-NRRi-M2 and CD25-NRRi-M3 oligonucleotides. Each 
oligonucleotide was radiolabelled and used to probe cell extracts. Binding was 
challenged by the individual addition o f all four unlabelled oligonucleotides in a two 
hundred-fold excess, starting with the same oligonucleotide that was used as the probe. 
This procedure was repeated until each oligonucleotide had been used to probe the cell 
extracts and had been challenged by all four excess unlabelled oligonucleotides.
Figure 4.4 shows a study o f tonsillar B cell nuclear extracts. The first EMSA panel in 
figure 4.4a shows that protein binding to radiolabelled CD25-NRRi was competed by an 
unlabelled two hundred-fold excess of CD25-NRRi and CD25-NRRi-M2 but not CD25- 
NRRi-Ml or CD25-NRRi-M3. The second EMSA panel shows that two main protein 
species bound to radiolabelled CD25-NRRi-Ml. These bands were not competed by an 
unlabelled two hundred-fold excess o f CD25-NRRi-Ml, CD25-NRRi-M2 or CD25- 
NRRi-M3 but partially competed by CD25-NRRi oligonucleotide. The first EMSA panel 
in figure 4.4b shows that three faster-migrating protein species bound to radiolabelled 
CD25-NRRi“M2. The middle band was competed by an unlabelled two hundred-fold 
excess o f CD25-NRRi-M2 and CD25-NRRi but not by CD25-NRRi-Ml or CD25- 
NRRi-M3 oligonuclotides. The second EMSA panel shows that four protein species 
bound to radiolabelled CD25-NRRi-M3. This binding was not competed by an
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unlabelled two hundred-fold excess o f CD25-NRRi-M3, CD25-NRRi-Ml or CD25- 
NRR1-M2  but partially competed by CD25-NRRi oligonucleotide.
Table 4.1 shows a summary o f the same experiments on a range o f B and T cell extracts. 
Experiments on P3HR1 B cell extract strongly suggested that, in common with tonsillar 
B cell nuclear extract, protein binding to radiolabelled CD25-NRRi oligonuclotide was 
competed by an unlabelled two hundred-fold excess of CD25-NRRi and CD25-NRRi- 
M2, but not by an excess of CD25-NRRi-Ml or CD25-NRRi-M3 oligonucleotides. 
Similarly, no specific binding was evident for radiolabelled CD25-NRRi-M 1 or CD25- 
NRRi-M3 oligonucleotides and binding to radiolabelled CD25-NRRi-M2 was competed 
by an unlabelled two-hundred fold molar excess o f CD25-NRRi and CD25-NRRi-M2. 
EDR B cell nuclear extracts bound protein to radiolabelled CD25-NRR% oligonuclotide. 
This binding was competed by an unlabelled two hundred-fold excess of CD25-NRRi 
and CD25-NRRi“M2 but not CD25-NRRi-M3 oligonucleotides. Protein binding was 
partially competed by an unlabelled two hundred-fold excess of CD25-NRRi-Ml 
oligonucleotide. These findings were also observed from studies in SMS-SB pre-B cell 
whole cell extracts and Jurkat T cell nuclear extracts. Data fi'om studies o f the IB4 B cell 
line whole cell extracts are in agreement with the other cell extracts, however protein 
binding to radiolabelled CD25-NRRi was not competed by an unlabelled two hundred­
fold excess o f CD25-NRRi-Ml oligonucleotide. EDR B cell nuclear extracts bound 
protein to radiolabelled CD25-NRRi-M2 oligonucleotide. This binding was competed by 
an unlabelled two hundred-fold excess o f CD25-NRRi-M2 but not by CD25-NRRi or 
CD25-NRRi-M3 oligonucleotides. Protein binding was partially competed by an 
unlabelled two hundred-fold excess o f CD25-NRRi-Ml oligonucleotide. The failure of 
unlabelled two hundred-fold excess CD25-NRRi to compete protein binding to 
radiolabelled CD25-NRRi-M2 was also observed in IB4 B cell extacts and in Jurkat T 
cell extracts, although unlabelled excess CD25-NRRi-Ml had no competing effects. 
SMS-SB pre-B cell extracts failed to bind radiolabelled CD25-NRRi-M2 
oligonucleotide. Radiolabelled CD25-NRRi-Ml or CD25-NRRi-M3 oligonucleotides
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failed to bind specific protein species to all extracts in Table 1. These data show that an 
intact NRE region is required for protein to bind to CD25-NRRi oligonucleotides, 
however in contrast to tonsillar B cell and P3HR1 B cell extracts, protein binding to 
radiolabelled CD25-NRR% was partially competed by an unlabelled excess of CD25- 
NRRi-Ml oligonucleotides and protein binding to radiolabelled CD25-NRRi-M2 was 
not competed by an unlabelled two hundred-fold excess of CD25-NRRi oligonucleotide.
4.4 EMSA Studies of a CD25"NRRi-Ml Titration on Radiolabelled CD25-NRRi 
Protein Binding.
Experiments on NRRi-protein binding showed that in most cell lines, protein binding to 
radiolabelled CD25-NRRi was partially competed by the addition o f excess CD25- 
NRRi-Ml oligonucleotide (Table 4.1). To finther investigate this, a titration of 
unlabelled CD25-NRRi-Ml was performed with samples containing EDR B cell nuclear 
extract and radiolabelled CD25~NRRi oligonucleotide. Figure 4.5a shows that three 
main protein species bound to radiolabelled CD25-NRRi The uppermost band was 
competed by an unlabelled two hundred-fold excess of CD25-NRRi oligonucleotide. 
Figure 4.5b indicates that increasing concentrations o f unlabelled CD25-NRRi-Ml 
diminished protein binding to radiolabelled CD25-NRRi. Protein binding was completely 
blocked by concentrations greater than or equal to an unlabelled two hundred-fold 
excess of CD25-NRRi-Ml oligonucleotide.
4.5 Characterisation of YYl and AP-1 Protein in Human B Cells.
The 65kDa ubiquitous transcription factor YYl was proposed as a possible NRE-BP 
candidate. The pattern of expression of YYl in resting and stimulated B cells was 
determined. Tonsillar B cells were treated with and without IL-4 and anti-p-antibody 
over a period of four hours, samples were taken every hour and whole cell extracts 
prepared. Figure 4.6a shows a Western blot o f nuclear extract derived from the cells.
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and anti-YYl-antibody bound a protein species of approximately 65kDa. The level of 
expression of this protein was unaffected in samples which had been treated with IL-4 or 
anti-p-antibody, relative to control, unstimulated B cells.
EDR B cell extracts were treated with and without IL-4 over a period of four hours, 
samples taken every hour and whole cell extracts generated. Cell extracts were assessed 
for AP-1 family member expression by Western blotting and incubation with antibodies 
against c-fos and c-jun. Figure 4,6b shows that anti-c-fos antibody bound a protein 
species o f approximately 60kDa which was unaffected in samples treated with IL-4, 
when compared to unstimulated cells. Anti-c-jun antibody failed to bind protein in both 
treated and untreated samples (data not shown).
4.6 Characterisation of YYl Binding to NRE.
In order to determine if YYl was in fact identical to NRE-BP, two EMSA experiments 
were designed. The first experiment involved probing untreated tonsillar B cell whole 
cell extracts with radiolabelled YYl oligonucleotide. Protein binding to YYl was then 
challenged with excess unlabelled YYl oligonucleotide or CD25-NRE oligonucleotide. 
Untreated extracts were probed with radiolabelled CD25-NRE and protein binding was 
challenged by excess unlabelled CD25-NRE and YYl oligonucleotide. Figure 4.7 shows 
that protein binding to radiolabelled YYl was specifically competed by an unlabelled 
one- or two-fold excess of YYl oligonucleotide, but not by an unlabelled one- or five­
fold excess o f CD25-NRE. One slower-migrating species bound to radiolabelled CD25- 
NRE. This band was competed by an unlabelled one- or five-fold excess of CD25-NRE 
but not by an unlabelled one- or two-fold excess o f YYl oligonucleotide.
The second EMSA experiment was a supershift of protein binding to radiolabelled YYl 
oligonucleotide with anti-YY1 -antibody. Supershifted bands were challenged with 
excess YYl oligonucleotide then excess CD25-NRE. Figure 4.8 shows that one species
120
of protein bound to radiolabelled YYl oligonucleotide. Additional treatment with anti- 
YYl-antibody caused a slower migratory species shift which was competed by an 
unlabelled one- or two-fold excess of YYl oligonucleotide. The shift was not competed 
by an unlabelled one- or five-fold excess o f CD25-NRE oligonucleotide.
4.7 EMSA Supershift Analysis of NRE-BP Candidates and AP-1 Binding.
The investigation of candidate proteins for NRE-BP continued with studies of protein 
binding to NRRi using EDR B cell whole cell extract in EMSA supershift experiments. 
The candidate proteins were YYl, Ets and CBP/p300. The latter protein was considered 
for a possible "bridging" role with proteins binding to NRRi. In addition, these 
experiments were performed to characterise the putative AP-1 binding site (TGACTCC) 
found within the NRRi region. Figure 4.9 shows that three protein species bound to 
radiolabelled CD25-NRRi. The two uppermost bands were competed by an unlabelled 
two-fold excess of CD25-NRRi oligonucleotide. The addition of anti- YYl, Ets and 
CBP/p300 antibodies failed to shift either of the two upper bands. Addition of anti-c-fos 
antibody shifted the lower o f the two uppermost bands. Addition of anti-c-jun antibody 
failed to shift either band. These data suggest that c-fos binds to NRRi, whereas c-jun, 
YYl, Ets and CBP/p300 fail to show binding to nucleotide sequences in this region.
4.8 Discussion.
The NRRi sequence of the human CD25 promoter gene is 31 bp long and contains 
several protein binding regions, the most important of which is an 1 Ibp NRE sequence 
that is bound, in T cells, by a silencer protein o f approximately 50kDa in mass. Previous 
studies of the NRE region showed that IL-4 diminished NRE-BP binding over a period 
of four hours. The effect o f IL-4 on protein binding to the entire NRRi region was 
unknown. Figures 4.1 and 4.2 show that EL-4 treatment of both tonsillar B cells and 
EDR B cells abrogated protein binding to radiolabelled CD25-NRRj after two hours of
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stimulation. This suggests that EL-4-induced up-regulation of CD25 expression in human 
B cells is acheived by the attenuation o f protein binding to the entire NRRi region and is 
not simply confined to the NRE region.
In B cells, the IL-4 receptor subunit mainly consists of the IL-4Ra subunit in complex 
with the yc chain. Both components are involved in signalling and it has not been 
determined whether signalling from the EL-4Ra subunit, the yc chain, or both is involved 
in the loss of protein binding activity for NRRi To address this question, tonsillar B cells 
were treated with rh-IL-13 as the IL-13 receptor complex consists of the IL-13R subunit 
and the IL-4Ra subunit, therefore removing the signalling input of the yc chain. Figure
4.3 shows that protein binding to radiolabelled NRRj is unaffected by IL-13. This 
indicates that the effect o f IL-4R signalling on protein binding to the NRRi region is 
likely to be mediated thiough the yc chain and not thi'ough DL-4Ra.
Adjacent to the NRE region is a retinoid-sensitive region which is characterised by the 
presence o f a consensus AP-1 binding domain. Little is known o f the role of the 
consensus AP-1 binding site in protein binding to the NRR% region. Figure 4.4 and Table 
4.1 show that, in tonsillar and P3HR1 B cells, protein binding to a series of NRRi 
oligonucleotides is dependent upon sequences containing an intact NRE region. Both 
EDR and tonsillar B cell extract proteins fail to bind oligonucleotides containing mutated 
NRE sequences. Compared with protein binding to the consensus CD25-NRRi 
oligonucleotide, the migration of protein species binding to radiolabelled CD25-NRRi- 
M2 was faster. This indicates that the mutation of the AP-1-homology region leads to an 
alteration in protein binding to NRRi and suggests that protein binds specifically to the 
AP-l-homolgy region as part of the NRRi-binding complex. Protein binding to 
oligonucleotides containing consensus AP-1 sequences was noted only when an intact 
NRE region was present indicating that NRE is required to facilitate protein binding to 
the putative AP-1 binding site. This suggests that the NRE region is the dominant region 
for protein binding in the NRRi sequence. Table 4.1 shows a summaiy of the
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Figure 4.5 shows the effect of a titration of unlabelled CD25-NRR%-M 1 on protein- 
binding to radiolabelled CD25-lSfRRi. Protein binding was blocked by concentrations 
greater than or equal to an unlabelled two-fold excess of CD25-NRRi-Ml. Therefore, 
CD25-NRRi-Ml can compete protein binding to the consensus CD25-NEJR.I 
oligonucleotide. This finding was unexpected because EMSA experiments showed that 
NRRi specific protein species failed to bind radiolabelled oligonucleotides which 
contained a mutated NRE region (Figure 4.4 and Table 4.1). This suggests that the 
competition o f protein binding to the consensus AP-1 binding region leads to the 
eventual loss of NRE binding activity. Therefore, proteins binding to the consenus AP-1 
binding site may have a role in NRE binding activity and as a result, negative regulation 
of the CD25 promoter.
The transcription factor YYl was a possible candidate for NRE-BP. NRE has a minimal 
5'- CAT -3' binding site for YYl and the negative regulatory capabilites of this 
transcription factor are documented (Slii et a l, 1991). Figure 4.6a shows a constitutively 
expressed protein of approximately 65kDa in treated and untreated tonsillar B cell 
extract. This is the same mass as YYl and suggests that this transcription factor is
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oligonucleotide study carried out in a range of B cells and the Jurkat T cell line. With the 
exception o f SMS SB pre-B cell extracts, which showed no specific binding activity for 
CD25-NRRi-M2, all other extracts showed that protein binding to radiolabelled CD25- 
NRRi-M2 was competed by the addition of an unlabelled two-fold excess of CD25- 
NRRi-M2 but was not competed by CD25-NRRi. Only tonsillar B cell and P3HR1 B 
cell extracts showed competition of protein binding to radiolabelled CD25-NRRi-M2 
with excess unlabelled CD25-NRRi. One explanation which may account for these 
inconsistent binding patterns is that the consensus and mutant oligonucleotides contained 
relatively minor differences and, as opposed to comparing YYl oligonucleotide binding 
with CD25-NRE, the comparison between the CD25-NRRi olignucleotides was o f a 
more subtle nature.
expressed in both quiescent and stimulated tonsillar B cells. Figure 4.7 shows that 
protein binding to radiolabelled YYl oligonucleotide was not competed by excess 
unlabelled CD25-NRE and vice versa. Figure 4,8 demonstrates that protein binding to 
radiolabelled YYl was supershifted by the addition of anti-YYl antibody. This shift was 
competed by the addition o f excess unlabelled YYl oligonucleotide but not by excess 
unlabelled CD25-KRE. The supershift EMSA increases certainty o f the identity of the 
protein binding to the oligonucleotide. This data supports the Western blot findings that 
YYl is present in tonsillar B cells and the initial EMSA experiments which showed no 
competition in binding between YYl and CD25-NRE oligonucleotides. The failure of 
CD25-NRE to compete both normal and supershifted binding to radiolabelled YYl 
oligonucleotide indicates that YYl is not NRE-BP.
The supershift EMSA experiment was extended to the fiill-length NRRi sequence. 
Figure 4.9 shows that anti-YYl antibody failed to shift protein binding to radiolabelled 
CD25-NRRi indicating again that YYl does not bind NRE, or any other region in NRRi 
In addition, anti-Ets antibodies failed to shift protein binding to radiolabelled CD25- 
NRRi indicating that the Ets is not NRE-BP. The failure of anti-CBP/p300 antibody to 
supershift protein binding to radiolabelled CD25-NRRi indicates that this larger 
transcriptional regulator is not involved in a bridging complex with proteins binding to 
NRRi In an attempt to characterise the putative AP-1 binding site, supershift
experiments assessed the common AP-1 family members, c-fos and c-jun. Figure 4.9 
shows that anti-c-fos supershifted a protein species binding to radiolabelled CD25- 
NRRi. Treatment with anti-c-jun failed to supershift these species. This is consistent 
with Figure 4.6b which shows that c-fos is constitutively expressed in IL-4-stimulated or 
untreated EDR B cells, whereas c-jun is not (data not shown). These findings are in 
agreement with reported AP-1 expression in B cells (Foletta et al, 1998). The capacity 
o f c-fos to supershift protein binding to CD25-NRRi indicates that the TGACTCC 
region o f NRRi is a bona fide  site for the binding of AP-1 proteins. The binding site for 
AP-1 is within the retinoid-sensitive sequence o f NRRi. RA upregulates CD25
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expression in human B cells (Bhatti and Sidell, 1994), therefore it is possible that both 
RA and AP-1 may interact with one another, leading to the loss o f NRE binding activity. 
A possible mechanism of action is that binding of RA to the AP-1 binding site causes the 
alteration o f AP-1 protein binding. This may result in the inactivation o f the AP-1 
protein, possibly dismpting NRE-BP binding and initiating the transcription of the CD25 
promoter. Therefore, RA may in fact up-regulate CD25 in B cells via AP-1 inactivation.
In summary, there are two main binding regions in NRRi; NRE and an AP-1 binding 
site. In addition to inducing loss of NRE-binding activity, IL-4 treatment abrogates 
protein binding to the entire NRRi sequence. IL-4R signalling which leads to this is likely 
to be mediated through the yc chain of the IL-4R complex. EMSA studies on lymphoid 
cells indicate that NRE is the dominant binding region o f NRRi and is required for AP-1 
protein binding. In addition, competition of AP-1 binding leads to the loss of NRRi 
binding activity suggesting that AP-1 may have a role in the suppression of CD25 
transcription. NRE-BP has yet to be identified, however supershift experiments revealed 
that it is not YYl or Ets. CBP/p300 does not form a bridging complex with NRRi 
binding proteins. Supershift experiments confirmed that the TGACTCC region of NRRi 
is an AP-1 binding region. The AP-1 family member c-fos binds the AP-1 region of 
NRRi
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Figure 4.1 EMSA Analysis on the Effect of IL-4R Signalling on NRRi Binding
Activity in EDR B Cells.
The binding activity of 5gg aliquots o f EDR B cell whole cell extract to ^^P-labelled 
CD25-NRRi was analysed by EMSA (Fig 4.1a) in the absence or the presence of 
unlabelled two hundre-fold excess CD25-NRRi oligonucleotide as competitor. Whole 
cell extracts were prepared at hourly intervals from EDR B cells after incubation in the 
absence (Fig. 4.1b) or presence (Fig 4.1c) of 500U/ml IL-4, and 5pg of protein extract 
assessed by EMSA for binding to ^^P-labelled CD25-NRRi. Specific binding activities 
are indicated with horizontal arrows.
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Figure 4.2 EMSA Study on the Effect of IL-4R Signalling on NRRi Binding 
Activity in Tonsillar B Cells.
The binding activity o f 5pg aliquots of tonsillar B cell nuclear extract for -labelled 
CD25-NRRj was analysed by EMSA in the absence or the presence o f unlabelled two 
hundred-fold excess CD25-NRRi oligonucleotide as competitor. Nuclear extracts were 
prepared at hourly intervals from tonsillar B cells after incubation in the presence of 
500U/ml IL-4, and 5pg o f protein extract assessed by EMSA for binding to ^^P-labelled 
CD25-NRRj. Specific binding activity is indicated by a horizontal arrow.
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Figure 4.3 Effect of IL-13R Signalling on NRRi Binding Activity in Tonsillar B
Cells.
The binding activity of 5pg aliquots o f tonsillar B cell nuclear extract for ^^P-labelled 
CD25-NRRi was analysed by EMSA (Fig. 4.3a) in the absence or the presence of 
unlabelled two hundred-fold excess CD25-NRRi oligonucleotide as competitor. Nuclear 
extracts were prepared at hourly intervals from tonsillar B cells after incubation in the 
absence (Fig. 4.3b) or presence (Figs. 4.3c, 4.3d and 4.3e) o f 3ng/ml, 6 ng/ml and 
12ng/ml IL-13, and 5pg o f protein extract assessed by EMSA for binding to ^^P-labelled 
CD25-NRRi. Specific binding activities are indicated by the horizontal arrow.
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Figure 4.4 EMSA Analysis of Protein Binding to NRRi in Tonsillar B Cells.
Nuclear extracts were prepared from resting tonsillar B cells (1 x 10'^  cells) which had 
been cultured overnight in fresh complete medium. The binding activity o f 5pg aliquots 
of protein to 32p_iabelled CD25-NRRi (Fig. 4.4a), CD25-NRRi-Ml (Fig. 4.4a), CD25- 
NRRi-M2  (Fig 4.4b), and CD25-NRRr-M3 (Fig 4.4bi oligonucleotide was assessed by 
EMSA in the absence or presence of unlabelled two hundred-fold excess CD25-NRRi 
(0), CD25-NRRI-M1 (1), CD25-NRRi-M2 (2), and CD25-NRRi-M3 (3) oligonucleotide 
as competitor, respectively. Specific binding activities are indicated with horizontal 
arrows.
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Table 4.1 Summary of NRRi Binding Activity in Lymphoid Cells.
Cell extracts were prepared from P3HR1, EDR, IB4, SMS B cells or Jurkat T cells. The 
binding activity o f 5pg aliquots o f protein for 32p_labelled CD25-NRRi, CD25-NRRi- 
M l, CD25-NRRi-M2, and CD25-NRRi-M3 oligonucleotides were assessed by EMSA in 
the absence or presence of unlabelled two hundred-fold excess CD25-NRR%, CD25- 
NRRi-Ml, CD25-NRRi“M2, and CD25-NRRi-M3 oligonucleotides. Table 4.1 shows 
the effect o f each unlabelled two hundred-fold excess oligonucleotide on protein binding 
for each ^^P-labelled oligonucleotide in P3HR1 B cells (panel 1), EDR B cells (panel 2), 
IB4 B cells (panel 3), SMS-SB B cells (panel 4), and Jurkat T cells (panel 5). Complete 
competiton o f protein binding for 2^p_iabelled oligonucleotide by unlabelled 2 -fold 
excess oligonucleotide is indicated by YES, incomplete competition of binding is 
indicated by PARTIAL, and no competition o f binding is indicated by NO.
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P3HR1 B Cell CD25-NRR| CD25-NRR|-M1 CD25-NRR(-M2 CD25-NRR|-M3
CD25-NRRj YES NO YES NO
CD25-NRR,-M1 NO NO NO NO
GD25-NRR,-M2 YES NO YES NO
CD25-NRR|-M3 NO NO NO NO
EDR B Cell CD25-NRR, CD25-NRR|-M1 CD25-NRR,-M2 CD25-NRR|-M3
CD25-NRR, YES NO NO NO
CD25-NRR,-M1 PARTIAL NO PARTIAL NO
CD25-NRR,-M2 YES NO YES NO
CD25-NRR,-M3 NO NO NO NO
IB4 B Cell CD25-NRR, CD25-NRR,-M1 CD25-NRR,-M2 CD25-NRR,-M3
CD25-NRR, YES NO NO NO
CD25-NRR|-M1 NO NO NO NO
CD25-NRR,-M2 YES NO YES NO
CD25-NRR|-M3 NO NO NO NO
SMS SB B Cell CD25-NRR, CD25-NRR|-M1 CD25-NRR|-M2 CD25-NRR,-M3
CD25-NRR, YES NO NO NO
CD25-NRR,-M1 PARTIAL NO NO NO
CD25-NRR,-M2 YES NO NO NO
CD26-NRR,-M3 NO NO NO NO
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Jurkat T Cell CD25-NRR, CD25-NRR,-M1 CD25-NRR|-M2 CD25-NRR|-M3
CD25-NRR, YES NO NO NO
CD25-NRR|-M1 PARTIAL NO NO NO
CD25-NRR|-M2 YES NO YES NO
CD25-NRR|-M3 NO NO NO NO
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Figure 4.5 Analysis on the Effect of CD25 NRRi-Ml Competition of CD25-NRRi
Binding Activity.
The binding activity of 5gg aliquots of EDR B cell nuclear extracts for ^^P-labelled 
CD25-NRRI oligonucleotide was analysed by EMSA (Fig. 4.6a) in the absence or 
presence o f unlabelled two hundred-fold excess CD25-NRRI oligonucleotide as 
competitor. Figure 4.6b shows the binding activity o f 5pg aliquots of EDR B cell 
nuclear extracts for ^^P-labelled CD25-NRRi oligonucleotide in the absence or presence 
o f unlabelled two hundred-fold excess CD25-NRR: oligonucleotide as competitor, in the 
presence o f unlabelled 25, 50, 75, 1, 125 and one hundred and fifty-fold CD25-NRRi- 
M1 oligonucleotide. Specific binding activities for protein binding to CD25-lSlRRi are 
indicated by the bold horizontal arrow.
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Figure 4.6 Western Blot Analysis of YYl and AP I Protein in Human B Cells.
Whole cell extracts were prepared at hourly intervals from quiescent tonsillar B cells 
which were either resting, treated with 500U/ml IL-4 or treated with Ipg/ml rabbit anti- 
p chain antibody, over a four hour period. 30pg of protein extract analysed by Western 
blotting with rabbit anti-YYl antibody (Fig. 4.7a). Whole cell extracts were also 
generated at hourly intervals from EDR B cells which were treated with 500U/ml IL-4 
over a four hour period, 30pg of extract was analysed with rabbit anti-c-fos antibody 
(Fig 4.7b).
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Figure 4.7 EMSA Study of Protein Binding to YYl and NRE in Tonsillar B Cells.
Whole cell extracts were prepared from resting tonsillar B cells (5 x 10  ^ cells), which 
had been cultured overnight in fresh complete medium. The binding activity of 5pg 
aliquots o f protein for ^^P-labelled YYl and CD25-NRE oligonucleotide was assessed 
by EMSA, in the absence or presence o f unlabelled 1- and 2-foId excess YYl 
oligonucleotide and unlabelled 1- and 5-fold excess CD25-NRE oligonucleotide. 
Specific binding activities are indicated with horizontal arrows.
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Figure 4.8 EMSA Supershift Analysis of Protein Binding to YYl.
Whole cell extracts were prepared from tonsillar B cells (5 x 10  ^ cells) which had been 
cultured overnight in fresh medium. The binding activity o f 5pg protein samples for 32p_ 
labelled YYl ohgonucleotide was assessed by EMSA supershift, in the presence of Ipg 
rabbit anti-YYl antibody, in the absence or presence of 1- and 2-foId excess unlabelled 
YYl oligonucleotide as competitor or in the presence of 1- and 5-fold CD25-NRE 
oligonucleotide. Specific binding activities are indicated with horizontal arrows.
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Figure 4.9 EMSA Supershift Analysis of Protein Binding to NRRi.
Whole cell extracts were prepared from EDR B cells (5 x 10  ^ cells). The binding activity 
o f 5pg protein samples for ^^P-labelled CD25-NRRi oligonucleotide was assessed by 
EMSA supersliift, in the absence or presence o f 2-fold excess unlabelled CD25-NRRi 
oligonucleotide as competitor or in the presence of Ipg o f the following rabbit 
antibodies; anti-YYl antibody, anti-CBP antibody, anti-Ets antibody anti-c-fos-antibody 
and anti-c-jun-antibody. Specific binding activities are indicated with horizontal arrows.
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CHAPTER 5
FUNCTIONAL STUDIES OF THE HUMAN CD25 PROXIMAL PROMOTER
REGION.
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5.1 Introduction.
The expression of the human CD25 gene is controlled by the regulatory regions PRRi-m 
and NRRi_n (see figure 1.5). With the exception of PRRm, these regions are found 
adjacent to one another between nucleotides -400 and -64, relative to the major ;?
transcription start site. Within the NRRj region are a core 11 bp NRE region and a 
retinoid-sensitive region characterised by the presence o f an AP-1 binding site. When 
NRE binding activity is diminished, the suppression of promoter activity is lost, allowing 
the transcription of the CD25 gene. Work detailed in Chapter 4 identified that NRE was 
the dominant protein binding region o f NRRi and that the AP-1 region was bound by c- 
fos. Having demonstrated protein binding to NRRi, the next step involved an 
investigation o f the transcriptional activity of the region. Previous work in this 
laboratory has established the transcriptional activity o f NRE in EDR B cells. Deletion 
of the NRE sequence lead to an elevation of CAT expression, relative to control levels.
However, the increase in reporter activity was not further enhanced upon the deletion of 
the entire NRRi region (Hewitt, Ozanne and Cushley, 1997).
Chapter 3 assessed the potential involvement of a number of IL-4R signalling pathways 
in the up-regulation of CD25. Data from these studies indicate that IL-4 up-regulates 
CD25 expression via a cAMP/PKA-sensitive pathway. A final pathway which may be 
involved in IL-4-driven CD25 expression is the JAK/STAT pathway, in particular, the 
pathway that leads to the induction of STAT6  activity. STAT6  is essential for the 
cellular responses of IL-4R signalling in lymphoid cells (Takeda et al., 1996). There are 
no STAT6  binding regions within the NRRi sequence itself although distal to this region 
are four putative STAT6  binding regions. The first putative binding site is located 
partially in NRRn between nucleotides -306 and -297, relative to the major 
transcriptional start site. The second site is found between PRRi and PRRn and is 
located between nucleotides -204 and -195. The final two sites are found within the 
PRRn region and are located between positions -139 to -131 and -124 to -115,
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respectively (John et al, 1996). These sites are additionally described in figure 1.5 and 
figure 5.1. By creating deletion constmcts of these particular regions, their sensitivity to 
IL-4-induced reporter activity could be determined.
5.2 Transient-Transfection Studies of NBJRi Deletion Mutants.
Previous work has investigated the transcriptional activity of the NRRi region in EDR B 
cells. In section 4.3, EMSA studies o f P3HRI B cells revealed strong protein binding 
activity within NRRi, but the transcriptional activity o f NRRi has not been characterised 
in this cell line. P3HRI B cells were transiently-transfected with NRRi deletion mutant 
constructs containing consensus CD25, NRE or NRRi-deleted sequences. These 
plasmids were named; pCD25 CAT-E', pANRE and pANRRi, respectively. NRRi 
deletion mutant constructs were generated in-house, as described in section 2.1.3 and 
2.2.19. P3HRI B cells were co-transfected with pCAT-E' CD25 plasmids and the 
control plasmid pSEAP. Cells transfected with pSEAP expressed and secreted human 
placental alkaline phosphatase (AP) winch was measured by assay of culture 
supernatants (see section 2.2.11). The amount of CAT reporter activity was quantitated 
relative to AP production in each transfection. Transiently-transfected cells were then 
stimulated with and without the mitogen phorbol myristate acetate (PMA). To control 
for CAT reporter activity, a sample of cells were transfected with the TK-promoter 
plasmid pLW2.
Figure 5.2a shows the analysis o f pCD25 CAT-E'-, pANRE- and pANRRi-transiently- 
transfected P3HRIB cells which were measured for reporter gene activity, by thin layer 
chromatography (TEC). Figure 5.2b shows a graph of quantitative data obtained from 
phosphorimage analysis o f the TLC plate and adjusted for relative alkaline phosphatase 
(AP) expression. Cells transfected with pCD25 CAT-E' showed a low level of CAT 
reporter activity that was enhanced by PMA stimulation. Transfection of cells with 
pANRE lead to an approximately two-fold increase in basal CAT activity and a similar
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increase in PMA-treated cells, relative to the control pCD25 CAT-E' reporter activity. 
Cells transfected with pANRRi showed a two-fold increase in basal reporter activity and 
a three-fold increase in PMA-stimulated cells, relative to control.
5.3 Western Blot Analysis of STAT6 Expression in Tonsillar B cells.
The levels o f STAT6  protein in quiescent tonsillar B cells stimulated with IL-4 or IL-13 
was assessed. Whole cell extract was prepared at hourly intervals over four hours, then 
again after 24 hours of stimulation. The extracts were analysed for the presence of 
STAT6  by Western blotting, followed by incubation with anti-STAT6  antibody. Figure
5.3 shows a band of approximately lOOkDa wliich is bound by anti-STAT6  antibody in 
each lane. Figure 5.3a shows samples prepared from untreated tonsillar B cells, this band 
was consistently expressed over 24 hours. In samples taken from IL-4-treated cells 
(Figure 5.3b), the band increased in intensity up to and including four hours of 
treatment, although the band returned to a basal-level intensity after 24h (data not 
shown). In IL-13-treated cells (Figure 5.3c) the band was consistently expressed at basal 
levels over 24h of incubation.
5.4 Creation of pCAT-E' CD25 STAT6 Deletion Mutant Constructs.
The role o f the putative STAT6  binding regions in the regulation of CD25 promoter 
activity was investigated by engineering STAT6  deletion constmcts for each proposed 
region. In common with the NRRi deletion constructs made by other workers, a pCAT- 
E' plasmid was used for this purpose. Figure 5.4a shows a restriction map o f pCAT-E' 
which contains an ampicillin resistance gene, a simian vims (SV)-40 enhancer region, a 
CAT reporter stmctural gene and a multiple cloning site. The STAT6  deletion primer 
sequences were amplified by PGR, as described in section 2.2.19, then purified and 
inserted into pCAT-E' between the Hind 111 and Sal I restriction sites within the multiple 
cloning region. The pCAT-E' CD25 STAT6  deletion mutant constmct was inserted into
139
competent E. coli cells then amplified by culturing transformed cells in LB broth. The 
plasmids were purified by maxi-prep, as described in section 2.2.18. Plasmids containing 
the mutant constructs were called pPRR%, pAPRRi, pAS6 -l and pAS6-2 with respect to 
the sequential order of putative STAT6  sites, as outlined in section 5.1. Figure 5.4b 
shows a restriction enzyme double-digest o f pCD25 CAT-E', pPRRi, pAPRRi, pAS6 -l 
and pAS6-2, cut by the restriction enzymes Hind III and Sal I. All digested plasmids 
were loaded on to a 1% agarose gel, along with IKbp and lOObp DNA-molecular 
weight markers and the fragments seperated by electrophoresis. The restriciton enzyme 
digest o f pCD25 CAT-E' cut a fragment which was approximately 425bp. The 
restriction enzyme digests of pPRRi, pAPRRi, pAS6 -l and pAS6-2 cut fragments of 
390bp, 380bp, 360bp and 355bp, respectively. All plasmids were sequenced in-house by 
co-workers.
5.5 Transient-Transfection Studies of STAT6 Activity in the Human CD25 
Proximal Promoter.
In order to assess a possible role for IL-4-stimulated STAT6  in CD25 expression in a 
range of lymphoid cells, equal amounts o f pCD25 CAT-E', pPRRj, pAPRRi, pAS6 -l and 
pAS6-2 were co-transfected with pSEAP into tonsillar B cells, EDR B cells and Jurkat- 
T cells. Initial experiments were performed to assess the effect of PMA stimulation on 
both PRRi_n regions. A second set of experiments involved the stimulation of transiently- 
transfected cells with and without IL-4 to assess the sensitivity of putative STAT6 
binding sites. After 48h incubation, whole cell extracts were prepared from each sample, 
then assayed for CAT reporter gene actvity.
Figure 5.5 shows the effect o f PMA on transiently transfected Jurkat T and EDR B cells. 
In both Jurkat T and EDR B cells, transfection of pCD25 CAT-E' showed low basal 
levels of reporter activity, which were enlianced when stimulated with PMA. EDR B 
cells which were transfected with with pPRRi showed higher basal levels o f reporter
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activity than control pCD25 CAT-E' transfectants. Jurkat T cell reporter activity was 
comparable to control levels. PMA treatment of Jurkat T and EDR B cells increased 
reporter activity three-fold in both cell lines. Transfection of cells with pDPRRi 
increased basal levels o f reporter activity, relative to control levels, which were 
enhanced by PMA stimulation. Lymphoid cells transfected with pAS6 - l showed low 
levels of reporter activity which were enhanced six-fold by stimulation with PMA. Cells 
transfected with pAS6~2 expressed lower basal levels which were enhanced by PMA 
stimulation.
The TLC analysis of the reporter activity of transiently-transfected tonsillar B cells is 
shown in Figure 5.6a. Figure 5.6b shows the AP-normalised graph o f CAT reporter 
activity. Cells which were transfected with pCD25 CAT-E' showed a low basal reporter 
activity which was increased three-fold by treatment with IL-4. Cells transfected with 
pPRRi and pAPRRi showed an approximately three-fold increase in basal reporter 
activity, relative to pCD25 CAT-E' basal levels although IL-4 treatment failed to 
enhance reporter activity. Cells transfected with pAS6 -l showed a two-fold increase in 
basal reporter activity, relative to control. Stimulation of cells with IL-4 minimally 
enhanced CAT expression. Cells transfected with pAS6-2 showed basal reporter activity 
that was similar to pCD25 CAT-E' basal levels. IL-4 treatment minimally enhanced 
reporter activity.
Figure 5.7a shows shows TLC analysis o f the reporter activity o f transiently-transfected 
Jurkat T cells. Figure 5.7b shows the AP-normalised graph o f reporter activity. The 
basal reporter activity in cells which were transfected with pCD25 CAT-E' was 
increased four-fold by treatment with IL-4. Cells transfected with pPRRi showed a 
higher basal level of reporter activity, which was not enhanced by IL-4 stimulation. The 
basal reporter activity o f cells transfected with pAPRRi was low and was not enhanced 
by IL-4 treatment. Jurkat T cells which were transfected with pAS6 - l and pAS6-2 
showed low basal levels of reporter activity, similar to pAPRRi levels. Treatment with
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IL-4 did not enhance either pAS6 -l or pAS6-2 reporter activity. This data leads to the 
conclusion that in lymphoid cells, the putative STAT6  binding site which overlaps NRRn 
is sensitive to IL-4 stimulation.
5.6 Discussion.
Chapter 4 investigated protein binding to the NRRi region and established that NRE had 
a dominant role with a secondaiy involvement of AP-1 proteins. Transcriptional activity 
o f NRRi was assessed to determine whether NRE had the same dominant role in the 
regulation o f transcription as it does in protein binding activity. Figure 5.2 demonstrates 
that basal and PMA-stimulated reporter activity in P3HR1 B cells transfected with either 
pANRE or pANRRi is markedly increased, relative to the basal reporter activity o f 
pCD25 CAT-E' transfected cells. These findings are in agreement with previous work on 
EDR B cells and indicate that NRE has a dominant role in NRRi transcriptional activity.
STAT6  is an important mediator o f IL-4 signalling. Investigation o f the CD25 promoter 
sequence lead to the identification of four putative STAT6  sites (Figure 5.1), located 
distal to NRRi. Figure 5.3 shows that STAT6  is constitutively expressed in tonsillar B 
cells. STAT6  expression was slightly increased in tonsillar B cells which had been 
treated with IL-4 but not with IL-13. The finding that STAT6  is expressed in B cells and 
is stimulated by IL-4 suggests that putative STAT6  binding sites which lie distal to 
NRRi may have an important role in mediating DL-4R signals which lead to the loss of 
NRE-BP and the initiation o f CD25 transcription.
Initial experiments investigated mitogen-sensitivity in cells transfected with deletion 
mutant constructs, designed to investigate each putative STAT6  binding region, within 
CD25 Figure 5.5 shows that PMA increased reporter activity in all transiently- 
transfected Jurkat T cells and EDR B cells. This was unexpected as pAS6 -l and pAS6-2 
delete the influence o f the mitogen-sensitive PRRi, leaving only PRRn This region has
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been shown to be involved in T cell-specific CD25 expression but there have been no 
reports o f a similar role in B cells (John et a l, 1995). Therefore, PRRn is sensitive to 
PMA stimulation and appears to be involved in CD25 expression in B cells.
Transient-transfection studies of lymphoid cells with the STAT6  deletion mutants 
pPRRi, pAPRRi, pAS6 -l and pAS6-2 assessed the capacity o f each putative STAT6  site 
to respond to IL-4 stimulation. Figure 5.6 demonstrates that tonsillar B cells transfected 
with the ST AT6  deletion mutant pPRRi showed an approximately three-fold increase in 
reporter activity, relative to the basal levels expressed by pCD25 CAT-E'. This was 
expected as the transfection of cells with pPRRi removes the influence o f both negative 
regulatory elements on the CD25 promoter, thereby removing all suppression o f CD25 
transcriptional activity. Therefore, the functional deletion of NRRj.h in tonsillar B cells 
leads to a slight enhancement of the reporter activity of the CD25 gene. Individual 
transfection of cells with pAPRRi showed a further increase in reporter activity wliich 
was unexpected, given that the PRRi region is removed by this plasmid. Cells transfected 
with pAS6 -l and pAS6-2 showed a sequential decrease of the influence of promoter 
regions PRRi and PRRn on levels of reporter activity. This was expected, as the deletion 
of the influence of PRRi and the partial deletion of PRRn removes NF-kB, SRF and 
HMG-l(Y) binding regions which would be predicted to reduce the transcriptional 
capacity o f the CD25 promoter. JL-4 stimulation of tonsillar B cells transfected with 
pCD25 CAT-E' increased levels of reporter activity, which was expected, given the 
capacity o f IL-4 to up-regulate CD25 expression (as outlined in Chapters 3 and 4). 
Figure 5.6 additionally shows that IL-4 had no influence on the reporter activity of cells 
transfected with pPRR% and pAPRRi, although pAS6 ~l and pAS6-2-transfectant reporter 
activity was slightly enhanced. This is in agreement with other experiments which 
indicated that EL-4 only enhances reporter activity from cells transfected with pCD25 
CAT-E' (data not shown). The finding that IL-4 consistently up-regulates reporter 
activity from cells transfected with pCD25 CAT-E' but not pPRRi suggests that the first 
putative ST AT6  binding site, which overlaps NRRn, is influential in IL-4-mediated up-
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regulation o f CD25 expression. The failure o f IL-4 to influence the reporter activity 
from cells transfected with pAPRR%, pAS6-1 and pAS6-2 suggests that the only putative 
STAT6  site which may be sensitive to IL-4 in tonsillar B cells is the site that overlaps 
NRRn. Transient-transfection of tonsillar B cells with pCD25 CAT-E' and the STAT6  
deletion mutants showed low levels of reporter activity in all experiments thus making 
interpretation o f results problematic. This was likely to be due to high cell death which 
occured as a result of electroporation of highly sensitive, freshly isolated quiescent 
tonsillar B cells which do not possess the resilience of transformed B cell lines.
Figure 5.7 shows that Jurkat T cells transiently-transfected with pCD25 CAT-E' 
expressed a level of basal CAT activity that was increased when cells were stimulated 
with IL-4. This is in contrast to the finding that IL-4 blocks CD25 expression in T cells 
(Jankovich et al, 1989). Transfection with STAT6  deletion mutants showed a decrease 
in reporter activity which, reflected the scale o f the CD25 deletion. IL-4 treatment failed 
to enhance the reporter activity o f cells transiently-transfected with each STAT6 
deletion mutant.
Therefore, in lymphoid cells, IL-4 treatment of cells transiently-transfected with pCD25 
CAT-E' increases basal levels of reporter activity. The failure o f IL-4 to raise basal levels 
of reporter activity from cells transfected with pPRRi, pAPRRi, pAS6 ~l and pAS6-2 
indicates that the putative STAT6  site which overlaps NRRn may be sensitive to IL-4 
treatment. Further work which could be done on this study would be to transfect 
lymphoid cells with pANRRi, in addition to the four STAT6  deletion mutants. The 
deletion o f NRRi would leave NRRn intact and if IL-4 stimulation o f transfected cells 
enhanced reporter activity, then a more definitive role for this STAT6  site might be 
demonstrated.
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In suininary, transient-transfection studies of NRRj deletion mutants on P3EGRI B cells 
confirms that NRE is the dominant region in the regulation o f NRRi transcriptional 
activity. Western blot studies show that STAT6  is expressed in tonsillar B cells. Studies 
o f PMA-sensitivity in lymphoid cells transfected with STAT6  deletion mutants show for 
the first time, that the PRRn region of CD25 is involved in the regulation of 
transcriptional activity in human B cells. Transient-transfection experiments o f STAT6 
deletion mutants in lymphoid cells show that IL-4 sensitivity may be lost to the CD25 
promoter upon deletion o f the NRRi_n regions. Therefore, the putative STAT6  binding 
site which lies in the NRRn region appears to be sensitive to EL-4 and may be involved in 
the transcription of the CD25 gene promoter. In addition to cAMP/PKA signalling, EL-4 
may also upregulate CD25 via a JAK/STAT pathway which leads to the activation of 
STAT6 .
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Figure 5.1 The Proximal Region of the Human CD25 Promoter.
The nucleotide sequence (-482 to +176) o f the human CD25 promoter region. In bold 
italics are the NRE and AP-1 regions, contained within NRRi (-400 to -368, 
encompassing a putative RARE site). In bold is the NF-kB site, found within the PRRi 
region (-276 to -244, also containing an SRF binding region). Underlined are four 
putative STAT6  binding sites which conform to a consensus (T>C)TNNNNNNAA 
sequence. The first sequence overlaps NRRn and lies between postitons -306 to -297. 
The second site lies between PRRi and PRRn, at nucleotides -204 and -195. The 
remaining sites are positioned between nucleotides -139 to -131 and -124 to 115, 
overlapping PRRn (-137 to -64, which additionally contains Elf-1 and HMG-l(Y) 
binding sites). The human CD25 promoter nucleotide sequence was obtained from (John 
et al, 1996)
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Figure 5.2 Activity of CD25-CAÏ Reporter Gene Constructs in P3HR1 B Cells.
Aliquots o f P3HRI B cells (5 x 10  ^ cells) were electroporated with the indicated 
plasmids at 0.35kV, at a capacitance of 960pF, then after a Ih rest period, were 
incubated in the absence or presence of InM PMA for 48h. Whole cell extracts were 
prepared and assayed for CAT reporter gene activity. Acetylated [i^Cj-chloramphenicol 
products were resolved by TLC (Fig. 5.2a) and quantitated by phosphorimage analysis 
(Fig. 5.2b). Values represent means of relative reporter activity (±SEM) from five 
independent assays.
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Figure 5.3 Western Bot Analysis of STAT6 in Tonsillar B Cells.
Whole cell extracts were prepared at hourly intervals from quiescent tonsillar B cells 
which were either resting (Fig 5.3a), treated with 500U/ml EL-4 (Fig 5.3b) or treated 
with 12ng/ml IL-13 (Fig 5.3c), and 30pg of protein extract analysed by Western blotting 
for binding to rabbit anti-STAT6  antibody.
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Figure 5.4 Restriction Enzyme Map of the pCAT Enhancer Plasmid and 
Restriction Enzyme Digest of CD25-CAT Reporter Gene Constructs.
The pCAT Enhancer (E‘) plasmid restriction enzyme map (Figure 5.4a). The region 
coding for CAT is located between positons 2315 (start site) and 2974 (stop site) and 
lies next to a multiple cloning site which contains regions for Hind  III (2242) and Sal I 
(2260). The plasmid also contains an ampicillin resistance gene and SV40 enhancer 
region.
Aliquots of pCD25 CAT-E', p?RRl pAPRRi, PAS6-1 and pAS6-2 plasmids (Ipg) were 
double-digested (Figure 5.4b) by incubation with Hind III and Sal I then samples were 
assessed by gel electrophoresis and UV analysis along with Ikb and lOObp molecular 
weight markers.
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Figure 5.5 Activity of CD25-CAT Reporter Gene Constructs in Lymphoid Cells.
Aliquots o f EDR B cells (Fig. 5.5a) or Jurkat T cells (Fig. 5.5b) (5 x 10  ^ cells) were 
electroporated with the indicated plasmids at 0.35kV, at a capacitance o f 960pF. After a 
Ih rest period, samples were incubated in the absence or presence o f InM PMA (5.5a) 
or lOnM PMA (5.5b), respectively, for 48h. Whole cell extracts were prepared and 
assayed for CAT reporter gene activity. Acetylated [^"^C]-chloramphenicol products 
were resolved by TLC and quantitated by phosphorimage analysis.
This figure is included with the kind permision of Tom Carr.
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Figure 5.6 Effect of IL-4 on Activity of CD25-CAT Reporter Gene Constrncts in
Tonsillar B Cells,
Aliquots o f quiescent tonsillar B cells (5 x 1 0  ^ cells) were electroporated with the 
indicated plasmids at 0.35kV, at a capacitance of 960pF. After a Ih rest period, samples 
were incubated in the absence or presence of 500U/ml IL-4 for 48h. Whole cell extracts 
were prepared and assayed for CAT reporter gene activity. Acetylated [^^C]- 
chloramphenicol products were resolved by TLC (Figure 5.6a) and quantitated by 
phosphorimage analysis (Figure 5.6b). This figure shows one experiment, representative 
o f five.
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Figure 5.7 Effect of IL-4 on Activity of CD25-CAT Reporter Gene Constructs in
Jurkat T Cells.
Aliquots o f Jurkat T cells (5 x 1 0 ® cells) were electroporated with the indicated plasmids 
at 0.35kV, at a capacitance of 960pF. After a Ih rest period, samples were incubated in 
the absence or presence o f 500U/ml IL-4 for 48h. Whole cell extracts were prepared and 
assayed for CAT reporter gene activity. Acetylated [i^C]-chloramphenicol products 
were resolved by TLC (Figure 5.7a) and quantitated by phosphorimage analysis (Figure 
5.7b). Values represent means o f relative reporter activity (±SEM) from ten independent 
assays.
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CHAPTER 6  
GENERAL DISCUSSION
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The high affinity IL-2 receptor consists of constitutively expressed P (75kDa) and yc 
(64kDa) subunits, and an unique inducible 55kDa a  subunit, called CD25. The IL- 
2Rp and yc subunits are expressed at the cell surface and have an intermediate affinity 
for IL-2. Expression of CD25 leads to the formation of a heterotrimeric IL-2 receptor 
complex which has a high affinity for IL-2. In generating a high affinity receptor for IL- 
2, CD25 expression potentiates the cellular signalling events generated by the IL-2Rp 
and yc subunits. IL-2 has an important role in the differentiation and apoptosis of 
lymphocytes, TSIK cells, and monocytes.
The human CD25 promoter has been well studied in human T cells, but little is known 
about the regulation of the gene in B cells. The expression of CD25 in T cells is 
stimulated by molecules such as PMA, TNF and IL-1 (Plaetinck et al., 1990;Toledano et 
al., 1990). Previous work in this laboratory demonstrated that while PMA stimulated a 
response in B cells, TNF and IL-1 failed to up-regulate CD25 expression. Molecules 
which were shown to upregulate CD25 expression in B cells were p chain specific 
antibody, CD40 specific antibody and IL-4 (Burlinson et al., 1995). In particular, further 
work on IL-4 identified that CD25 expression was regulated by the removal of NRE 
binding activity and that the IL-4-driven loss of NRE-BP binding was achieved via a 
cAMP/PKA-sensitive pathway (McKay et al., 1999).
Figure 3.2 shows that IL-4 up-regulates CD25 expression in tonsillar B cells over 24 
hours. IL-4 abrogates NRE-BP binding to NRE, thereby removing the suppressive 
influence on the CD25 promoter and enabling transcription (Figure 3.3b). B cells treated 
with Forskolin, which up-regulates the production of cAMP by activating adenylate 
cyclase, provoked a similar loss of NRE binding activity over the same period of 
treatment (Figure 3.3c). These findings indicate that IL-4 influences CD25 expression by 
abolishing NRE binding activity via a cAMP/PKA-sensitive pathway. This is in 
agreement with the findings of McKay (McKay, 1996). The precise mechanism and 
targets o f cAMP/PKA signalling in this process are unclear. The ligation of the IL-4
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receptor is unlikely to activate a G-protein complex as a reported intracellular rise of 
cAMP occurs ten to fifteen minutes after stimulation (McKay et al, 1999) If IL-4
stimulated a G-protein complex, then the rise in cAMP would be evident within seconds 
(Daniel et al, 1998). The fact that it is delayed suggests that IL-4 stimulates an indirect 
increase in cAMP levels.
A possible mechanism by which IL-4 may increase intracelluar cAMP is by stimulating 
the expression of CD23 at the cell surface (Figure 6.1). CD23 is the low affinity FcsRII 
receptor for IgE which can also released in a soluble form into the extracellular 
enviromnent. IL-4 treatment induces a marked up-regulation o f CD23 in B cells. Soluble 
(s)CD23 has an auto/paracrine effect on surrounding B cells and can induce cell 
signalling by binding receptors such as CD 11 a, CD 11b, CD21 and possibly CD23 itself 
(Bonnefoy et a l, 1997a). The interaction between CD23 and other binding receptors in 
B cells has a wide range of effects including; the regulation of IgE production, the anti- 
apoptotic role in germinal centres and mediation of T-B cell interactions (Bonnefoy et 
al, 1997b). Given the multifunctional roles of CD23 and CD21 it is possible that a target 
receptor for soluble sCD23 may be CD21, which may lead to its activation and the 
generation o f signalling events. One such signalling pathway is a cAMP/PKA-sensitive 
pathway (Mossalayi et al, 1997;Paul-Eugene et al, 1992). Thus, a potential mechanism 
o f action is that IL-4 treatment o f B cells increases the expression of surface CD23 
which, in turn, leads to a rise in the extracellular concentration of sCD23. The 
auto/paracrine effect of CD23 causes an increase in the production o f cAMP, activating 
PKA which attenuates NRE-BP binding via the activation o f downstream signalling 
molecules. A possible experiment which could test this hypothesis is the treatment of 
quiescent tonsillar B cells with sCD23. After a period of incubation, cells could be 
analysed for increased CD25 expression by flow cytometry. A further experiment which 
may clarify the involvement of cAMP/PKA signalling would be the pre-treatment of 
quiescent tonsillar B cells with the PKA-specific inhibitor H-89 before stimulation with 
sCD23. The inhibition o f CD25 expression would indicate that sCD23 may up-regulate
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CD25 via a cAMP/PKA-sensitive pathway. Such a finding would also provide a possible 
explanation for the slow kinetics of the IL-4-stimulated rise in intracellular cAMP 
concentrations.
Another possible explanation of the delayed elevation in cAMP levels is a decrease in 
PDE activity. In most cells, a ratio of basal PDE activity to AC activity regulates cAMP 
signalling. If  AC becomes activitated then the balance swings away fi'om PDE until the 
G-protein stimulation has diminished or the levels of PDE have raised suficiently to 
counteract the AC activity (Houslay and Milligan, 1997). Thus, a possible stimulatory 
action of IL-4 may be to down-regulate the intracellular activity of PDE The balance 
would be in the favour o f AC and would therefore increase cAMP levels witliin the cell, 
resulting in the activation of a cAMP/PKA-sensitive pathway. A possible experiment 
which could test this theory is the treatment of resting tonsillar B cells with a 
methylxanthine-family compound i.e caffeine, theobromine and theophylline. 
Methylxanthines are a class of pharmacological compounds which have a broad 
therapeutic range, being useful in the treatment of asthma, the central nervous and 
cardiovascular systems, and in kidney diuretics. One of the mechanisms of action of 
methylxanthines is the inhibition of PDE activity. Thus, if quiescent tonsillar B cells 
expressed. CD25 in response to treatment with, for example, theophylline then this 
would be induced by stimulation o f the cAMP/PKA-sensitive pathway via a decrease in 
PDE activity. (Rang et al, 1995). The delay in accumulation o f cAMP which follows IL- 
4 stimulation may be due to the period of time required to sufficiently lower PDE 
activity levels.
A possible direct phosphorylation o f NRE-BP by the active catalytic subunit of PKA, 
(PKAc) was proposed and an assay (as outlined in Figure 3.4) was set up to investigate 
this hypothesis. The assay demonstrated that PKAc had no direct effect on NRE-BP 
(Figure 3.5), but could not mle out an indirect effect. Although PKAc did not induce 
loss of NRE binding activity, it is difiQcult to lule out any indirect effect on NRE-BP
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using this assay. Potential downstream effectors of PKAc which act on NRE-BP have 
not been identified and, owing to the dilution factor for the incubation reaction, it is 
unknown whether enough o f these molecules would be stimulated to affect NRE binding 
activity. fL-4-driven CD25 expression clearly involves the stimulation of a cAMP/PKA- 
sensitive pathway, therefore it is probable that PKAc does have an indirect effect on the 
loss of NRE binding activity (Figure 6.1). The pleiotropic nature of IL-4 suggested that 
other IL-4-stimulated signalling pathways may have a role in the up-regulation of CD25 
in B cells. The activation of IL-4R initiates a number of signalling pathways including 
the stimulation o f the PI-3 kinase and JAK/STAT pathways, mainly through 1RS 
signalling. Experiments, shown in Figure 3.6, demonstrated that Wortmannin and 
Rapamycin had no effect on the capacity of IL-4 to induce CD25 expression in tonsillar 
B cells. This suggests that PI-3 kinase and p70^® kinase are not involved in the IL-4- 
driven upregulation of CD25. Further work could focus on the effect of PI-3 kinase 
signalling on cAMP levels witliin the cell. Pre-treatment of quiescent tonsillar B cells 
with Wortmannin and Rapamycin before IL-4 stimulation will inhibit PI-3 kinase 
signalling and after a period o f incubation cAMP accumulation assays could be 
performed to determine whether cAMP signalling was affected.
The investigation of JAK/STAT signalling involved transfection experiments which 
studied the effect of IL-4 treatment on cells that had been transfected with one of four 
CD25 promoter deletion mutants (Figure 6.3), where STAT6  sites had been eliminated 
(Figures 5.6 and 5.7). This study indicated that IL-4-driven CD25 expression may 
involve the activation of the JAK/STAT pathway. The putative STAT6  site which 
overlaps NRRn may be sensitive to IL-4 although further transfections with an NRR% 
deletion mutant plasmid (pANRRi) are required to verify this hypothesis. If IL-4 
sensitivity was demonstrated in cells transfected with pANRRi and lost in cells 
transfected with pPRRi, then the STAT6  site located on NRRn would be clearly 
identified as being STAT6 -sensitive.
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EMSA studies on the role o f NF-kB in IL-4 signalling in B cells indicated that in whole 
cell or cytosolic extracts, IL-4 failed to directly effect the expression of NF-kB (Figure 
3.7). This was unexpected given the proximity of an NF-kB binding site to NRRi (Joltn 
et al., 1995). These data suggest that STAT6  activation may be the dominant factor in 
upregulating CD25 transcription, following the IL-4-driven loss of NRE-BP activity. 
Previous work in this laboratory indicated that PKC activation has no effect on the 
expression of CD25 (McKay and Cushley, 1996) and the fact that IL-4 does not 
stimulate Ras/MAP kinase signalling in B cells (Welham et al., 1994) suggests that it is 
unlikely any other IL-4 stimulated pathways are involved in the up-regulation o f CD25 
expression. Therefore, IL-4 appears to up-regulate CD25 expression via two specific 
signalling pathways; a cAMP/PKA-sensitive pathway stimulating effector molecules 
further downstream of PKAc to abolish NRE binding activity and remove the 
suppression o f the CD25 gene, and the possible stimulation of the JAK/STAT pathway, 
that leads to the activation of STAT6  (Figure 6.1). Thus, IL-4 may upregulate CD25 
primarily by stimulating a cAMP/PKA-sensitive pathway which leads to the loss of NRE 
binding activity. The loss of NRE-BP removes the suppressive effect on the CD25 
promoter, allowing transcription. IL-4 may also activate JAK/STAT signalling which 
stimulates a STAT6  binding region overlapping NRRn Tliis would further potentiate the 
transcriptional activity o f CD25 and enhance gene expression.
Further studies revealed that the capacity o f IL-4 to abolish NRE binding activity is also 
obsei-ved on protein binding to the entire NRRi (Figures 4.1 and 4.2). The nature of IL-4 
signalling was investigated to determine whether the diminution o f NRE and NRRi 
binding activity was a result o f signalling mediated via the IL-4Ra or yc subunit. Figure 
4.3 shows that stimulation of quiescent tonsillar B cells by IL-13 fails to abolish NRRi 
binding activity. The IL-13 receptor complex consists of an IL-13R subunit and the IL- 
4Ra chain. The failure o f IL-13 to abolish NRRi binding activity indicates that the loss 
o f protein binding to NRRi is likely to be delivered via IL-4 signalling through the yc 
subunit. A second experiment which would verify this observation would be to analyse
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peripheral blood B cells from an XSCID patient and compare the effect of lL-4 
stimulation on CD25 expression, with normal B cells. If the XCSID B cells failed to up­
regulate CD25 expression then this would provide further evidence that IL-4-driven loss 
o f NRE binding activity is dependent on yc signalling. XSCID patients express mutated 
forms o f yc leading to a loss of intracelular signalling capabilities and serious 
immunodeficiency (Uribe and Weinberg, 1998). Previous work in this laboratoiy showed 
that treatment o f quiescent tonsillar B cells with EL-4 stimulated an intracellular rise in 
the concentration of cAMP; IL-13 did not induce cAMP accumulation (McKay, 1996). 
These findings further support the hypothesis that IL-4-driven CD25 expression is 
partially dependent on signalling through the IL-4R yc subunit. In addition, the analysis 
of potential signalling pathways for IL-4 in Chapter 3 showed a number of signalling 
mechanisms which were not involved in CD25 expression. These pathways are 
stimulated by 1RS signalling which is stimulated by the IL-4Ra subunit. The finding that 
EL-4 does not up-regulate CD25 expression via IL-4Ra signalling is further support for 
the hypothesis that signalling events generated via the IL-4R yc subunit are required for 
full CD25 expression (Figure 6.1).
The identity o f proteins binding to NRRi remains to be fially defined. Of two potential 
binding sites, NRE is bound by a 50kDa silencer protein in T cells and RA may 
upregulate CD25 expression by attenuating binding of AP-1 proteins to their binding 
site, wliich overlaps the retinoid sensitive region. The identity o f NRE-BP is unknown 
and work is being undertaken in this laboratory by other workers to characterise this 
protein. Some proteins, were proposed as candidates for NRE-BP The l lbp 
TTCATCCCAGG NRE region contains a minimal 5'- CAT -3' binding region for the 
transcription factor YYl and although 65kDa in mass, has been reported to have 
negative regulatory capabilites (Shi et al., 1991). EMSA studies o f B cell extract showed 
that the protein species which bound radiolabelled YYl oligonucleotide was different to 
the species which bound radiolabelled CD25-NRE oligonucleotide (Figure 4.7). The 
failure o f unlabelled excess CD25-NRE oligonucleotide to compete the supershifr of
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proteins binding to anti-YYl antibody and radiolabelled YYl oliognucleotide was 
further evidence that YYl is unlikely to be NRE-BP (Figure 4.8). A second candidate 
for NRE-BP was Ets on account o f the minimal 3'- GGA -5' core binding site found on 
the antisense strand, within NRE. EMSA studies showed that protein binding to 
radiolabelled CD25-NRRi was not supershifted by anti-Ets antibody, therefore it is 
unlikely that an Ets family member is NRE-BP. The IFN-regulated protein Staf-50 has 
been reported to negatively regulate the transcriptional activity o f the promoter region of 
the HIV-1 3' LTR region by binding to a sequence which is highly homologous (9/11 
bases) to NRE (Tissot and Mechti, 1995). The hypothesis that Staf-50 is identical to 
NRE-BP is currently under evaluation.
The putative AP-1 binding site was investigated by Western blot, screening B cell 
extracts for the expression of AP-1 family members (Figure 4.6b) then assessing the 
capacity o f some identified family members to supershift protein binding to radiolabelled 
CD25-NRRi oligonucleotide. The AP-1 family member c-fos (Figure 4.9), caused a sliift 
o f one protein species binding to CD25-NRRi whereas c-jun, which is not expressed in 
B cells, failed to do so. This is in agreement with Figure 4.6b as c-fos was expressed in 
EDR B cells although c-jun was not present. This is also consistent with the fact that c- 
jun is not expressed in B lymphocytes (Foletta et al., 1998). Therefore, AP-1 family 
members are expressed in B cells and the capacity for c-fos antibody to induce a 
supershift o f protein binding to radiolabelled CD25-NRRi suggests that NRRi contains 
an active AP-1 binding site. In addition, the fact that this binding site overlaps a putative 
retinoid sensitive region suggests that RA may up-regulate CD25 expression in B cells 
via an influence upon AP-1 transcription. Further work is needed to fiilly characterise 
the AP-1 family members which bind to this region. This would be established by further 
supershift experiments, using antibodies against AP-1 family members which are 
expressed in B cells and, as a control, those which are not.
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The proteins which bind to NRRi appear to be NRE-BP and AP-1. EMSA experiments 
have determined that NRE is the dominant region of protein binding although the AP-1 
site is also involved. EMSA experiments in tonsillar B cell and P3HR1 B cell extracts 
(Figure 4.4 and Table 4.1) showed that different patterns o f binding to NRE and the 
entire NRRi region. In addition, the partial competition of protein binding to 
radiolabelled CD25-NRRi in some cell lines by CD25-NRRi-Ml (Table 4.1 and Figure 
4.5) suggests that NRE-BP and AP-1 proteins may bind NRRi as a complex. A possible 
explanation o f the complex is a larger protein "bridging" NRE-BP and AP-1. A 
candidate molecule for such a bridging effect was CBP/p300 owing to the fact that it is 
activated by cAMP/PKA signalling events (Kwok et al, 1994) and the AP-1 binding site 
within the NRR% sequence is also homologous to a CREB binding site. EMSA supershift 
studies (Fig 4.9) showed that anti-CBP/p300 antibody failed to supershift protein species 
which bound to radiolabelled CD25-NRRi. Therefore if such a bridging protein exists, 
then it is unlikely to be CBP/p300.
The precise mechanism by which NRE-BP is lost from NRE has yet to be determined, 
but is likely to involve the entire NRRi region. Several hypotheses for the role o f NRE- 
BP on the suppression of CD25 transcription can be considered (Figure 6.2). The first 
proposes the simple loss of NRE binding activity in response to IL-4 (or other) 
treatment. This involves the loss o f NRE-BP from NRE. A loss of NRE-BP removes the 
suppression of CD25 transcription and as a result enables positive factors such as NF-kB 
or SRF to initiate gene expression. The AP-1 proteins binding to NRRi may possibly be 
removed or exchanged for different family members. It is unclear whether the AP-1 
region has a positive or negative regulatory role in the loss of NRE-BP or on the 
transcription o f the CD25 gene. This model is referred to as the "handbrake" model, as it 
envisages a straight-forward removal o f NRE-BP from NRE resulting in transcription, in 
much the same way as a handbrake is released before driving off in a car. By extension 
o f this analogy, positively-acting factors (i.e NF-kB or STAT6 ) would function as
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accelerators, and therefore this is refeixed to as the "handbrake" model of CD25 
transcription.
The second model focuses on the AP-1 binding site and proposes that stimulation may 
initiate an exchange of AP-1 family members leading to transcriptional activation. This 
model is refened to as the "exchange" model. This activation could affect the rest of 
NRRi and lead to the loss of NRE-BP binding, enabling CD25 transcription. Such a 
model requires the full characterisation of the family members binding to the AP-1 
binding region before it can be fiilly tested. The third and final model considers a 
potential role of a bridging protein, which may link NRE-BP and AP-1 together. Thus, 
stimulation via IL-4 signalling may remove the bridging protein fiom NRE-BP and AP-1 
and result in the uncoupling o f NRE-BP fiom NRE AP-1 may or may not be affected. 
Although studies show that it is unlikely that CBP/p300 (Figure 4.10) is involved in this 
bridging complex, the finding that unlabelled excess CD25-NRRi-Ml can compete 
protein binding to radiolabelled CD25-NRRi although protein cannot bind to 
radiolabelled CD25 -NRRi-Ml itself, indicates that a protein complex may link NRE-BP 
and AP-1  together. This model is referred to as the bridging model. The findings from 
EMSA studies o f NRRi (Figure 4.4 and Table 4.1) show that NRE is the dominant 
binding region and the fact that IL-4 treatment of B cells stimulates a loss of protein 
binding to both CD25-NRE and CD25-NRRi oligonucleotides indicates that the loss of 
NRE-BP may result in concomitant loss of AP-1 binding. This is reflected in the loss of 
"total" NRRi binding activity. These data suggest that the favoured model for the loss of 
the suppression o f CD25 transcription is the "handbrake" model.
NRE is the dominant region o f protein binding in NRRi, and the AP-1 binding site 
appears to have a minor role. This relationship was also studied at a transcriptional level 
by the transient transfection of P3HR1 B cells with NRRi deletion mutants that either 
deleted the NRE region or the NRRi region in its entirety. Both deletion mutants 
showed a marked increase in both basal and PMA-stimulated levels of reporter activity.
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in comparison to full-length CD25 reporter activity (Figure 5.2). These findings indicate 
that the deletion of NRE leads to the loss of suppression of the CD25 promoter thus 
enhancing levels of reporter activity. Complete deletion of the NRRi region showed an 
increase in reporter activity, which was comparable to the NRE deletion. The finding, 
over a number o f experiments, that the complete removal o f NRRi did not further 
increase reporter activity is consistent with the interpretation that NRE is the dominant 
transcriptional region within NRRi.
Four putative STAT6  sites were identified at positions along the proximal CD25 
promoter (Figures 1.5 and 5.1), each one with the potential to respond to IL-4 
stimulation and up-regulate transcriptional activity. Reporter constructs were designed 
to assess these regions by deleting the appropriate sequence; one overlapping NRRn, 
one between PRRi and PRRn and the final two, within PRRn itself (Figure 6.3). The 
STAT6  deletion mutants assessed the effect o f PMA on the reporter activity levels of 
transfected lymphoid cells (Figure 5.5). Both PRRi_n regions appeared to to contribute 
to the rise in basal and PMA stimulated reporter activity, upon the deletion o f NRRnn- 
Cells transfected with each STAT6  deletion mutant showed that stimulation with PMA 
enhanced basal reporter activity levels. The further increase in reporter activity 
expressed by cells transfected with pDPRRi suggests that PRRn may be more sensitive 
to mitogen in the absence o f PRRn The finding that PRRn is sensitive to PMA is the first 
time that this region has been shown to be mitogen-responsive in B cells.
Lymphoid cells transfected with a full-length pCD25 CAT-E' plasmid showed basal 
reporter activity levels which were enhanced by IL-4 stimulation (Figures 5.6 and 5.7). 
Each cell line transfected with the STAT6  deletion mutants showed basal reporter 
activity levels which were unaffected by IL-4 stimulation. This indicates that only one 
STAT6  site is sensitive to IL-4 stimulation. Cells transfected with pCD25 CAT-E' 
showed increased levels of reporter activity after stimulation with IL-4 although cells 
transfected with pPRRi did not. As transfection with pPRRi deletes both NRRi_n
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regions, this suggests that the putative site which overlaps NRRn is IL-4 sensitive and S'
therefore may be a bona fide  ST AT6  binding site. These findings suggest that IL-4 
stimulates a STAT6  binding site which lies close to NRE and enhances CD25 promoter 
activity following the loss o f NRE-BP.
In summaiy, the human CD25 promoter region in B cells contains a negative regulatory 
region, NRRi, comprised o f an l lbp  core negative regulatory element and a retinoid 
sensitive region bound by AP-1 proteins. NRE is regulated, in T cells, by an unidentified 
50kDa NRE-binding protein. IL-4 has been shown to up-regulate the expression of 
CD25 in human B cells through a cAMP/PKA-sensitive pathway which attenuates the 
binding of NRE-BP to NRE. NRE binding activity is not lost by the direct actions of 
PKAc, although it is likely that PKAc has an indirect effect via the activation of 
unidentified downstream molecules. Studies with cell signalling inhibitors and the 
transient-transfection o f lymphoid cells showed that IL-4 up-regulates CD25 expression 
via a cAMP/PKA-sensitive pathway and possibly via the activation of a JAK/STAT 
pathway which stimulates a STAT6  binding site overlapping NRRn- IL-4 signalling is 
mediated via the yc chain of the IL-4R complex. EMSA studies showed that NRE is the 
dominant protein binding region o f NRRi, and supershift experiments characterised the 
retinoid sensitive region as an AP-1 binding site for c-fos. Models for the loss o f the 
suppressive effect o f NRE-BP on CD25 transcription were proposed covering possible 
roles of NRE-BP, AP-1 and a complex formed by a bridging protein, in response to 
stimulation. Data indicate the most likely model is the so-called "handbrake" model 
which proposed that stimulus-induced CD25 expression is caused by the loss of NRE- 
BP binding, which may or may not affect AP-1 binding, that leads to the loss of a 
suppressive effect on CD25 transcription. The identity of NRE-BP remains unknown; 
supershift experiments revealed that YYl and Ets are not identical to NRE-BP. The 
same experiments showed that CBP/p300 does not form a bridging complex over NRE- 
BP and AP-1. Transfection studies involving NRRi deletion mutants revealed that NRE 
is the dominant transcriptional region within NRRi. Studies with deletion mutants
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suggested that a STAT6  site adjacent to NRRn is IL-4 sensitive and showed for the first 
time that PRRn, in common with PRRi, is responsive to mitogenic stimulation in B cells.
The CD25 promoter responds to signalling fi'om a range of surface receptors. It remains 
to be resolved which intracellular signalling pathways influence the activités of 
transcriptional regulatory proteins associated with individual regions of the CD25 
promoter and, in particular, those signals which positively and negatively regulate the 
activities o f the NRE-BP and AP-1 proteins interacting with NRRi. Further work is 
required to identify NRE-BP and to define the role of the AP-1 binding site in regulation 
of CD25 transcription.
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Figure 6.1 Model of IL-4R Signalling Involved in the Removal of Suppression of 
CD25 Transcription.
A model o f the signalling events generated by IL-4 which lead to the loss of NRE 
binding activity and the suppression of CD25 expression. Included is the cAMP/PKA- 
sensitive pathway and an assessment o f other IRS-linked signalling pathways as outlined 
in Chapter 3, the NRRi region and signalling generated by the IL-4R yc subunit, as 
described in Chapter 4, and the putative STAT6  sites within the CD25 proximal 
promoter region, described in Chapter 5.
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Figure 6.2 Hypothesis for the Regulation of NRE by NRRi Binding Proteins 
Which Suppress CD25 Transcription.
Three models are proposed for the suppressive effect o f NRE-BP on CD25 
transcriptional activity.
Model A (Fig 6.1 A) shows that NRE-BP and AP-1 proteins bind to NRRi in the resting 
state. Upon stimulation ie. by IL-4, the stimulus acts on NRE-BP and possibly AP-1 
proteins to attenuate binding to NRRi. This leads to a loss of negative regulation of the 
CD25 promoter gene and the initiation of transcriptional activity. This will result in the 
expression of CD25. The removal o f NRE-BP, coupled with the possible activation of 
the AP-1 region is analogous to releasing the handbrake (NRE-BP) when driving a car. 
This model is hence called the "handbrake" model.
Model B (Fig 6 . IB) centres on the role of AP-1 and shows that a stimulus causes an 
exchange o f proteins binding to the AP-1  region o f NRRi. The alteration o f AP-1 family 
members binding to NRRi activates the region leading to the removal o f NRE-BP and 
the initiation o f CD25 transciptional activity. This model is termed the "exchange" 
model.
Model C (Fig 6 .1C) shows that in a resting state, NRRi is bound by NRE-BP, AP-1 
family proteins and a larger protein complex which "bridges" the proteins. The stimulus 
directly attenuates the binding o f the large protein complex to NRE-BP and AP-1. Loss 
of binding also removes the binding o f NRE-BP and possibly AP-1 to NRRi NRE-BP 
binding to NRE is lost leading to CD25 promoter transcription. The linking of NRE-BP 
and AP-1  by the large protein complex is termed the "bridging" model.
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Figure 6.3 Summary of Deletion Mutant Plasmids for Putative STAT6 Binding 
Regions Within the CD25 Promoter.
Deletion mutant constructs for putative STAT6  sites within the CD25 promoter were 
created by inserting mutated sequences for CD25 within the Hind in and Sal I 
restriction sites of a pCAT-Enhancer plasmid. A control plasmid, pCD25 CAT-E' 
contained the full length proximal CD25 promoter sequence. pPRRj contained a deletion 
mutation for a putative STAT6  site found within the NRRi_n regions. pAPRRj further 
deleted the second STAT6  site between PRRi_n. The third and fourth putative STAT6  
sites within PRRn were deleted by the plasmids pAS6 -I and pAS6-2, respectively. DNA 
binding regions are indicated by open boxes, putative STAT6  sites are shown as black 
boxes.
169
Ori
SV40 Eiiliancer
SV40
Amp r
CAT
NRR, NRR„ PRR, PRR„
“C pCD25CAT-E’
pPRR,
’=3.
r w
pAPRR,
pAS6-1
pAS6-2
REFERENCES
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., GafEhey, P. R J., Reese, C. 
B., and Cohen, P. (1997). Curr. Biol 7, 261-269.
Alt, F. W., Yancopolous, G. D., Blackwell, T. K., Wood, C , Thomas, E., Boss, M., 
Cofïman, R., Rosenborg, N., Tonegawa, S., and Baltimore, D. (1984). EMBO J. 3, 
1209-1219.
Aman, M. J., and Leonard, W. J. (1997). Curr. Biol. 7, R784-R788.
Aman, M. J., Tayebi, N., Obiri, N. I., Puri, R K., Modi, W. S., and Leonard, W. J. 
(1996). J. Biol. Chem. 271, 29265-29270.
Angel, P., and Karin, M. (1991). Biochim. Biophys. Acta 1072, 129-157.
Ashman, R. F., Peckham, D , and Stunz, L. L. (1996). J. Immunol. 157, 5-11.
Baeurle, P. A., and Henkel, T. (1994). Annu. Rev. Immunol. 12, 141-179.
Baird, A. M., Gerstein, R. M., and Berg, L. J. (1999). Curr. Opin. Immunol. 11, 157- 
166.
Baldwin, A. S. (1996). Annu. Rev. Immunol. 14, 649-681.
Bemark, M., Martennson, A., Liberg, D., and Leanderson, T. (1999). J. Biol. Chem. 
272, 10259-10267.
Benschop, R. J., and Cambier, J. C. (1999). Curr. Opin. Immunol. 11, 143-151.
Bhatti, L., and Sidell, N. (1994). Immunology 81, 273-279.
Bijsterbosch, M. K., Meade, C. J., Turner, G. A., and Klaus, G G. B. (1985). Cell 41, 
999-1006.
170
Blery, M., Kubagawa, H., Chen, C C., Vely, F., Cooper, M. D , and Vivier, E. (1998). 
Proc. Natl. Acad. Soi. USA 95, 2446-2451.
Bonnefoy, J , Lecoanet-Henchoz, S., Gauchat, J., Graber, P., Aubry, J., Jeannin, P., and 
Plater-Zyberk, C (1997a). Intern. Rev. Immunol. 16, 113-128.
Bonnefoy, J.-F., Aubry, J.-P., Gauchat, J. F., Graber, P., and Lecoanet-Henchoz, S. 
(1997b). (M. M. Harnett, K. P. Rigley, éd.), p. 65-71. John Wiley & Sons Ltd.
Boriak-Sjodin, P., Margarit, S. M., Bar-Sagi, D , and Kuriyan, J. (1998). Nature 394, 
337-343.
Brocker, T., Gulbranson-Judge, A., Flynn, S., Riedinger, M., Raykundalia, C , and Lane, 
P. (1999). Eur. J. Immunol. 29, 1610-1616.
Bucher, P., Corthesy, P., Imbeit, J., and Nabholz, M. (1997). Immunobiol. 198, 136- 
143.
Buhl, A. M., and Cambier, J. C. (1999). J. Immunol. 162, 4438-4446.
Burlinson, E. L., Pringle, H. M., Ozanne, B. W., and Cushley, W. (1995). Immunol. 
Lett. 45, 93-98.
Burnet, M. F. (1959). “The clonal selection theory of aquired immunity”, Cambridge 
University Press. London.
Busslinger, M., and Urbanek, P. (1995). Curr. Opin. Genet. Dev. 5, 595-601.
Butcher, E. C., and Picker, L. J. (1996). Science 272, 60-66.
Butcher, R. D. J., McGarvie, G. M., and Cushley, W. (1990). Immunology 69, 57-64.
Campbell, S. L., Khosravi-Far, R , Rossman, K. L , Clark, G. J., and Der, C. J. (1998). 
Oncogene 17, 1395-1413.
171
Caput, D , Laurent, P., Kaghad, M., Lelias, J. M., Lefort, S., Vita, N., and Ferrara, P.
(1996). J. Biol. Chem. 271, 16921-16926.
Chan, M. A., McGi'ath, T. H., and Gelfand, E. W. (1993). Cell. Immunol. 146, 300-312.
Chang, Y., Bosma, M. L, and Bosma, G. C. (1999). J. Exp. Med. 189, 1295-1305.
Chen, E. H., Gadina, M., Galon, J., Chen, M., and O'Shea, J. J. (1998). Immunol. Today 
19, 338-341.
Chiu, R., Angel, P., and Karin, M. (1989). Cell 59, 979-986.
Chung, C. D., Liao, J., Liu, B., Xiaoping, R , Jay, P., Berta, P., and Shuai, K. (1997). 
Science 278, 1803-1805.
Cohen, P. (1997). Trends Cell Biol. 7, 353-361.
Cohney, S. J., Sanden, D , Cacalano, N. A., Yoshimura, A., Mui, A., Migone, T. S., and 
Johnston, J. A. (1999). Mol. Cell. Biol. 19, 4980-4988.
Colledge, M., and Scott, J. D. (1999). Trends Cell Biol. 9, 216-221.
Daniel, P. B., Walker, W. H., and Habener, J. F. (1998). Annu. Rev. Nutr. 18, 353-383.
Darnell Jr., J. E. (1997). Science 277, 1630-1635.
Dawson, C. H., Brown, B. L., and Dobson, P. R. M. (1997). Biochem. Biophys. Res. 
Comms. 233, 279-282.
Dent, A. L., Schaffer, A. L., Yu, X., Allman, D., and Staudt, L. M. (1997). Science 276, 
589-592.
Dhand, R., Hiles, I., Panayotou, G , Roche, S., Fry, M. J., Gout, I., Totty, N. F., 
Truong, O , Vicendo, P., Yonezawa, K., Kasuga, M., Courtneidge, S. A., and 
Waterfield, M. D. (1994). EMBO J. 13, 522-533.
172
Dickensheets, H. L., Venkataraman, C., Schindler, U., and Donnelly, R. P. (1999). Proc. 
Natl. Acad. Sci. USA 96, 10800-10805.
DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandhi, E., and Karin, M. (1997). 
Nature 388, 548-554.
Domin, J., and Waterfield, M. D. (1997). FEBS Lett. 410, 91-95.
Eckholm, D , Belffage, P., Manganiello, V., and Degerman, E. (1997). Biochim. 
Biophys. Acta 1356, 64-70.
Eicher, D. M., and Waldmann, T. A. (1998). J. Immunol. 161, 5430-5437.
' â
El-Hillal, O , Kurosaki, T., Yamamura, H., Kinet, L, and Scharenberg, A. M. (1997).
Proc. Natl. Acad. Sci. USA 94, 1919-1924.
Evans, G. A., Goldsmith, M. A., Johnstone, J. A., Xu, W. D., Weiler, S. R., Erwin, R ,
Howard, O. M. Z., Abraham, R. T., O'Shea, J. J., Greene, W. C , and Farrar, W. L.
(1995). J. Biol. Chem. 270, 28858-28863. %
Finney, M., Guy, G. R , Michell, R. H., Gordon, J., Dugas, B., Rigley, K. P., and
Callard, R. E. (1990). Eur. J. Immunol. 20, 151-156.
Foletta, V. C., Segal, D. H., and Cohen, D. R. (1998). J. Leuk. Biol. 63, 139-152.
Forni, L., Coutihno, A., Kohler, G., and Jerne, N.K. (1979). Proc. Natl. Acad. Sci.
USA. 77, 1125-1128
Franke, T. F., Kaplan, D. R , and Cantley, L. C. (1997). Cell 8 8 , 435-437.
Franke, T. F., Kaplan, D. R., Cantley, L. C., and Toker, A. (1997). Science 275, 665- 
668 .
Freimuth, W. W., Depper, J. M., and Nabel, G. J. (1989). J. Immunol. 143, 3064-3068.
173
.....j:;
Friedrich, K., Kammer, W., Erhardt, I., Brandlein, S., Sebald, W., and Moriggl, R. 
(1999). Int. Immunol. 11, 1283-1293.
Fu, C., Turck, C., Kurosaki, T., and Chan, A. C. (1998). Immunity 9, 93-103.
Fujimoto, M., Poe, J. C., Jansen, P. J., Sato, S., and Tedder, T. F. (1999). J. Immunol. 
162, 7088-7094.
Fukuda, T., Yoshida, T., Okada, S., Hatano, M., Miki, T., Ishibashi, K., Okabe, S., 
Koseki, H., Hirosawa, S., Taniguchi, M., Miyasaka, K., and Tokuhisa, T. (1997). J. 
Exp. Med. 186, 439-448.
Garret-Sinha, L. A., Su, G. H., Rao, S., Kabak, S., Hao, Z., Clark, M. R., and Simon, 
M. C. (1999). Immunity 10, 399-408.
Gascan, H., Gauchat, J. F., Roncarolo, M. G., Yssel, H., Spits, H., and de Vries, J. E. 
(1991). J. Exp. Med. 173, 747-750.
Georgopoulos, K., Winandy, S., and Avitahl, N. (1997). Annu. Rev. Immunol. 15, 155- 
176.
Gerritsen, M. E., Williams, A. J., Neish, A. S., Mo ore. S., Shi, Y , and Collins, T.
(1997). Proc. Natl. Acad. Sci. USA 94, 2927-2932.
Ghia, P., Boekel, E., Rolink, A. G., and Melchers, F. (1998). Immunol. Today 19, 480- 
485.
Godfrey, D. L., and Zlotnick, A. (1993). Immunol. Today 14, 547-553.
Gonzalez, G A., and Montminy, M. R. (1989). Cell 59, 675-680.
Grant, P. A., Thompson, C. B , andPettersson, S. (1995). EMBO J. 14, 4501-4513. 
Graves, B. J., and Petersen, J. M. (1998). Adv. Cancer Res. 75, 1-55.
174
Hagman, J., Belanger, C., Travis, A., Turck, C. W., and Grosschedl, R. (1993). Genes 
Dev. 7, 760-773.
Halazonetis, T., Georgopoulos, K., Greenberg, M. E., and Leder, P. (1988). Cell 55, 
917-924.
Hamm, H. E., and Gilchrist, A. (1996). Curr. Opin. Cell. Biol. 8 , 189-196.
Han, S., Zheng, B., Schatz, D. G., Spanopoulo, E., and Kelsoe, G. (1996). Science 274, 
2094-2097.
Haque, S. J., Wu, Q., Kammer, W., Friedrich, K., Smith, J. M., Kerr, I. M., Stark, G. 
R , and Williams, B. R. G. (1997). Proc. Natl. Acad. Sci. USA 94, 8563-8568.
Hardy, R. R , Carmack, C. E., Shinton, S. A., Kemp, J. D., and Hayakawa (1991). J. 
Exp. Med. 173, 1213-1225.
Hashimoto, A., Okada, H., Jiang, A., Kurosaki, M., Greenberg, S., Clark, E. A., and 
Kurosaki, T. (1998). J. Exp. Med. 188, 1287-1295.
Henderson, A., and Calame, K. (1998). Annu. Rev. Immunol. 16, 163-200.
Herblot, S., Chastagner, P., Samady, L., Moreau, J. L., Demaison, C., Froussard, P., 
Liu, X., Bonnet, J., and Theze, J. (1999). J. Immunol. 162, 3280-3288.
Hess, J., Laumen, H., Muller, K. B., and Wirth, T. (1998). J. Cell. Physiol. 177, 525- 
534.
Hewitt, E. L., Ozanne, B. W , and Cushley, W. (1997). Cytokine 9, 982-991.
Houslay, M. D , and Milligan, G. (1997). TIBS 2 2 , 217-224.
Howard, M., Farrar, J., Hilhker, M., Johnson, B., Takatsu, K., Hamaoka, T., and Paul, 
W. E. (1982). J. Exp. Med. 155, 914-923.
175
Hozumi, N., and Tonegawa, S. (1976). Proc. Natl. Acad. Sci. USA. 73, 3628-3632.
Huo, L., and Rothstein, T. L. (1995). J. Immunol. 154, 3300-3309.
Huo, L., and Rothstein, T. L. (1996). J. Immunol. 157, 3812-3818.
Ihle, J. N. (1996). Cell 84, 331-334.
Imani, P., Rager, K. J., Catipovic, B , and Marsh, D. G. (1997). J. Biol. Chem. 272, 
7927-7931.
Ishiai, M , Kurosaki, M., Pappu, R., Okawa, K., Ronko, I., Fu, C., Shibata, M., 
Iwamatsu, A., Chan, A. C., and Kurosaki, T. (1999). Immunity 10, 117-125.
Jain, J., McCafFerty, P. G , Valge, A. V., and Rao, A. (1992). Nature 356, 801-804.
Jankovich, D. L., Gibert, M., Baran, D., Ohara, J., Paul, W. E., and Theze, J. (1989). J. 
Immunol. 142, 3113-31320.
Jelinek, D. F., and Lipsky, P. E. (1988). J. Immunol. 141, 164-173.
John, S., Reeves, R. B., Lin, J.-X., Child, R., Leiden, J. M., Thompson, C. B., and 
Leonard, W. J. (1995). Mol. Cell. Biol. 15, 1786-1796.
John, S., Robbins, C M., and Leonard, W. J. (1996). EMBO J. 15, 5627-5635.
Johnston, J. A , Wang, L. M., Hanson, E. P., Sun, X. J., White, M. F., Oakes, S. A., 
Pierce, J. H., and O'Shea, J. J. (1995). J. Biol. Chem. 270, 28527-28530.
Kadesch, T. (1992). Immunol. Today 13, 31-36.
Kammer, W., Lischke, A., Morrigl, R., Groner, B., Ziemiecki, A , Gurniak, C. B., Berg, 
L. J., and Friedrich, K. (1996). J. Biol. Chem. 271, 23634-23637.
Kaplan, M. H., Schindler, U., Smiley, S. T., and Grusby, M. J. (1996). Immunity 4, 313- 
319.
176
Karasuyama, H., Rolink, A., and Melchers, F. (1993). J. Exp. Med. 178, 469-478.
Karin, M., Liu, Z. G., and Zandi, E. (1997). Curr. Opin. Cell Biol. 9, 240-246.
Karras, J. G., Wang, Z., Coniglio, S. J , Frank, D. A., and Rothstein, T. L. (1996). J. 
Immunol. 157, 39-47.
Kawakami, K., and Parker, D C. (1993). Eur. J. Immunol. 23, 77-84
Kee, B. L., and Paige, C. J. (1995). Int. Rev. Cytol. 157, 129-179.
Keegan, A. D., Nelms, K., Wang, L., Pierce, J. H., and Paul, W. E. (1994a). Immunol. 
Today 15, 423-431.
Keegan, A. D., Nelms, K , White, M , Wang, L. M., Pierce, J. H., and Paul, W. B. 
(1994b). Cell 76, 811-820.
Keegan, A. D , and Paul, W. E. (1992). Immunol. Today 13, 63-68.
Kennelly, P. J., and Krebs, E. G. (1991). J. Biol. Chem. 266, 15555-15558.
Kim, C. H., and Broxmeyer, H. E. (1999). J. Leukoc. Biol. 65, 6-15.
King, L. B., Norvel, A., and Monroe, J. G. (1999). J. Immunol. 162, 2655-2662.
Kolanus, W., Romeo, C., and Seed, B. (1993). Cell 74, 171-183.
Kolch, W., Heidecker, G , Kochs, G., Hummel, R , Vahidi, H., Mischak, H., 
Finkenzeller, D., Marme, D., and Rapp, U. R (1993). Nature 364, 249-252.
Kuhn, R., Rajewsky, K., and Muller, W. (1991). Science 254, 707-710.
Kurosaki, T. (1999). Annu. Rev. Immunol. 17, 555-592.
Kurosaki, T., and Kurosaki, M. (1997). J. Biol. Chem. 272, 15595-15598.
177
Kwok, R, P., Lundblad, J. R., Chrivia, J. C., Richards, J. P., Bachinger, H. P., Brennan,
R G , Roberts, S. G. E., Green, M. R., and Goodman, R. H. (1994). Nature 370, 223-
!
Landshuiz, W. H., Johnson, P. P., and McKnight, S. L. (1988). Science 240, 1759-1764. A:
Landsman, D., and Bustin, M. (1993). BioEssays 15, 539-546.
Lane, P. (1996). Curr. Opin. Immunol. 8 , 331-336.
LeBien, T. W. (1998). Curr. Opin. Immunol. 10, 188-195.
Lecine, P., Algarte, M., Rameil, P., Beadling, C., Bucher, P., Nabholz, M., and Imbert,
J. (1996). Mol. Cell. Biol. 16, 6829-6840.
Lee, K. A. W., and Masson, N. (1993). Biochim. Biophys. Acta 1174, 221-223.
Leonard, W. J. (1996). Annu. Rev. Med. 47, 229-239.
Letzelter, F., Wang, Y., and Sebald, W. (1998). Eur, J. Biochem. 257, 11-20.
Li, H., Davis, W., and Pure', E. (1999). J. Biol. Chem. 274, 9812-9820.
Li, N., Batzer, A , Daly, R , Yajnik, V., Skolnik, E., Chardin, P., Bar-Sagi, D., Margolis,
B., and Schlessinger, J. (1993). Nature 363, 85-88.
Lin, H., and Grosschedl, R. (1995). Nature 376, 263-267.
Lin, J., Migone, T., Tsang, M., Friedmann, M., Weatherbee, J. A , Zou, L., Yamauchi,
A., Bloom, E. T., Mietz, J., John, S., and Leonard, W. J. (1995). Immunity 2 , 331-339.
Lishke, A., Morigg, R., Brandlein, S., Berchtold, S., Kammer, W., Sebald, W., Groner,
B., Liu, X., Hennighausen, L , and Freidrich, K. (1998). J. Biol. Chem. 273, 31222- 
31229.
178
Liu, B., Liao, J., Rao, X., Kushner, S. A., Chung, C. D., Chang, D. D., and Shuai, K.
(1998). Proc. Natl. Acad. Sci. USA 95, 10626-10631.
Liu, W. S., and Heckman, C. A. (1998). Cell. Signal. 10, 529-542.
Lomo, J., Smeland, E. B., Ulven, S., Natarajan, V., Blomhoff, R , Gandhi, U., Dawson, 
M. L, and Blomhoff, H. K. (1998). J. Cell. Physiol. 175, 68-77.
Maeda, A., Scharenberg, A. M., Tsukada, S., Bolen, J. B., Kinet, J., and Kurosaki, T.
(1999). Oncogene 18, 2291-2297.
Malek, T. R , and Ashwell, J. D. (1985). L Exp. Med. 161, 1575.
Maniatas, T. (1997). Science 278, 818-819.
Marais, R., Light, Y., Mason, C., Paterson, H , Olson, M. P., and Marshall, C. J. (1998). 
Science 280, 109-112.
Martensson, A., Argon, Y., Melchers, P., Dul, J. L., and Martensson, I. (1999). Int. 
Immunol. 11, 453-460.
May, M. J., and Ghosh, S. (1998). Immunol. Today 19, 80-88.
McHeyzer-Williams, M. G , and Ahmed, R. (1999). Curr. Opin. Immunol. 11, 172-179.
McKay, C. E. (1996). Ph.D. Thesis. 'Tnterleukin-4-Mediated Regulation o f CD25 Gene 
Expression in Human B Lymphocytes". University of Glasgow.
McKay, C. E., Hewitt, E. L , Ozanne, B. W , and Cushley, W. (1999). In Press.
McKay, C. E., and Cushley, W. (1996). Cytokine 8 , 305-312.
Meisner, H., Conway, B. R., Hartley, D , and Czech, M. P. (1995). Mol. Cell. Biol. 15, 
3571-3578.
179
Melchers, F,, Rolink, A., Grawunder, U., Winkler, T. H , Karasuyama, H., Ghia, P., and 
Anders son, J. (1995). Curr. Opin. Immunol. 7, 214-227.
Meyer, T. E., and Habener, J. F. (1993). Endoc. Rev. 14, 269-290.
Meyer, W. K. H., Reichenbach, P., Schindler, U., Soldain, E., and Nabholz, M. (1997). 
J. Biol Chem. 272, 31821-31828.
Minami, Y., Kono, T., Miyazaki, T., and Taniguchi, T. (1993). Ann. Rev. Immunol. 11, 
245-67.
Mînegishi, Y., Hendershot, L. M., and Conley, M. E. (1999). Proc. Natl. Acad. Sci. 
USA 96, 3041-3046.
Miyajima, A., Kitamura, T., Harada, N., Yokota, T., and Arai, K. (1992). Ann. Rev. 
Immunol. 1 0 , 295-331.
Miyazaki, T., Kawahara, A., Fujii, H , Nakagawa, Y., Minami, Y., Liu, Z. J., Oishi, I., 
Silvennoinen, O., Witthuhn, B. A., Ihle, J. N., and Taniguchi, T. (1994). Science 266, 
1045-1047.
Montminy, M R., Sevarino, K. A., Wagner, K. A., Mandel, G., and Goodman, R. H. 
(1986). Proc. Natl. Acad. Sci. USA 83, 6682-6686.
Montoya, M. C., Holtmann, K., Snapp, K. R., Borges, E., Sanchez-Madrid, F., 
Luscinskas, F. W., Kansas, G , Vestweber, D., and de Landazuri, M. O. (1999). J. Clin. 
Invest. 103, 1317-1327.
Morgan, B., Sun, L., Avithal, N., Andrikopoulos, K., Ikeda, T., Gonzalez, E., Wu, P., 
Neben, S., and Georgopoulos, K. (1997), EMBO J. 16, 2004-20013.
Morgan, D. A , Ruscetti, F. W., and Gallo, R. (1976). Science 193, 1007-1008.
Mossalayi, M. D., A ock, M., and Debre, P. (1997). Int. Rev. Immunol. 16, 129-146.
180
-
Murata, T., Noguchi, P. D., and Puri, R. K. (1996). J. Immunol. 156, 2972-2978.
Murata, T , Taguchi, J., and Puri, R. K. (1998). Blood 91, 3884-3891.
Nabholz, M., Soldaini, E., Sperisen, P., Pla, M., Wang, S. M., MacDonald, R., 
Reichenbach, P., Beerman, P., and Bucher, P. (1995). Immunobiol. 193, 259-262.
Nagata, K., Nakamura, T., Kitamura, P., Kuramochi, S., Taki, S., Campbell, K. S., and 
Karasuyama, H. (1997). Immunity 7, 559-570.
Nakabeppu, Y., and Nathans, D. (1991). Cell 64, 751-759.
Nakajima, H., Liu, X.-W., Wynshaw-Boris, A., Rosenthal, L. A., Imada, K., Finbloom,
D. S., Henighausen, L., and Leonard, W. J. (1997). Immunity 7, 1-20.
Nelms, K., Kegan, A. D., Zamorano, J., Ryan, J. J., and Paul, W. E. (1999). Annu. Rev. 
Immunol. 17, 701-738.
Nelson, B. H., and Willerford, D. M. (1998). Adv. Immunol. 70, 1-79.
Newton, A. C. (1995). J. Biol. Chem. 270, 28495-28498.
Noben-Trauth, N., Shultz, L. D., Brombacher, P., Urban Jr., J P., Gu, H., and Paul, W.
E. (1997). Proc. Natl. Acad. Sci. USA 94, 10838-10843.
Noelle, R , Krammer, P. H., Ohara, J., Uhr, J. W., and Vitetta, E. S. (1984). Proc. Natl. 
Acad. Sci. USA 81, 6149-6153.
Nosaka, T., van Deursen, J. M. A., Tripp, R. A , Thierfelder, W. E., Witthuhn, B. A., 
McMickle, A. P., Doherty, P., Grosveld, G. C., and Ihle, J. N. (1995). Science 270, 
800-802.
Nutt, S. L., Heavey, B., Rolink, A. G , and Busslinger, M. (1999). Nature 401, 556-562. 
O'Shea, J. J. (1997). Immunity 7, 1- 1 1 .
181
Ollivier, V., Parry, G. C. N., Cobb, R. R., de Prost, D., and Mackman, N. (1996). J. 
Biol Chem. 271, 20828-20835.
Orchansky, P. L., Kwan, R., Lee, F., and Schrader, J. W. (1999). J. Biol. Chem. 274, 
20818-20825.
Oshima, Y., Tanaka, Y., Tozawa, H., Takahashi, Y., Maliszewski, C , and Delespesse,
G. (1997). J. Immunol. 159, 3838-3848.
Osmond, D. G , Rico-Vargas, S., Valenzona, H., Fauteux, L., Liu, L., Janani, R., Lu, L., 
and Jacobsen, K. (1994). Immunol. Rev., 209-230.
Osmond, D. G., Rolink, A., and Melchers, F. (1998). Immunol. Today 19, 65-68.
Park, S. Y., Saijo, K., Takahashi, T., Osawa, M., Arase, H., Hirayama, N., MiyakeK., 
Nakauchi, H., Shirasawa, T., and Saito, T. (1995). Immunity 3, 771-782.
Parker, D., Ferreri, K., Nakajima, T., LaMorte, V. J., Evans, R., Koerber, S. C., 
Hoeger, C , and Montminy, M. R. (1996). Mol. Cell. Biol. 16, 694-703.
Paul-Eugene, N., Kolb, J.-P., Abadie, A., Gordon, J., Delespesse, G., Sarfati, M., 
Mencia-Huerta, J.-M., Braquet, P., and Dugas, B. (1992). J. Immunol. 149, 3066-3071.
Pierce, J. W., Jamieson, C. A., Ross, J. L., and Sen, R. (1995). J. Immunol. 155, 1972- 
1980.
Plaetinck, G , Combe, M. C., Corthesy, P., Sperisen, P., Kanamori, H., Honjo, T., and 
Nabholz, M. (1990). J. Immunol. 145, 3340-3347.
Qin, X., Reichlin, A., Luo, Y , Roeder, R. G., and Nussenzweig, M. C. (1998). EMBO 
J. 17, 5066-5075.
Rabin, E. M., Mond, J. J., Ohara, J., and Paul, W. E. (1986). J. Immunol. 137, 1573- 
1576.
182
Rameh, L. E., and Cantley, L. C. (1999). J. Biol. Chem. 274, 8347-8350.
Rane, S. G., and Reddy, E. P. (1994). Oncogene 9, 2415-2423.
Rang, H. P., Dale, M. M., and Ritter, J. M. (1995). “Pharmacology.” 3rd éd., Churchill 
Livingstone.
Rao, A., Luo, C., and Hogan, P. G. (1997). Annu. Rev. Immunol. 15, 707-747.
Raskin, N., Jakubowski, A., Sizing, L, Oison, D. L., Kalled, S. L., Hession, C. A., 
Benjamin, C. D., Baker, D. P., and Burkly, L. C (1998). J. Immunol. 161, 3474-3483.
Rawlings, D. J., Scharenberg, A. M., Park, H., Wahl, M. I., Lin, S., Kato, R. M., 
Fluckiger, A. C., Witte, O. N., and Kinet, J. P. (1996). Science 271, 822-825.
Reth, M. (1989). Nature 338, 383-384.
Rolink, A., Grawunder, U., Winkler, T. H., Karasuyama, H., and Melchers, F. (1994). 
Int. Immunol. 6 , 1257-1264.
Rolling, C , Treton, D., Pellegrini, S., Glanaud, P., and Richard, Y. (1996). FEBS Lett. 
393, 53-57.
Rothenberg, E. V. (1992). Adv. Immunol. 51, 85-214.
Russell, S. M., Keegan, A. D , Harada, N., Nakamura, Y., Noguchi, M., Leland, P., 
Friedmann, M. C., Miyajima, A., Puri, R. K., Paul, W. E., and Leonard, W. J. (1993). 
Science 262, 1880-1883.
Russell, S. M., Tayebi, N., Nakajima, H., Riedy, M. C., Roberts, J. L , Aman, M. J., 
Migone, T. S., Noguchi, M., Markert, M. L., Buckley, R. H., O'Shea, J. L, and Leonard, 
W. L (1995). Science 270, 797-800.
Rusterholz, C , Henrioud, P. C., and Nabholz, M. (1999). Mol. Cell. Biol. 19, 2681- 
2689.
183
Sandel, P. C., and Monroe, J. G. (1999). Immunity 10, 289-299.
Sanz, E., and de la Hera, A. (1996). J. Exp. Med. 183, 2693-2698.
Saouaf, S. J., Mahajan, S., Rowley, R. B., Kut, S. A., Fargnoli, J., Burkhardt, A. L., 
Tsukada, S., Witte, O. N., and Bolen, J. B. (1994). Proc. Natl. Acad. Sci. USA 91, 
9524-9528.
Sarmay, G., Koncz, G., Pecht, I., and Gergely, J. (1999). Immunol. Lett. 6 8 , 25-34.
Sato, S., Jansen, P. J., and Tedder, T. F. (1997). Proc. Natl. Acad. Sci. USA 94, 13158- 
13162.
Satterthwaite, A., and Witte, O. (1996). Annu. Rev. Immunol. 14, 131-154.
Satterthwaite, A. B., Li, Z., and Witte, O. N. (1998). Semin. Immunol. 10, 309-316.
Schanke, J. T., Marcuzzi, A., Podzorski, R. P., and Van Ness, B. (1994). Nucleic Acids 
Res. 22, 5425-5432.
Scharenberg, A. M., and Kinet, J. P. (1996). Cell 87, 961-964.
Schubart, D. B., Rolink, A., Kosco-Vilbois, M. H., Botteri, F , and Matthais, P. (1996). 
Nature 383, 538-542.
Schuh, K., Twardzik, T., Kneitz, B , Heyer, J , Schimpl, A., and Serfling, E. (1998). J. 
Exp. Med. 188, 1369-1373.
Serdobova, I., Pla, M., Reichenbach, P., Sperisen, P., Ghysdael, J., Wilson, A., Freeman, 
J., and Nabholz, M. (1997). J. Exp. Med. 185, 1211-1221.
Shen, C. H., and Stavnezer, J. (1998). Mol. Cell. Biol. 18, 3395-3404.
Shi, Y., Seto, E., Chang, L.-S., and Shenk, T. (1991). Cell 67, 377-388.
Shikama, N., Lyon, J., and La Thangue, N. B. (1997). Trends Cell Biol. 7, 230-236.
184
Shimoda, K., van deursen, J., Sangster, M. Y , Sarawar, S. R., Carson, R. T., Tripp, R. 
A., Chu, C., Quelle, F. W., Nosaka, T., Vignali, D. A. A., Doherty, P. C., Grosveld, G , 
Paul, W. E., and Ihle, J. N. (1996). Nature 380, 630-633.
Simmonds, W. F. (1999). Trends Pharm. Sci. 20, 66-73.
Smith, K. A. (1988). Science 240, 1169-1176.
Smith, M. R., and Greene, W. C. (1989). Proc. Natl. Acad. Sci. USA 86, 8526-8530,
Sperisen, P., Wang, S. M., Soldaini, E., Pla, M., Rusterholz, C., Bucher, P., Cothesy, P., 
Reichenbach, P., and Nabholz, M. (1995). I. Biol. Chem. 270, 10743-10753.
Stein, B., Baldwin Jr., A. S. J., Ballard, D. W., Gieene, W. C., Angel, P., and Herrlich, 
P. (1993). EMBO J. 12, 3879-3891.
Stuber, E., and Strober, W. (1996). J. Exp. Med. 183, 979-989.
Su, G. H., Chen, H., Muthusamy, N., Garrett-Sinha, L. A., Baunoch, D., Tenen, D G , 
and Simon, M. C. (1997). EMBO J. 16, 7118-7129.
Sun, L., Liu, A., and Georgopolous, K. (1996). EMBO J. 15, 5358-5369.
Sun, X. J., Rothenburg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., Cahill, 
D. A., Goldstein, B. J., and White, M. F. (1991). Nature 352, 73-77.
Sun, X. J., Wang, L. M., Zhang, Y , Yenush, L., Myers Jr., M. G., Glasheen, E., Lane, 
W. S., Pierce, J. H., and White, M. F. (1995). Nature 377, 173-177.
Takata, M., and Kurosaki, T. (1996). J. Exp. Med. 184, 31-40.
Takeda, K., Tanaka, T., Shi, W., Matsumoto, M., Minami, M., Kashiwamura, S., 
Nakanishi, K., Yoshida, N., Kishimoto, T., and Akira, S. (1996). Nature 380, 627-630.
Tamir, I ,  and Cambier, J. C (1998). Oncogene 17, 1353-1364.
185
i
Taniguchi, T. (1995). Science 268, 251-255.
Tarlinton, D. (1998). Curr. Opin. Immunol. 10, 245-251.
Taylor, S. S., Buechler, J. A., and Yonemoto, W. (1990), Annu. Rev. Biochem. 59, 971- 
1005.
Tissot, C , andMechti, N. (1995). J. Biol. Chem. 270, 14891-14898.
Tissot, C , Taviaux, S. A., Diriong, S., and Mechti, N. (1996). Genomics 34, 151-153.
Toledano, M. B., Roman, D. G , Halden, N. F., Lin, B B., and Leonard, W. J. (1990). 
Proc. Natl. Acad. Sci. USA 87, 1830-1834.
Torchia, J., Rose, D. W., Inostroza, J., Kamei, Y., Westin, S., Glass, C. K., and 
Rosenfeld, M. G. (1997). Nature 387, 677-84.
Ueno, H., Sasaki, K., Honda, H., Nakamoto, T., Yamagata, T., Miyagawa, K., Mitani, 
K., Yazaki, Y., and Hirai, H. (1998). Blood 91, 46-53.
Urbanek, P., Wang, Z. Q., Fetka, I., Wagner, E. F., and Busslinger, M. (1994). Cell 79, 
901-912.
Uribe, L., and Weinberg, K. I. (1998). Semin. Hematol. 35, 299-309. 
vanFreeden-Jeffiy, U. (1995). J. Exp. Med. 181, 1519-1526.
Vitetta, E. S., Ohara, L, Myers, C. D , Layton, J. E., Kiammer, P. H., and Paul, W. E. 
(1985). J. Exp. Med. 162, 1726-1731.
Vogt, P. K., and Bos, T. J. (1990). Adv. Cancer Res. 55, 1-35.
Waldmami, T., Tagaya, Y., and Bamford, R. (1998). Intern. Rev. Immunol. 16, 205- 
226.
186
Wang, H. Y., Shelburne, C. P., Zamorano, J., Kelly, A. E., Ryan, J. J., and Keegan, A.
D. (1999). J. Immunol. 162, 4385-4389.
Wang, H. Y., Zamorano, J , Yoerkie, J. L , Paul, W. E., and Keegan, A. D. (1997). J. 
Immunol. 158, 1037-1040.
Wang, L. M., Myers Jr., M. G., Sun, X. J., Aaronson, S. A., White, M., and Pierce, J.
H. (1993). Science 261, 1591-1594.
Welham, M. J., Duronio, V., and Schrader, J. W. (1994). J. Biol. Chem. 269, 5865- 
5873.
Weng, W. K., Jarvis, L , and LeBien, T. W. (1994). J. Biol. Chem. 269, 32514-32521.
Werlen, G., Jacinto, E., Xia, Y., and Karin, M. (1998). EMBO J. 17, 3101-3111.
Whitmarsh, A. J., and Davis, R. J. (1996). J. Mol. Med. 74, 589-607.
Wienands, J., Schweikert, J., Wollscheid, B., Jumaa, H., Nielsen, P. J., and Reth, M.
(1998). J. Exp. Med. 188, 791-795.
Wilks, A. F., Harpur, A. G., Kurban, R. R , Ralph, S. J., Zurcher, G , and Ziemiecki, A. 
(1991). Mol. Cell. Biol. 11, 2057-2065.
Worm, M., Krah, J. M., Manz, R. A., and Henz, B. M. (1998). Blood 92, 1713-1720.
Xie, H., Wang, Z., and Rothstein, T. L. (1996). Cell. Immunol. 169, 264-270.
Xing, J,, Ginty, D. D., and Greenberg, M. E. (1996). Science 273, 959-963.
Yamamoto, K. K , Gonzalez, G. A., Biggs, W. H. D , and Montminy, M. R. (1988). 
Nature 334, 494-498.
187
Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T.,
Ohtsuka, S., Imiaizumi, T., Matsuda, T., Ihle, J. N., and Yoshimura, A. (1999). EMBO 
J. 18, 1309-1320.
Yin, T. G., Keller, S. R., Quelle, F. W., Witthuhn, B. A., Tsang, M. L. S., Lienhard, G.
E., Ihle, J. N., and Yang, Y. C. (1995). J. Biol. Chem. 270, 20497-20502.
I
Yu, W., Nagaoka, H., Jankovich, M., Misulovin, Z , Suh, H., Rolink, A., Melchers, F., |
Mefïre, E., and Nussenzweig, M. C. (1999). Nature 400, 682-687.
Zamorano, J., Wang, H. Y , Wang, L. M., Pierce, J. H., and Keegan, A. D. (1996). J.
Immunol. 157, 4926-4934,
Zhang, S., Mantel, C , and Broxmeyer, H. E. (1999). J. Leukoc. Biol. 65, 372-380.
Zhong, H., Suyang, H., Erdjument-Bromage, H., Tempst, P., and Ghosh, S. (1997). Cell 
89, 413-424.
Zhuang, Y., Soriano, P., and Weintraub, H. (1994). Cell 79, 875-884.
Zola, H., Weedon, H., Thompson, G. R., Fung, M. C , Ingley, E., and Hap el, A. J.
(1991). Immunol. 72, 167-173.
188
Appendix
AET Solution
50mM Tris-HCl, pH 8.0 
lOmMEDTA
Buffer PI
lOOpg/ml RNase A 
102mg/ml AET, pH 9.0 
I x P B S
Buffer P2
200mM NaOH
1% (w/v) SDS
Buffer P3
3M CH3 COOK, pH 5.5
Buffer QBT
0.75MNaCl
50mM 3-pSF-MorpholinoJpropane 
sulfonic acid (MOPS), pH 7.0 
15% (v/v) (CH3)2CH0 H 
0.15% (v/v)Triton-X-100
Buffer QC
IMNaCl
50mMMOPS, pH7.0 
15% (v/v) (CH3)2CH0 H
Buffer QF
1.25MNaCl, pH 8.5 
50mM Tris-HCl 
15% (v/v) (CH3)2CH0 H
Cytosolic Extraction Buffer
ImM HEPES-KOH, pH 8.0
2mM MgCl2
15mMKCl
O.linMEDTA
O.lmMEGTA
ImMDTT
0.25mMPMSF
2 pg/ml leupeptin
2 |ig/ml aprotinin
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Discontinuous PercoII Gradient
Percoll
10 X filter-sterile PBS
5% (w/v) Acrylamide Stacking Gel
13% (v/v) acrylamide
40% (w/v) bis acrylamide
26% (v/v) 0.5M Tris-HCl, pH 6.8
1% (v/v) CNH4)2S20g
0.1% (w/v) SDS
0.07% (v/v) TEMED
5x Binding Buffer
20% glycerol
5mM MgCh
2.5mMDTT
250mM NaCl
50mM Tris-HCl, pH 7.5
0.25mg/ml poly (dl-dC).poly (dl-dC)
5% Non-SDS Denaturing Gel
8% (v/v) acrylamide 
40% (w/v) bis aciylamide 
5% (v/v) 5 X TBE, pH 8.3 
0.5% (v/v) (NH4)2S20g 
05% (v/v) TEMED
5x PKA Buffer
0.2M M 0PS, pH7.0 
0 .16M (CH3COO)2Mg.4H20
5x TBE
0.9M Tris base, pH 8.3 
O.9M H 3BO3
0.02M disodium EDTA.2 H2O
LB Agar
1.5% (w/v) bacto agar 
1% (w/v) bacto tiyptone 
0.5% (w/v) bacto yeast 
1% (w/v) NaCl 
pH 7.5
LB Media
lOg/1 bacto tryptone 
5g/l bacto yeast 
0.17MNaCl 
pH 7.5
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